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Paracetamol overdose is responsible for 46% of drug-induced liver injury in the 
Western world, causing 200 deaths in the UK and 500 deaths in the USA per annum. 
The current therapy, N-Acetyl-Cysteine, is only effective within 12 hours after 
overdose. When the overdose is moderate, it is still possible for the liver to recover 
through its innate healing process. However, after a severe overdose this is not the 
case. Severe liver injury prevents the liver from performing vital tasks. This results in 
multiple organ failure and fatality. The only effective option for treatment is a liver 
transplantation, which is limited by organ availability and associated transplant related 
morbidity. New therapies are needed outside the initial 12 hour window to improve 
the outcome of paracetamol induced liver injury.  
The liver’s innate healing process involves immune cells which remove debris caused 
by paracetamol injury and promote liver regeneration. Understanding how immune 
cells promote these healing processes and how to manipulate the immune cells to 
perform these healing therapies, may lead to the development of new regenerative 
therapies for paracetamol overdose.  
In this thesis, I investigate the role the signalling protein Semaphorin 7a, which has 
previously been shown to manipulate the immune system. I show that Semaphorin 7a 
is expressed by liver cells which act to contain the spread of damage caused by 
paracetamol injury. A deficiency of Semaphorin 7a, results in more paracetamol 
induced liver injury and inflammation.   
This work builds on previous knowledge on how Semaphorin 7a modulates the 
immune system and demonstrates a novel role where Semaphorin 7a limits the 
spread of damage caused by paracetamol. By understanding how the liver protects 
and repairs itself following paracetamol injury, we can continue to develop innovative 




Paracetamol (Acetaminophen, APAP) overdose is responsible for 46% of drug 
induced liver injury in the Western world, causing 200 deaths in the UK and 500 
deaths in the USA per annum. The current treatments for APAP overdose are N-
Acetyl-Cysteine, which is only effective in the first 12 hours after overdose, or in most 
serious cases a liver transplantation. Novel therapies are needed outside of this 12 
hour window. After a moderate APAP overdose, patients will recover. This process 
involves macrophages which phagocytose necrotic cells and secrete signals which 
stimulate hepatocyte proliferation. Understanding and manipulating pathways 
involved in this endogenous repair process may lead to new therapeutic strategies.  
Semaphorins are a diverse group of signalling proteins that modulate axon guidance 
and immune responses. Semaphorin 7a (Sema7a) is a chemoattractant for dendritic 
cells, monocytes and macrophages. It can also modulate if macrophages secrete pro- 
or anti- inflammatory cytokines. This thesis investigates the role of Sema7a during 
APAP injury.   
24 hours after a 350 mg/kg APAP overdose, Sema7a was expressed by viable 
Hnf4α+ peri-necrotic hepatocytes. To further examine the role of Sema7a during 
APAP injury, mice deficient for Sema7a (Sema7a KO) were compared to wild type 
(WT) mice, during a time course of APAP injury and recovery. Histological analysis 
displayed increased injury and necrosis in the Sema7a KO mice, with significantly 
more neutrophils in the necrotic area at 24 hours post APAP administration. In 
addition, Sema7a KO mice had increased serum levels of the pro-inflammatory 
cytokines IL-6 and CXCL1, in comparison to WT mice. These findings demonstrate 
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Introduction   
Paracetamol (Acetaminophen, APAP) is a widely used analgesic and antipyretic. 
Whilst safe at therapeutic doses, APAP overdoses cause 46% of acute liver failure in 
the western world. This equates to 50,000 emergency room visits, 26,000 
hospitalisations and 500 deaths in the USA and 200 deaths in the UK per annum 1,2. 
Overdosing on APAP occurs intentionally but is more commonly accidental, through 
patients taking a combination of painkillers for acute and chronic pain syndromes  3.  
An overdose of APAP induces hepatocyte necrosis and inflammation. The clinical 
outcome can vary from a complete recovery to cerebral oedema, coagulopathy and 
death.  In the short term, patients can be treated with N-acetylcysteine (NAC) which 
restores intracellular levels of glutathione, an antioxidant essential for APAP 
metabolism. Unfortunately, NAC is only truly effective in the first 12 hours after 
ingestion of APAP 3. In extreme cases, the only viable therapy is a liver 
transplantation, but donor organs are in short supply. Research is therefore needed 
to find a suitable therapy to prevent liver failure after the initial 12 hour time window 
3,4.  
Basic liver anatomy  
The liver is the largest internal organ with over 500 functions. It main roles include: 
filtering nutrient rich blood from the intestines, detoxification of xenobiotics and drugs, 
bile synthesis, glucose and lipid metabolism 5. 
To facilitate these diverse functions the liver has a unique vasculature system 
consisting of densely packed fenestrated capillaries, termed sinusoids. Blood is 
supplied to the liver through both the hepatic artery (HA), which supplies oxygenated 
blood; and the portal vein (PV), which delivers nutrient rich blood from the intestine, 
to be filtered by the liver. The terminal branches of the HA and PV are associated with 
a biliary ductule, forming the portal triad (PT) (Figure 1. 1). Blood flows from the PT 
along the sinusoids and is collected by the central vein (CV), forming an oxygen 
concentration gradient. Adjacent to the sinusoids are cords of hepatocytes, the major 
epithelial cells of the liver, which perform the liver’s functions. In between the 
hepatocytes are the bile canaliculi, which collect bile and excretory products from the 
hepatocytes. The bile canaliculi drain into the bile ductule in the PT. The bile is then 
transported to the gallbladder for storage (Figure 1. 1) 5.   
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Hepatocytes located along the PT to CV axis are heterogeneous in function and can 
be separated into three zones. These functional zones correlate with the oxygen 
concentration gradient (highest at the PT, zone 1) and an opposing Wnt signalling 
gradient (highest at the CV, zone 3) (Figure 1. 1) 6. Zone 1 periportal hepatocytes 
contain high levels of the antioxidant glutathione. Zone 1 hepatocytes perform oxygen 
demanding roles such as gluconeogenesis and urea synthesis. Zone 2 is poorly 
defined and is often seen as a transient zone between the highly distinct zones of 1 
and 3. Zone 3 centrilobular hepatocytes contain high levels of cytochrome P450, 
which enables the metabolism of drugs such as APAP and alcohol. However, 
hepatocytes within zone 3 contain low levels of the antioxidant glutathione, making 
them susceptible to reactive oxygen species (ROS) (Figure 1. 1) 5.  
Hepatocytes have exceptional proliferative capacity, making the liver a highly 
regenerative organ. After 70% partial hepatectomy, the liver regenerates through 
hyperplasia. Mice will restore their liver mass within one week, and be fully functional 
within a month 7. However, if the insult or damage to the liver outweighs its 
regenerative capacity, the liver cannot regenerate. In chronic liver injury, this results 
in fibrosis and cirrhosis 8. In acute injury such as APAP overdose, this results in acute 
liver failure  (ALF) and potentially death 3.  
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Figure 1. 1 Liver microstructure and zones 
 
Figure 1. 1  
A) The liver has a dual blood supply from the hepatic artery (red) and the portal vein 
(blue), which are accompanied by a bile ductule (green) to form the portal triad (PT). 
Blood flows along the sinusoids from the PT to the central vein. Adjacent to the 
sinusoids are hepatocytes. Hepatocytes secrete bile into the bile canaliculi, which 
flows in the opposite direction to the blood (white arrows) and is collected by the bile 
ductule. Kupffer cells are the liver’s resident macrophage. They scavenge the 
sinusoids for pathogens and damaged blood cells. 
B)  Opposing oxygen and Wnt signalling gradients separate the hepatocytes into three 
functional zones. Zone 1 hepatocytes surrounding the PT perform β-oxidation and 
gluconeogenesis. Zone 3 hepatocytes perform glycolysis, triglyceride synthesis and 
drug metabolism.  
 
CV, Central vein; HA, hepatic artery; PT, portal triad; PV, portal vein. 
 
Adapted from: Birchmeier, W. (2016) ‘Orchestrating Wnt signalling for metabolic liver 
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Pathophysiology and treatment of APAP induced liver 
injury 
APAP is a dose related toxin that causes 46% of ALF in the USA and the UK 3. ALF 
is defined as the abrupt loss of hepatocellular function resulting the sudden onset of 
coagulopathy and encephalopathy, in a patient with no prior history of liver disease 
10. In patients, APAP toxicity is worsened by several factors including starvation and 
alcohol abuse 11–13. Over the past few decades, the hepatotoxicity pathway has been 
well described. 
Ingested APAP passes from the small intestine to the liver after a few hours of 
consumption. At safe doses, 90% of APAP is readily esterified by glucuronic acid and 
sulfotransferases to form glucuronate and sulfate conjugates, respectively, which are 
safely excreted through the bile or urine 3,14. Once the esterification capacity is 
saturated, APAP is oxidised by cytochrome P450 2E1 (Cyp2E1), to generate a toxic 
intermediate: N-acetyl-p-benzoquinone imine (NAPQI). Glutathione S-transferase 
converts NAPQI into a safe inactive form by conjugating it to the antioxidant 
glutathione (GSH), to form 3-glutathionyl acetaminophen. This safe metabolite can 
then be excreted from the body (Figure 1. 2) 3,4,14.  
In the overdose scenario, the esterification process becomes saturated, and APAP is 
predominantly metabolised by Cyp2E1. As a result, GSH becomes depleted from the 
cytosol and mitochondria of hepatocytes, and NAPQI accumulates 14. NAPQI is a 
highly reactive metabolite and will covalently bind to free cysteines to form protein 
adducts. This includes NAPQI binding complex I and III in the electron transport chain, 
halting adenosine triphosphate (ATP) production, and enhancing the formation of 
ROS.  
ROS can be dismutated into hydrogen peroxide and molecular oxygen in the 
mitochondria, or react with endogenous nitric oxide to form peroxynitrite 15. Both 
hydrogen peroxide and peroxynitrite are detoxified by GSH, further depleting the GSH 
supply.  As peroxynitrite accumulates it nitrates tyrosine residues in mitochondrial 
DNA and proteins to form 3-nitrotyrosine proteins. Nitrated proteins are a biomarker 
for nitrogen stress, and correlate with APAP injury 16,17.   
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Figure 1. 2 The APAP induced hepatotoxicity pathway 
 
Figure 1. 2 
APAP is converted into NAPQI, a toxic metabolite, by the Cyp2E1 enzyme. If there is 
sufficient glutathione (GSH) available, it is conjugated to NAPQI by Glutathione S- 
transferase, to form an inactive reduced compound, 3-glutathionyl APAP, which is 
safely secreted from the body. In the overdose setting, GSH becomes depleted, 
allowing NAPQI to accumulate. This leads to the formation of protein adducts, reactive 
oxygen species, mitochondrial dysfunction and hepatocyte death. NAC, the only 
current therapy, is a precursor to GSH, and limits APAP injury by restoring GSH 
levels.  
 
APAP, acetaminophen, paracetamol; GSH, glutathione; NAC, N-acetylcysteine; 
NAPQI, N-acetyl-p-benzoquinone imine. 
 
Adapted from: Lee, W. M. (2017) ‘Acetaminophen (APAP) hepatotoxicity-Isn’t it time 
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ROS activates the c-Jun N-terminal kinase (JNK) pathway which induces the 
mitochondrial permeability transition (MPT) pore to open, which ultimately leads to 
necrotic cell death. Hydrogen peroxide causes the activation of apoptosis signalling-
regulating kinase 1 (ASK-1) which phosphorylates mitogen-activated protein kinase 
kinase 4/7 (MKK4/7), which phosphorylates JNK. The phosphorylation of JNK results 
in an activated form of the protein that can translocate to the mitochondria. Once 
within the mitochondria, JNK phosphorylates SH3 homology-associated BTK-binding 
protein (Sab). Sab activation leads to the dysfunction of the electron transport chain, 
and further increases ROS production. As ROS increases it creates a self-sustaining 
feedback loop with JNK. Continual activation of JNK causes the phosphorylation and 
activation of bax. Bax translocates into the mitochondria, where it initiates MPT pore 
opening. This causes the depolarisation of the inner mitochondrial membrane. The 
loss of structural integrity prevents adequate ATP production, increases oxidative 
stress, and release of intermembrane mitochondrial proteins including endonuclease 
G, which triggers DNA fragmentation and necrotic cell death 14,15,17.  
Cyp2E1 is expressed by zone 3 hepatocytes, which metabolises APAP. 
Consequently, zone 3 hepatocytes are the first to succumb to APAP toxicity. The 
resultant centrilobular cell death is a hallmark of APAP injury 17. In addition to 
hepatocyte death, centrilobular liver sinusoidal endothelial cells (LSECs) are also 
damaged. APAP toxicity causes LSECs to swell, and to become permeable 18,19. This 
results in reduced perfusion, erythrocytes extravasation 20,21, coagulation and more 
liver injury 15,17. In severe APAP overdose, hepatocytes in zone 2 and even 1 can 
undergo cell death, ultimately leading to liver failure as necrosis spreads through the 
liver.   
Cell death in APAP injury  
Cell death can occur through several distinct mechanisms including: apoptosis, 
necrosis and necroptosis. Apoptosis is an energy dependant controlled method of cell 
death mediated by a tightly regulated caspase cascade 22. During APAP injury, ATP 
depletion prevents apoptosis. This is confirmed in mouse models where pan caspase 
inhibitors did not protect or prevent cell death 23,24.  
Necrosis is a passive, uncontrolled, energy independent form of cell death. Necrosis 
occurs after a toxic or hypoxic injury, when cells are depleted of energy. It is 
characterised by mitochondrial dysfunction, organelle and cell swelling and a loss of 
cellular integrity. As the cell membrane ruptures, it leaks its contents into the 
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surrounding tissue, releasing damage-associated molecular patterns (DAMPs) (for 
example ATP, DNA fragments and high mobility group box protein 1 (HMGB1)), which 
activates the innate immune system. Cellular leakage and infiltrating immune cells 
can cause substantial collateral damage to the surrounding tissue and systemic injury 
22,25.  
Necroptosis is a controlled mechanism of cell death, with similar characteristics to 
necrosis; swelling, loss of cell integrity, cell leakage, release of DAMPs, and the 
consequent pro-inflammatory response 25. Unlike necrosis, necroptosis occurs 
through a specific pathway: in the absence of caspase 8 activity, receptor interacting 
protein kinase 1(RIPK1) recruits RIPK3 to form the necrosome, which recruits and 
phosphorylates the mixed-lineage kinase domain-like protein (MLKL). MLKL then 
destabilises the plasma membrane and initiates cell lysis 26. In addition, RIPK3 
activates pathways to induce ROS production and mitochondrial fission 25.  
As the mechanisms of necroptosis and necrosis are morphologically similar, it has 
been debated which mechanism is involved in APAP induced cell death. Sensitive 
antibodies for necroptosis are unavailable. RIPK1 inhibitors (necrostatin -1 (Nec-1), 
or the more sensitive Nec-1s), have been used to study necroptosis in APAP injury, 
but as Nec-1 is unstable in vivo, and RIPK1 is involved in both apoptosis and 
necroptosis these studies gave conflicting results 22,27,28. However, studies using mice 
deficient for either RIPK3 or MLKL, proteins specific for necroptosis, had no protection 
from APAP induced cell death as the mice displayed the same levels of necrosis and 
alanine transaminase (ALT) as wild type (WT) mice 27,29. This data demonstrates 
APAP cell death is mediated by necrosis.  
Treatment of APAP overdose in the clinic  
The only viable treatment for APAP overdose is NAC, which restores the depleted 
GSH. NAC is only effective with in the first 12 hours of APAP overdose (Figure 1. 2), 
or in select cases a liver transplantation 3,4. APAP overdose is either intentional with 
patients ingesting over 12 grams of APAP in a single time point, or accidental. 
Accidental overdose patients typically ingest 6-10 grams/ day over several days 3, 
either as APAP tablets or in combinatorial painkillers. The most common reasons for 
an accidental overdose are: postoperative pain or to treat pancreatitis, toothache or 
chronic back pain 3. Patients who unintentionally overdose on APAP, arrive later to 
hospital than intentional overdose patients, and are more likely to be outside the 12 
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hour window that NAC is effective and therefore have worse outcomes from APAP 
overdose.   
APAP injury evolves rapidly in a dose dependant manner, with patients initially 
suffering from nausea and abdominal pain. These symptoms are associated with 
extremely high levels of aspartate transaminase (AST) and alanine transaminase 
(ALT) which are markers of hepatocellular injury. As injury continues, liver function is 
compromised. This leads to hyperammonaemia, coagulopathy, acute kidney injury, 
encephalopathy, and cerebral oedema 3,30. In the healthy state, the liver acts as a 
‘firewall’ to prevent commensal bacteria and pathogens absorbed by the intestines 
from spreading around the body 31. During APAP injury, the liver loses this function, 
allowing intestinal bacterial translocate into the bloodstream causing sepsis 4,32. If 
multi-organ failure does not occur from the effects of APAP injury, patients have a 
chance of recovering with no lasting side effects 3. Resolution of APAP-mediated 
injury is as rapid as its onset, with 64% of patients making spontaneous recoveries, 
and 7% recover with the aid of liver transplant surgery. The remaining 28.5% die either 
of multi-organ failure or whilst awaiting a liver transplant 3.  New therapies are needed 
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The innate immune system during APAP injury  
The innate immune system is crucial during both APAP injury and recovery. However, 
the roles of the innate immune system are still being clarified, with many controversies 
over roles and benefits of different cell types. This section will focus on neutrophils 
and macrophages during APAP injury and recovery.  
Kupffer cells during homeostasis   
Every minute 30% of the total blood volume passes through the liver, carrying 100 
million peripheral blood lymphocytes per 24 hours 33. A third of the liver’s blood supply 
is oxygenated blood from the hepatic artery. The remaining two thirds is delivered by 
the portal vein. It carries nutrient rich blood and potential pathogens from the 
intestines. One of the primary roles of the liver is to filter this blood, by removing any 
ingested toxins and pathogens 34. As such, the liver hosts a large population of 
resident liver macrophages known as Kupffer cells (KCs). For every 100 hepatocytes 
there is an estimated 20 – 40 KCs in healthy rodent livers 35, constituting 20% of the 
non-parenchymal cell (NPC) fraction of the liver 33.  
Kupffer cells are predominantly stationary, self-renewing phagocytes. KCs originate 
from colony stimulating factor 1 receptor (CSF1R) + erythromyeloid progenitors in the 
yolk sac that  seed the liver from embryonic day 10.5 in mice 36,37. Once seeded in the 
foetal liver, the inhibitor of DNA binding 3 (Id3) mediates the differentiation of 
erythromyeloid progenitors towards adult KCs 37. 
KCs are located on the luminal side of the hepatic sinusoids (Figure 1. 1). They sense 
and scavenge their environment with long cytoplasmic protrusions, and efficiently 
phagocytose cellular debris and pathogens, maintaining homeostasis in the liver and 
prevent unnecessary inflammatory reactions 35. During homeostasis, KCs are 
continually bombarded by commensal and dietary bacteria from the gut, which it 
phagocytoses 31. To prevent continual initiation of an inflammatory reaction to these 
bacteria, KCs respond to bacterial endotoxin by producing the anti-inflammatory 
cytokine interleukin- (IL-)10 38,39. This prevents the production of the pro inflammatory 
cytokines Interferon gamma (IFN-γ), IL-12, and Tumour-like necrosis factor α (TNFα) 
40. In addition, KCs preferentially present antigens of phagocytosed bacteria to 
regulatory T cells (Tregs), which also produce IL-10 and to promote tolerance 38,39.  
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Recent findings indicate resident tissue macrophages “cloak” single cell microlesions 
created by mechanical stress. Hiding these microlesions from neutrophils prevents 
them initiating an immune response. Uderhardt et al. used a laser to damage a single 
cell in the peritoneal wall. Resident tissue macrophages “cloaked” these microlesions 
with their pseudopods and scavenged for any inflammatory molecules released by 
the dying cell. This prevented patrolling neutrophils from detecting the damage and 
initiating an inflammatory response. However, if multiple cells were ablated by the 
laser to form a “macrolesion”, the resident tissue macrophage could not cloak the 
damage, and an inflammatory response was initiated 41. This data demonstrates how 
resident tissue macrophages limit neutrophil driven inflammation to non-apoptotic cell 
death of a single cell. Most of these experiments were performed on the peritoneal 
wall, or muscle fibres which may be more subjected to mechanical stress than other 
tissues. It will be interesting to see if these cloaking events are performed by tissue 
resident macrophages in dense organs such as the liver, which are subjected to less 
mechanical stress. However, this is outside the scope of my project.  
KCs are also capable of mounting rapid immune responses to both injury and 
pathogens by releasing cytokines to activate the immune system. The threshold 
between promoting tolerance and initiating an immune response against pathogens 
depends on Toll like receptor (TLR) signalling. The TLRs detect bacterial 
proteoglycans or foreign RNA and DNA structures. If a high concentration of their 
cognate ligand is detected, or if several TLRs are simultaneously activated, an 
immune response will be activated 42,43. In the context of necrotic cell death, DAMPs 
are detected by KCs. KCs initiate the inflammasome, an intracellular multiprotein 
complex, which activates IL-1β and IL-18, and triggers the innate immune system. In 
APAP injury, the inflammasome is activated by DAMPs including ATP, HMGB1 and 
mitochondrial DNA 43,44.   
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Roles of monocytes and macrophages during APAP injury  
Experimental APAP overdose mouse models have been used to study the roles of 
KCs. During APAP injury, KCs act as the first line of defence for the innate immune 
system. Necrosis of the hepatocytes causes DAMPs to be released, including DNA, 
ATP, HMGB1 and heat-shock protein-70 (HSP-70). KCs detect the DAMPs and 
become activated to secrete a plethora of cytokines including: TNFα, IL-6, IL-1α and 
IL-18 to activate and recruit the innate immune system 4,45. TNFα also acts to prime 
hepatocytes for apoptosis, enhancing hepatocyte loss 46,47. During APAP injury, KCs 
are depleted by the APAP toxicity. Macrophages and neutrophils infiltrate the liver, 
tripling the total number of leukocytes in the liver 48–51, and gravitate towards necrotic 
areas 48,52,53.  
To examine if reducing inflammation induced by KCs was protective against APAP 
injury, KC depletion studies have been performed. Gadolinium chloride (GdCl3) 
inactivates KC ROS production and phagocytosis 54. Pre-treatment of mice with GdCl3 
reduced ALTs, and enhanced survival 55,56, but mice had more acetaminophen-protein 
adducts 57. In addition, mice deficient for ROS production showed no protection 58–60, 
suggesting that KCs do not produce ROS to enhance APAP injury. Liposomal 
clodronate macrophage depletion reduced TNFα and IL-1β secretion. However, 
treated mice had increased ALTs throughout APAP injury, and reduced IL-10 
secretion 61,62. Together, macrophage depletion reduces pro-inflammatory cytokine 
secretion, but delays recovery as mice had persistent APAP adducts or raised ALTs, 
and reduced IL-10.  
In mice, KCs become depleted during APAP injury 48–51. The dwindling KC population 
is replaced by highly plastic infiltrating monocytes 48. There are two major populations 
of circulating monocytes in the blood. In mice they are the patrolling pro-inflammatory 
population, which is identified by: CCR2+ CX3CR1lo Ly6Chi; and the anti-inflammatory 
population, which is identified by CCR2- CX3CR1hi Ly6Clo 45. From here on referred to 
as Ly6Chi and Ly6Clo monocytes, respectively. CCL2 (also known as monocyte 
chemoattractant protein-1 (MCP-1)) attracts Ly6Chi monocytes to the mouse liver via 
CCR2 48,49,63. Once the Ly6Chi monocytes have entered the liver they can differentiate 
into Ly6C+ macrophages 64.  
After peak APAP injury in mice, the depleted KC population is restored by either self-
renewal 48, or the infiltrating macrophages can occupy the KC niche and adopt a 
phenotype similar to KCs. For example, when the KC population is completely 
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abolished by a diphtheria toxin 65, irradiation 66,  or liposomal clodronate 67, infiltrating 
macrophages convert into a resident phenotype and repopulate the liver.  
During APAP injury, infiltrating monocytes/ macrophages have been shown as both 
harmful and beneficial. In the initial stages of APAP injury (6 - 24 hours post overdose 
in mice) Ly6Chi monocytes secrete pro-inflammatory cytokines such as IFNγ, IL-6, 
TNFα and IL-1α, further enhancing inflammation and hepatocyte damage 4,35,68. In 
support of this deleterious role, preventing Ly6Chi infiltration by antagonising or 
genetically depleting CCR2 in mice reduced necrosis and ALTs 49. However, these 
CCR2 Knock Out (KO) mice had persistent necrosis after APAP injury 51. Pre-
treatment with liposomal clodronate to ablate macrophages reduced IL-1α secretion 
and enhanced survival of mice in the early stages of APAP injury 68. However, by 72 
hours of 550 mg/kg APAP treatment, liposomal clodronate treated mice had 100% 
mortality compared to 50% survival of the WT controls 68. In a different study, total 
macrophage ablation by treating CCR2 KO mice with liposomal clodronate, prevented 
vascular restoration and liver regeneration 21. Therefore, the initial wave of 
inflammation mediated by infiltrating monocytes and potentially resident 
macrophages, contributes to hepatocyte damage and necrosis. Conversely, without 
this infiltration of monocytes, and without resident macrophages there is a lack of 
tissue repair, persistent necrosis, reduced regeneration and revascularisation. 
There is a possible third source of macrophages during hepatic injury. The 
surrounding peritoneal cavity is home to a complex milieu of immune cells which 
monitor the visceral organs and mesothelium 69. The two dominant peritoneal 
macrophages populations are the large mature F4/80+ and the F4/80lo MHC IIhi small 
peritoneal macrophages 69,70. Recently, GATA-binding protein 6 (GATA6)+ F4/80+ 
peritoneal macrophages have been shown to infiltrate the liver 1 hour after a sterile 
thermal injury 71. These GATA6+ macrophages are recruited by ATP and hyaluronan 
released by necrotic cells. At the site of injury, these GATA6+ macrophages adopt a 
restorative phenotype, as characterised by the expression of arginase and the 
mannose receptor, CD206. They then proliferate, dismantle the necrotic nuclei, and 
aid revascularisation. Specific deletion of GATA6 only delayed the time it took for 
these peritoneal macrophages to arrive at the site of injury, but ablation of all 
peritoneal macrophages delayed necrosis resolution. An oral dose of CCl4 to induce 
acute liver injury caused GATA6+ macrophage recruitment into the liver. Liposomal 
clodronate prior to CCl4 depletion prevented recovery of and mice had to be 
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euthanised 71. It will be interesting to see how these GATA6+ macrophages behave 
in the context of sterile APAP liver injury, where there is mass necrosis across the 
whole liver, and not at a focal point in near the mesothelium. It would also be 
interesting to see how these peritoneal macrophages interact with hepatic 
macrophages or modulate cytokine production during APAP injury. Understanding 
these mechanisms may develop into new therapeutics through the modulation of 
different macrophage populations.  
 
Roles of monocytes and macrophages during APAP recovery  
Recovery from APAP injury requires several factors: an end to necrosis, removal of 
necrotic debris proliferation of the remaining hepatocytes, and resolution of 
inflammation. As professional phagocytes, macrophages remove debris and secrete 
anti-inflammatory cytokines which reduce inflammation and prime hepatocytes to 
proliferate. The importance of macrophages during recovery from APAP is shown in 
macrophage depletion studies. Depleting the infiltrating macrophages delays 
recovery from APAP injury 21,48,51.  
Kupffer cells are a source of the anti-inflammatory cytokine IL-10 62,72. IL-10 together 
with IL-13 and IL-4 dampen pro-inflammatory events and promote expression of anti-
inflammatory genes 73–75. Mice treated with liposomal clodronate, but not GdCl3, did 
not express IL-10 during APAP injury 62. The importance of IL-10 and IL-13 during 
APAP injury is highlighted in IL-10 KO and IL-13 KO mice, which have continually 
higher ALT and necrosis and reduced survival during APAP injury 73,76,77. During 
recovery, infiltrating macrophages convert from Ly6Chi macrophages to a Ly6Clo 
restorative phenotype 48,78. These restorative macrophages also secrete anti-
inflammatory factors to inhibit neutrophil activation and recruitment such as 
prostaglandin E2 (PGE2) 48,79.  
Macrophages are professional phagocytes which remove the necrotic debris after 
APAP injury. They also phagocytose apoptotic neutrophils 80,81. The act of 
phagocytosis also converts macrophages from a pro-inflammatory to a restorative 
phenotype 72,82. Phagocytosing macrophages secrete IL-10 72, to reduce 
inflammation. Depleting monocytes from the liver with either a MC21 antibody or 
CCR2 KO mice, delays neutrophil clearance from the liver and recovery from APAP 
injury 48. Recently, a subset of restorative KCs have been identified in both humans 
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and mice that express Mer tyrosine kinase (MerTK) 81. These MerTK+ macrophages 
release secretory leukocyte protease inhibitor (SLPI) to induce infiltrating 
macrophages and KCs towards the pro-restorative phenotype and enhance 
phagocytosis of neutrophils in vitro.  Mice deficient in MerTK display delayed liver 
regeneration after APAP injury 81.  
To restore the liver parenchyma, a scaffold of extracellular matrix (ECM) must be 
prepared, the microvascular restored and the remaining hepatocytes must proliferate 
to replace those lost. Macrophages express factors such as matrix metalloproteinases 
(MMPs) which can remodel the ECM to facilitate wound closure 48,83  and vascular 
endothelial growth factor (VEGF) to restore the vasculature 21,48. Macrophage ablation 
delayed vascular regrowth, with treated mice having highly permeable vasculature at 
48 and 72 hours post APAP administration, compared to control mice 21.  
Macrophages also secrete TNFα and IL-6, which prime hepatocytes to be more 
responsive to hepatocyte mitogens 84,85. These mitogens include hepatocyte growth 
factor (HGF), Transforming Growth Factor Alpha (TGFα) and Epidermal Growth 
Factor (EGF). In the presence of growth factors, TNFα activates NF-κB to enhance 
the activation of hepatocyte proliferation genes. It was previously mentioned that 
TNFα can cause hepatocyte apoptosis. This occurs in the absence of NF-κB, and in 
the presence of stress factors including free radicals and depleted cellular energy 
levels. Hepatocyte proliferation and microvascular regrowth is a collaborative 
process, with hepatocytes secreting VEGF and LSECs secreting HGF to stimulate 
liver regeneration 17,86. 
The possibility of using macrophages as a cellular therapy have been examined 
during chronic liver disease. Injection of BMDMs ameliorated liver fibrosis in mice in 
two separate studies 87,88. In both studies, the injected BMDMs reduced the number 
of activated HSCs and produced MMP-9 and 13 to degrade collagen scars. The 
BMDMs also recruited endogenous macrophages which amplified and extended 
these beneficial effects 87,88. The second study demonstrated that BMDMs were 
polarised to the pro-inflammatory phenotype by LPS and IFN-γ were responsible for 
these beneficial effects. In addition, the polarised BMDMs significantly promotes 
hepatocyte proliferation 88. Hepatocyte proliferation was detected in the original study, 
but not at significant level 87. The injected BMDMs only survived for a short time in the 
liver, therefore repeated injections may be needed for continued efficacy 87–89.  
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In APAP injury, administration of CSF1-Fc to mice at 12 hours APAP injury promotes 
recovery. CSF1-Fc enhanced Ly6Chi monocyte recruitment, promotes KC and 
infiltrating macrophage proliferation and macrophage phagocytosis 32. However, 
injection of macrophages into healthy mice induces biliary epithelial expansion, a 
process normally restricted to the chronic liver injury setting 90. Therefore, 
understanding how to control or direct macrophage behaviour during liver injury will 
lead to novel therapeutic tools. 
 
 
Roles of neutrophils during APAP injury  
Neutrophils are short lived polymorphonuclear leukocytes, which originate in the bone 
marrow and are key effectors of the innate immune system. These cells patrol the 
body for invading microbes or DAMPs. Neutrophils react rapidly upon appropriate 
stimulation; migrating to areas of inflammation as the first leukocytes arriving at the 
site of injury 91.  
Classical recruitment of neutrophils to injured tissue has been well defined in mice 91–
94. Endothelial cells capture neutrophils from the circulation through P and E selectin. 
The neutrophils then roll along the endothelium in the direction the blood flow 95–97. 
Endothelial cells express cytokines such as TNFα and IL-1β which prime neutrophils 
for maximum neutrophil activation and release 98,99. Chemokines including CXCL1, 2 
and 5 (IL-8 in humans) are also expressed by endothelial cells and bind to chemokine 
receptor 2 (CXCR2) on the neutrophils, causing them to activate and to firmly adhere 
to the endothelial wall. This firm adhesion is facilitated by endothelial intercellular 
adhesion molecule-1 (ICAM-1) binding to Integrin αMβ2 (MAC-1) on the neutrophil 
52,91,95,100. The neutrophil then crawls along the endothelium following a chemotactic 
gradient. Neutrophils exit the vessel by transmigrating between or directly through the 
endothelial cells. The exact mechanisms of neutrophil migration and extravasation is 
organ and context dependent 52,91,94,101.  For details on how neutrophils migrate 
through the liver during sterile injury, see below.  
At the site of injury, activated neutrophils can phagocytose debris and pathogens, 
modify tissue architecture via proteases or directly kill bacteria through the release of 
ROS, antibacterial granules or neutrophil extracellular traps (NETs). These neutrophil  
weapons have poor specificity and can cause collateral damage to the host tissue 
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91,92. Neutrophils also recruit and activate monocytes by the secretion of proteins such 
as azurocidin and cathepsin G. Neutrophils also modulate vasculature permeability 
and release IL-6 to promote endothelial cell expression of CCL2 and adhesion 
molecules (VCAM) which facilitate transmigration of monocytes into the injured tissue 
102–104. Activated neutrophils have longer lifespans than their non-activated 
counterparts, ensuring the presence of activated neutrophils at the site of injury 105–
107. With these pro-inflammatory effects, neutrophils are typically seen as detrimental 
during injury. However, ablation of neutrophils prevents the clearance of infection 91. 
In humans, reduced numbers of neutrophils in the blood causes immunodeficiency 
108,109. 
During APAP injury, neutrophils are recruited to necrotic sites by a plethora of 
chemokines secreted by macrophages and DAMPs released by dying hepatocytes 4. 
Key DAMPs include: formylated peptides (FP) which bind to the FP receptor 1 (FPR1) 
52; HMGB1 which binds to the receptor for advanced glycation end-products (RAGE) 
on neutrophils 53; and free DNA received by TLR9 110.  
During sterile injury in the mouse liver, neutrophils do not roll along the highly 
fenestrated sinusoids, but immediately adhere to the LSECs, by binding to ICAM-1 
via MAC-1 (CD11b/ CD18) 52,91,101. The neutrophils then crawl along the LSECs 
towards a hierarchy of chemokines and DAMPs. In a model of sterile thermal injury, 
neutrophils crawl along the LSECs and towards an intravascular gradient of CXCL1 
in mice and CXCL2 (also known as macrophage inflammatory protein-2; MIP-2) via 
CXCR2. This chemokine gradient guides the neutrophils to within 100-150 μm of the 
necrotic injury. From here, DAMPs dominate over chemokines secreted from healthy 
cells to precisely direct neutrophils into the necrotic zone 52,111.  
The precise roles of neutrophils during APAP injury are still being defined, with 
conflicting opinions on whether their activities are beneficial or detrimental. Activated 
neutrophils can promote hepatocyte loss by releasing ROS 110,112. Marques et al. 
argue that neutrophils are detrimental during APAP injury 110,113. By reducing 
neutrophil recruitment during APAP injury with either CXCR2 or FPR1 antagonists or 
TLR9 KO mice,  the authors showed  there was a reduction in serum ALTs, CXCL1 
and CXCL2, and the pro-inflammatory cytokines IL-1β and TNFα 110,113. In accordance 
with this, mice with a hepatocyte deletion of HMGB1 had less infiltrating neutrophils 
and reduced necrosis and ALTs during APAP injury 53. Depletion of neutrophils by 
pre-treatment with a Gr-1 antibody also reduced serum ALT and necrosis and 
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improved survival of APAP treated mice 112,113. These results suggest that recruited 
neutrophils are detrimental during APAP injury, and release ROS to induce 
hepatocyte death.  
However, pre-treating mice with neutropenia – inducing antibodies have been shown 
to be protective. The antibody tagged neutrophils become trapped in the LSECs and 
phagocytosed by KCs. Subsequently, KCs and hepatocytes temporarily produce 
protective genes and making them resistant to APAP injury 114,115. Depleting 
neutrophils with a Ly6G antibody after APAP administration 60; or genetically 
preventing neutrophil production with granulocyte-colony stimulating factor (GSCF) 
KO mice 60;  or preventing neutrophil recruitment with CD18 deficient mice 116; had 
the same levels of ALT and necrosis during APAP injury. In addition, mice with 
defective ROS production had the same ALTs as WT mice during APAP injury, but 
prolonged recovery times 59,60. These later studies suggest that neutrophils are not 
detrimental during APAP.  
 
Roles of neutrophils during APAP recovery  
As neutrophils are the first responders to injury, they have been primarily studied as 
pro-inflammatory mediators of injury. However, there is mounting new evidence that 
neutrophils promote recovery by phagocytosing bacteria, removing cellular debris, 
promoting revascularisation and remodelling the ECM to facilitate wound closure 91,117  
In a mouse model of thermal sterile injury, Wang et al. demonstrated that neutrophils 
can remove small fragments of DNA and dismantle phagocytose and damaged 
LSECs 117. Neutrophils also deposited collagen in the necrotic area, forming a 
framework for tissue regeneration. Depletion of neutrophils with a Ly6G antibody 24 
hours prior to injury, delayed revascularisation. Necrosis was still present 4 weeks 
later in neutrophil depleted mice, whereas control mice had recovered 117. However, 
the authors also demonstrated that if neutrophils do not reverse migrate back into the 
circulation when required, tissue regeneration and revascularisation is delayed.   
In support of their revascularisation role, neutrophils express vascular endothelial 
growth factor A (VEGF-A) a mitogen for endothelial cells. Pro-angiogenic neutrophils, 
which constitute 3% of the circulating neutrophil population 118, release 10-fold more 
matrix MMP-9 than other neutrophil populations. MMP-9 is required to degrade the 
ECM to create tunnels for the new blood vessels, and to promote blood vessel growth 
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by releasing matrix bound VEGF 119. Therefore, neutrophils facilitate tissue 
regeneration and revascularisation, but must be cleared from the site of injury for the 
tissue to recover.  
Neutrophils are cleared from the tissue by reverse migration or by macrophages 
phagocytosing apoptotic or necrotic neutrophils. These actions are performed by the 
neutrophils themselves, or in cohesion with monocytes/ macrophages 93,120,121.  
Neutrophils recruit circulating monocytes by secreting chemokines, and aid monocyte 
extravasation. IL-6 complexes from neutrophils cause endothelial cells to upregulate 
adherent molecules and CCL2 to specifically recruit monocytes 91. Apoptotic 
neutrophils also release “find me” signals that target them for phagocytosis 91. 
Phagocytosing monocytes and macrophages switch from a pro-inflammatory to an 
anti-inflammatory phenotype 72, thus aiding regeneration. 
Neutrophils can also reverse migrate out of the inflamed tissue, by remodelling the 
ECM. They then travel through the circulation or lymphatics back to the bone marrow 
or lymph nodes, where they apoptose and can be recycled 93,117. In zebra fish, 
macrophages directly contact neutrophils at a wound, promoting neutrophil reverse 
migration 122.  
In experimental mouse models of APAP injury, neutrophils infiltrate the liver from 4 
hours post APAP and accumulate until peak injury, defined by levels of ALT and 
necrosis, at 24 hours post APAP administration. From this time onwards, the number 
of neutrophils in the liver decreases, but a reduced population of neutrophils is 
retained until 72 hours following APAP overdose 59. New evidence suggests that these 
persistent neutrophils secrete factors including ROS to promote monocytes and 
macrophages to switch between phenotypes that can be described by Ly6C activity. 
Distinct pro- and anti-inflammatory phenotypes occur in monocytes and macrophages 
with high and low Ly6C expression, respectively.  Ly6G antibody depletion of 
neutrophils six hours after APAP administration, or genetically with GCSF KO mice, 
reduced hepatocyte proliferation and necrosis resolution at 72 hours post APAP. 
There were also less Ly6Clo monocytes and macrophages present in the livers of the 
neutrophil depleted mice. Yang et al. demonstrate that the delayed recovery in these 
mice was mediated by a lack of ROS secretion from neutrophils, as mice treated with 
the Ly6G antibody could be rescued by adoptively transferring WT 
polymorphonuclear leukocytes (PMNs) from WT mice, but not ROS defective PMNs 
60.     
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Figure 1. 3 Inflammation during APAP injury 
 
Figure 1. 3  
APAP induces hepatocyte necrosis. This causes the passive release of DAMPs 
(HMGB1, HSp70, free DNA) which are detected by KCs and patrolling neutrophils. 
This leads to the activation of KCs and neutrophils. Activated KCs secrete pro- 
inflammatory cytokines including CCL2, CXCL1, CXCL2, CXCL8, TNFα, IL-1β and 
IL-6 which activate and recruit the innate immune system to the liver. CCL2 
specifically recruits infiltrating macrophages. CXCL1, CXCL2 and CXCL8 recruit 
neutrophils. KCs also secrete IL-23 which activates γδ T cells, which further activate 
neutrophils through IL-17 secretion. TNF-α also promotes hepatocyte apoptosis.   
 
Infiltrating Ly6Chi monocytes are likely to mature into Ly6Clo macrophages under the 
influence of CCL2 and IL-6. Restorative KC and infiltrating macrophages secrete IL-
10 to reduce inflammation and promote recovery.  
 
MoMF, monocyte derived macrophage 
 
Adapted from: Krenkel, O., Mossanen, J. C. and Tacke, F. (2014) ‘Immune 
mechanisms in acetaminophen-induced acute liver failure.’, Hepatobiliary surgery and 
nutrition, 3(6), pp. 331–43.  
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Regulation of tissue and barrier integrity 
During APAP injury, the spread of necrosis and toxic solutes must be contained to 
prevent collateral damage in healthy tissue. Cell junctions maintain tissue integrity, 
cellular polarity, epithelial barriers, mechanical strength and intracellular 
communication, and have been suggested to have a role in preventing the spread of 
toxicity. There are four different types of cell junctions: Tight junctions, adherens 
junctions (AJ), desmosomes and gap junctions.  
Tight junctions are apical connections of epithelial cells which form a physical barrier 
to control the lateral flux of solutes, and maintain apical- basal cell polarity 123. Cell 
polarity is essential to asymmetrically organise components of a cell. This polarisation 
propagates across the tissue, optimising tissue function 123,124. Tight junctions consist 
of membrane proteins including occludins, claudins and Junction Adhesion Molecules 
(JAMs). Zonal occludin proteins (ZO 1-3) attach the tight junction complex to the actin 
cytoskeleton 125,126. During APAP injury tight junctions within the liver become 
disrupted in a dose dependant manner 127,128. It was suggested that this permitted the 
spread of APAP toxicity. Although this was not demonstrated.  
Adherens junctions are formed by cadherins and catenins. They form strong 
intracellular connections to maintain lateral integrity of the epithelial cell layer, and 
regulate cytoskeletal networks to facilitate cell movement  129. In the vasculature, 
vascular endothelial (VE)-cadherin maintains the permeability barrier of the vessel 130. 
In APAP injury, the sinusoids become damaged and more permeable, resulting in the 
extravasation of erythrocytes 18,20. It is likely that the VE-cadherin junctions become 
destabilised during APAP injury, but this has not been examined.  
Gap junctions are intracellular channels which allow the exchange of ions and small 
metabolites, including ROS and GSH, between cells. Gap junctions are composed of 
six connexin (Cx) proteins. These transmembrane proteins oligomerise to form a six 
protein hemi channel known as a connexon. Connexons on adjacent cells align to 
form a gap junction. Gap junctions are essential for cell differentiation growth and 
metabolic co-ordination 131,132. Opening and closure of Gap junctions is influenced by 
pH, calcium ions, transmembrane voltage and phosphorylation of the intracellular 
domains of the connexons 133–135. Outside of their channel function, gap junctions can 
influence the cytoskeleton to regulate cell morphology and movement 131,132.  
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In the liver the predominant Cx protein is Cx32 136. During APAP injury, it has been 
proposed that Cx32 transmits toxic APAP solutes between cells, increasing liver 
injury. Genetic deletion of Cx32, or application of the Cx32 small inhibitor, 2-ABP, 
prevents the spread of APAP induced necrosis 137. However, a different study 
indicated the protective effects of 2-ABP were partially mediated by the 
hepatoprotective factor dimethyl sulfoxide (DMSO), and a reduction of JNK signalling, 
and not a block of Cx32 junctions 138. In another study Cx32 KO mice were not 
protected from APAP injury, but had less APAP protein adducts at 6 hours post APAP 
administration 139. Nevertheless, in vitro, deletion of the Cx32-Cx26 gap junction in 
coupled hepatocytes prevented synchronised necrotic cell death. Furthermore, fusing 
a single female hepatocyte, which are naturally resistant to APAP toxicity, to a single 
male hepatocyte, which are more susceptible to APAP toxicity, prevented cell death 
of the male hepatocyte 140.  
Cx43 is upregulated during APAP injury, and Cx43 +/- mice had elevated ALT and 
increased IL-1β and TNFα secretion at 24 hours post APAP injury, suggesting Cx43 
protects against APAP injury 141. Together these results indicate APAP toxicity may 
spread through gap junctions.  
Macrophages also have protective barrier roles. This function has been observed in 
CX3CR1+ macrophages lining the synovial cavity in healthy mice. RNAseq analysis 
revealed these cells have an anti-inflammatory and an epithelial-like profile. They 
expressed the tight junction proteins JAM1, ZO-1 and claudin 5. They also expressed 
Fat4 and Vangl2 which are required for planar polarity. In a model of arthritis, these 
barrier macrophages became active and entered the synovial joint leading to reduced 
inflammation, independent of infiltrating PMNs or monocytes. Selective ablation of the 
barrier macrophages accelerated PMN influx and exacerbated the early stages of 
arthritis 142. These results reveal that specialist barrier macrophages protect the 
synovial joint and reduce the onset of inflammation injury. Future investigations could 
examine if the protective role of these macrophages could be upregulated to prevent 
arthritis. It will be fascinating to see if these macrophages also “cloak” microtears in 
the joint to prevent inflammation, as reported in the peritoneum and muscle 41. It would 
also be interesting to explore if KCs or infiltrating macrophages can form a barrier 
against the spread of APAP toxicity within the liver.   
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What shifts the balance between injury and recovery?  
Recovery from APAP injury requires several processes. These include: preventing 
the spread of necrosis, a switch from promoting inflammation to promoting restoration, 
clearance of necrotic debris and proliferation of the remaining hepatocytes to restore 
the parenchyma (Figure 1. 4).  
Necrosis will end once the APAP has been metabolised and cleared from the body, 
as to when this happens is dose dependant. Currently there is little knowledge on how 
the spread of necrosis is limited. Epithelial cells form barriers through cellular 
junctions. Tight junctions are down regulated during APAP injury, but the effects of 
this is unknown. Preventing the spread of APAP toxicity through the gap junction Cx32 
has been investigated but with conflicting results. For an epithelial barrier to be 
sustained, the cells in the barrier must stay alive. Potentially this is maintained by cell 
cycle arrest. 
Cell cycle arrest or senescence is induced during times of oxidative stress or DNA 
damage to prevent damaged cells from replicating. Senescent cells also secrete 
factors which attract the immune system. Senescence is marked by p21 and other 
bona fide markers, which can be induced by TGFβ signalling in times of cellar stress 
143,144. Senescence can be beneficial, as it can prevent the spread of damage and 
mass cell death during tissue insult 145. However senescence can be detrimental if it 
persists and prevents tissue regeneration 143,144,146.   
In APAP injury, peri-necrotic p21 expression correlates with the degree of injury in 
both humans and mice 144,147. Macrophages secrete TGFβ to induce cell cycle arrest 
in peri-necrotic hepatocytes and prevents hepatocyte proliferation required for APAP 
recovery. Preventing TGFβ macrophage secretion, TGFβR1 inhibition, or genetically 
deleting p21 increased hepatocyte proliferation. However, p21 KO mice had elevated 
serum ALTs, a marker for hepatocyte injury. The area of necrosis in the p21 mice was 
not reported 144. p21 expression might be needed to prevent peri-necrotic hepatocyte 
cell death, and therefore prevent the spread of necrosis.  
To recover from APAP injury, the innate immune system must switch from promoting 
inflammation to an anti-inflammatory, restorative machine. Macrophages and 
monocyte are highly plastic cells which easily switch from Ly6Chi pro-inflammatory to 
a Ly6Clo pro-restorative phenotype. This is mediated by several factors including: 
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colony-stimulating factor-1 (CSF-1, also known as M-CSF) 32, IL-4, IL-6,  IL-13 148;  
and the act of phagocytosis 72,149.  
Restorative macrophages secrete IL-10 to reduce inflammation, phagocytose debris 
and secrete IL-6 and TNFα to prime the hepatocytes for proliferation 21,62,72,82,84,85. 
They are also responsible for secreting Wnt and TGFβ, which induce regeneration or 
senescence respectively 144,150. Manipulating the actions of macrophages may be a 
novel and powerful approach to treat APAP injury. 
Hepatocyte proliferation is synchronised with the microvasculature restoration, with 
hepatocytes secreting VEGF to promote angiogenesis and LSECs secreting HGF to 
stimulate hepatocyte proliferation 17,86,147. Wnt/ β- catenin signalling is important in 
liver regeneration in both APAP injury and chronic liver injury 147,150. Bhushan et al. 
compared mice which recover from APAP injury, by using a 300 mg/kg dose of APAP, 
to mice treated with 600 mg/kg APAP, which do not recover 147. In the 300 mg/kg 
APAP treated mice, mRNA expression of Wnt4 and Wnt5a were elevated 6 hours 
post APAP injury, and β-catenin localised to the nucleus between 12 and 24 hours 
post APAP injury. However, in the 600 mg/kg treated mice, Wnt/ β-catenin signalling 
was not induced 147. What promotes Wnt signalling is unknown. Mice with forced 
nuclear β-catenin signalling had more hepatocyte proliferation, but ALT and necrosis 
was unchanged, compared to control mice 147. This suggests Wnt -β-catenin signalling 
promotes hepatocyte proliferation but does not protect against APAP injury. In chronic 
injury, macrophages secrete Wnt to differentiate hepatic progenitor cells into 
hepatocytes 150.  
Whilst the aforementioned factors are important during recovery from APAP injury, it 
is still unknown what shifts the balance from the injury setting, to the recovery setting 
during APAP injury (Figure 1. 4). The cellular source and specific type of Wnt present 
during APAP injury and recovery remains to be investigated, it is also not clear why 
or how Wnt signalling was initiated in the 300mg/kg APAP treated mice and not the 
600 mg/kg APAP treated non-regenerative mice. The mechanisms underlying TGFβ 
signalling, and the TGFβ mediated senescence were not fully examined. It is still 
unclear what prevents the spread of necrosis during APAP injury. In addition, factors 
that orchestrate the innate immune system to shift from a pro-inflammatory phenotype 
to a restorative phenotype remain to be elucidated. Understanding these processes 
will lead to novel regenerative therapies.   
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Figure 1. 4 What shifts the balance between injury and regeneration?  
 
 
Figure 1. 4 
During the injury phase, APAP toxicity promotes inflammation and necrosis.  
Regeneration of the liver requires the necrotic debris to be removed, inflammation to 
resolve and convert to the anti-inflammatory restorative phenotype, and hepatocytes 
to proliferate.  
 
After peak APAP injury there is a shift from APAP induced necrosis to a recovery 
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Semaphorins 
The semaphorins are a diverse family of over 20 signalling proteins. They were 
originally identified as axon guidance molecules but have since been found to mediate 
a diverse array of functions from immune responses, axon migration and bone 
homeostasis 151,152.  
The structure of semaphorins  
All semaphorins contain a conserved 500 residue ‘sema’ domain at their N- terminus. 
Adjacent to the sema domain is the cysteine-rich plexin-semaphorin- Integrin  (PSI) 
domain, named after the similarity to the beta chain of integrins and regions found 
within the Plexin family 153.  
The semaphorin family is divided into 8 classes, based on defining structural features. 
Within each class the semaphorins are labelled alphabetically (e.g. Sema3a) (Figure 
1. 5). Class 1 and 2 semaphorins are exclusively expressed in invertebrates. Classes 
3 – 7 are expressed by vertebrates. Class 3 semaphorins are secreted; Classes 4, 6 
and 7 are membrane associated 152. Classes 3, 4, 7 and V have Ig like domains. Class 
5 semaphorins are defined by their thrombospondin repeats. In Class 6, the sema-
PSI domain constitutes the whole of the extracellular domain of the protein. Class 8 
or V are viral semaphorins, which are a structural mimics of Sema7a (Figure 1. 5) 153, 
154. 
Crystal structures of Sema3a 155, Sema4d 156, Sema6a 157, and  Sema7a 158 reveal 
that the sema domain consists of a seven bladed β propeller fold, which forms a stable 
platform for homodimerisation of the semaphorin which is required for sema function. 
The sema domain also facilitates binding, with one homodimer binding to two receptor 
proteins. So far no heterodimers of semaphorins have been found 152.  
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Semaphorin receptors 
The main semaphorin receptors are plexins and neuropilins. Plexins are large 
transmembrane receptors which contain an extracellular sema - PSI domain and 
three immunoglobulin–plexin–transcription factor (IPT) domains, but unlike the 
semaphorins, the plexin’s sema domains do not dimerise to be active. Currently 11 
vertebrate plexins have been identified: Plexin A1-4, B1-3, C1, and D1 152,159. The β 
propeller fold in the plexin’s sema domain inserts into the semaphorin’s β propeller 
fold, with the angle and length of insertion defining receptor-ligand specificity 158,160 
(Figure 1. 5). Semaphorin - plexin binding induces conformational changes which 
triggers signalling 161.  
Membrane bound semaphorins in classes 4 - 7 directly bind to activate their 
respective Plexin receptor. As class 3 semaphorins are secreted, a neuropilin (Nrp) 
co-receptor is required to stabilise the Sema3- Plexin A interaction 152, the exception 
being Sema3e which can bind directly to Plexin D1 153. Downstream signalling is 
mediated by the intracellular region of the plexin which contains a conserved GTPase 
activating protein (GAP) domain. This conducts signalling through activation of protein 
kinases, GTPases and cytoskeleton associated proteins 152.  
Nrps are membrane spanning glycoproteins with a short intracellular domain, making 
them unable to transmit semaphorin signalling independently 161. However, Nrp can 
determine the outcome of downstream semaphorin signalling. For example, during 
neurone development, secreted Sema3e repels ventrolateral and striatal axons by 
binding to Plexin D1. However, in subicular axons, Sema3e acts as a 
chemoattractant, when received by Plexin D1 and Nrp1 162.   
Nrps can act as co-receptors to a diverse range of signalling proteins outside of the 
plexins, where they direct downstream signalling. The best characterised is Nrp acting 
as a co-receptor for VEGF with VEGFR on endothelial cells to promote angiogenesis 
163. Nrp1 can also bind to TGFβ, and increase its affinity to TGFβR receptors in T cells 
164. In myofibroblasts, binding of Nrp1 to TGFβR2 directs TGFβ signalling away from 
SMAD 1/5/8 to SMAD 2/3 signalling, causing myofibroblasts to activate 165. Nrp1 and 
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Figure 1. 5 
Semaphorins all have a conserved 500 amino acid ‘Sema’ domain and can bind to 
plexins, Integrin s or neuropilins (Npn). Adjacent to this is the PSI domain.  
Class 1, 2 are found in invertebrates 
Class 3 semaphorins are secreted and bind to the Plexin A neuropilin 1 complex to 
regulate neurone growth and immune cell trafficking.  
Class 4 are transmembrane proteins which bind to Plexin Bs to repel neurones or 
activate immune cells.  
Class 6 semaphorins are transmembrane proteins which bind to plexin A1 in cohesion 
with either VEGFR during development, or TREM-2 or DAP2 to modulate immune 
system function 
Class 7 has a single member, Sema7a. It is linked to the cell membrane by a GPI 
linker, and binds to Plexin C1 or Integrin β 1 in the immune and nervous system. 
Class V are viral semaphorins   
 
From: Alto L.T., Terman J.R. (2017) Semaphorins and their Signalling Mechanisms. 
In: Terman J. (eds) Semaphorin Signalling. Methods in Molecular Biology, vol 1493. 
Humana Press, New York, NY 153 
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Roles of semaphorins  
Semaphorins were originally identified as axon guidance molecules which fine tune 
neurone guidance during development and in adults. Semaphorins have since been 
found to have roles in angiogenesis and the immune system.  
During development semaphorins guide neurones to their final destination to ensure 
the correct wiring of the neuronal network. This is achieved by chemoattraction and 
chemorepulsion of neurones, or promoting and inhibiting of neurone outgrowth (Table 
1. 1). For example, Sema4d triggers the growth cone collapse through Plexin B1 and 
Rho GTPase signalling 167.  
Semaphorins can promote opposite actions in their target cell by binding different 
receptors. Sema3e attracts axons by binding Nrp1 and Plexin D1 but repels neurones 
by binding exclusively to Plexin D1 168. Being able to bind two distinct receptors 
diversifies the functions of the semaphorins, and enables the delicate fine tuning 
needed to assemble the neuronal network.   
In the adult, semaphorins can guide axons during neurogenesis and injury. Piaton et 
al. investigated the potential role of semaphorins in multiple sclerosis. In their murine 
demyelination model, they found that Sema3a prevents oligodendrocyte precursor 
(OPCs) cell recruitment, whereas Sema3f enhanced recruitment of the OPCs and 
increased the remyelination rate 169.  
Table 1. 1 Roles of Semaphorins in the nervous system  
Semaphorin  Receptor  Function Reference 
Sema3a Plexin A1 Growth cone collapse, repulsion of 
OPCs 
169–171 
Sema3b Nrp2 Attraction and repulsion of 
neurones 
172 
Sema3e Nrp1 and Plexin 
D1 
Attracts axons 168 
Sema3e Plexin D1 Repels axons  168 
Sema3f Nrp2 Axon guidance of cranial nerve, 
recruitment of OPCs 
169,173 
Sema3g Nrp2 Repels axons in the cerebellum 174 
Sema4d Plexin B1 Growth cone collapse 167 
Sema5a Plexin A1  Inhibits growth of retinal ganglion 
cells 
175 
Sema7a Integrin β1 Axon outgrowth and branching. 
Guidance of GnRH neurones 
176–180 
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Semaphorins can also directly regulate angiogenesis, by binding to Nrp1 with VEGFR 
as a co-receptor. During development, Sema3a and Sema3e repel the developing 
microvasculature to ensure the correct vascular patterning of the embryo 181,182. Class 
3 semaphorins also reduce angiogenesis by competing with VEGF for is receptor 161. 
In the adult, Sema3a inhibits VEGF mediated angiogenesis, and destabilises VE 
cadherin junctions to induce microvascular permeability 183,184. Preventing Sema3a 
induced permeabilisation with Sema3a KO mice, reduced brain haemorrhage and 
ischemic damage in a stroke injury model 185.  
In the adult liver, Sema3e is transiently secreted by damaged hepatocytes, after an 
acute CCl4 injury. It binds to Plexin D1 on LSECs and causes them to contract. After 
the expression of Sema3a diminishes from its peak at 24 hours post injury, the LSECs 
expand and reform their radial pattern around the central vein, a process which is 
absent in mice with persistent Sema3e 186.  
Class 4 and 7 semaphorins promote angiogenesis, independent of VEGFR. Sema4d 
binds to Plexin B1 on endothelial cells to induce angiogenesis. In vitro, porcine aortic 
endothelial cells treated with Sema4d migrate and form tube like structures that mimic 
angiogenesis 187. With its pro-angiogenic roles, Sema4d facilitates tumour growth 
through angiogenesis. Treatment with a Sema4d blocking antibody reduced tumour 
growth, even in tumours resistant to anti-VEGF treatment 188.  
To conclude, semaphorins regulate axon outgrowth or retraction, and the direction of 
growing axons. These actions are not class specific. In contrast, semaphorins 
regulate vasculature growth and permeability in a class dependant manner. Class 3 
semaphorins prevent angiogenesis, repel the growing vasculature and induce 
vascular permeability by destabilising VE-cadherin. Sema4d and Sema7a promote 
angiogenesis, particularly during tumour development (Table 1. 2).  
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Table 1. 2 Roles of Semaphorins in the vasculature system 
 
Semaphorin  Receptor  Function Reference 
Sema3a 
(embryo) 





Integrin ανβ3 Vascular remodelling by inhibiting 





Plexin A1 Inhibits VEGF mediated 
angiogenesis, and induces 
microvascular permeability, by 
destabilising VE cadherin 
junctions  
183,184 
Sema3e Plexin D1 Repels Plexin D1 expressing 
endothelial cells, in a Nrp1 
independent mechanism 
182 
Sema3e Plexin D1 LSEC contraction during liver 
fibrosis 
186 
Sema5a Plexin B3 Angiogenesis in the cranium and 
tumours   
190 
Sema4d Plexin B1 Works in cohesion with VEGF to 
promote in vivo angiogenesis, 
during development and cancer 
187,188 
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Immune functions of semaphorins  
Semaphorins have diverse roles in the immune system and have been implicated in 
inflammatory diseases. The outcome of semaphorin signalling are defined by the 
receptor which receives the semaphorins and the location and cell type. For a 
summary see Table 1. 3.  
Sema4d (or CD100) was the first semaphorin to be discovered as an immune 
semaphorin 192. It has since been shown to have pro- and anti-inflammatory roles, and 
can act as a transmembrane protein or a secreted molecule 193. On human B cells, 
Sema4d binds to CD72 or Plexin B1 to promote proliferation and antibody generation 
193. Sema4d signalling in human monocytes promotes the secretion of the pro-
inflammatory cytokines TNFα and IL-6 194,195. Conversely, when neutrophil Sema4d 
binds to Plexin B2 on endothelial cells, neutrophil activation is prevented 196.  
Sema4a drives T helper 1 (TH1) differentiation and stabilises Tregs. DCs express 
Sema4a which binds to Tim-2 receptor on T cells, promoting T cell activation and 
proliferation 197. Sema4a is highly expressed by during T cell differentiation into TH1 
cells, suggesting Sema4a might act in an autocrine manner to promote T cell 
differentiation 193. In Sema4a KO mice, the differentiation of naive T cells to TH1 is 
impaired 197. The experimental autoimmune encephalomyelitis (EAE) mouse model is 
commonly used to study multiple sclerosis, an autoimmune disease driven by T cell 
inflammation 198. Blocking Sema4a with an antibody reduced the progression of EAE 
197, indicating Sema4a as a driver for T cell activation and inflammation.  
Sema4a also stabilises Tregs by binding to Nrp1 199. Treg expression of Sema4a is 
required to limit IL-13 secretion from TH2 cells, which drives pulmonary inflammation 
in an asthmatic model. Sema4a KO mice have increased IL-13, and reduced Tregs, but 
were rescued by treatment with recombinant Sema4a 200,201. Together, Sema4a 
promotes inflammation through the activation and differentiation of TH1 cells but 
reduces inflammation of TH2 cells through the action of Tregs.  
Class 3 semaphorins also modulate the actions of T cells. Sema3a binds to Plexin A4 
and Nrp1 to on T cells to prevent T cell priming and proliferation 202. Plexin 4A KO 
mice had exacerbated EAE inflammation 203, underscoring that Sema3a limits T cell 
activation. Conversely, Sema3a can indirectly activate T cells by promoting DC 
migration into the lymph nodes.  
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Activated dendritic cells (DCs) migrate from the peripheral tissues into the lymphoid 
organs, where they activate T cells. Lymphatic endothelial cells secreted Sema3a and 
binds to Plexin A1 and Nrp1 on the DC. This causes the phosphorylation of the myosin 
light chain within the DC, causing the DC to contract allowing it to squeeze through 
the small gaps between lymphatic endothelial cells. Genetic deletion of Sema3a or 
Plexin A1 impairs T cell activation in the lymph node 204.  
Class 3 semaphorins can cause macrophages to be pro-inflammatory. LPS challenge 
induces peritoneal macrophages to express Sema3a. Sema3a binds to Plexin A4, 
inducing optimal cytokine production in macrophages. Plexin A4 KO mice were 
protected from LPS induced septic shock, with improved survival from LPS treatment 
and polymicrobial peritonitis 205.  In dietary obesity, Sema3e is expressed by adipose 
tissue and chemoattracts macrophages to the tissue by binding to macrophage Plexin 
D1. This results in macrophage infiltration to the tissue and TNFα production. Plexin 
D1 knock down with a short hairpin RNA, prevented macrophage infiltration 206.  
Sema3e prevents inflammation by repelling neutrophils and preventing neutrophil 
cytokine secretion. In human neutrophils, Sema3e binds to Plexin D1 and acts a 
chemorepellent. Sema3e also prevents neutrophils migrating towards IL-8 207, a 
known neutrophil chemoattractant 52. Treating mice with Sema3e during an allergic 
asthma model, reduced the presence of neutrophils in the lungs 207.   
Sema6d is expressed by Natural Killer cells (NKs), T and B cells. The receptor for 
Sema6d is PlexinA1. Sema6d contributes to CD4+ T cell endogenous signalling. 
When Sema6d is received by DCs, they produce IL-12, a cytokine which promotes 
the development of TH1 T cells. Although no defect in T cell priming was detected in 
Sema6d KO mice 151,193,208.   
Overall, semaphorins promote and reduce inflammation, in a context dependant 
manner. The Sema3a- Plexin A4 axis prevents T cell activation but promotes 
macrophages to secrete pro-inflammatory cytokines. Sema3e-Plexin D1 signalling 
attracts macrophages but repels neutrophils. Sema4a promotes the production of TH1 
and also stabilises Treg cells to reduce pulmonary inflammation. Sema4d stimulated 
pro-inflammatory cytokine production from monocytes and antibody production from 
B cells. In APAP injury, the innate immune system is activated, and semaphorins may 
help modulate the immune system. In line with this, a microarray detected Sema4a 
and Sema4d expression by restorative Ly6Chi monocytes during APAP injury 48. 
Although the function of these semaphorins was not described.  
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Receptor  Immune cell  Function Reference 
Sema3a Plexin A4 
and Nrp1 




Sema3a Plexin A4 
and Nrp1 
DC DC contraction to 
facilitate migration 
into the lymph node  
204 
Sema3a Plexin A4  Macrophages  Pro-inflammatory 
cytokine production 
from macrophages 
during LPS challenge 
205 
Sema3e Plexin D1 Macrophages  Macrophage 
infiltration into 
adipose tissue and 
TNFα production 
206 
Sema3e Plexin D1 Neutrophil Neutrophil 
chemorepellent  
207 
Sema4a Tim-2 T cells Induces T cell 
proliferation and the 
production of IL-4 
and IL-17  
197 




Sema4d Plexin B1 B cells  Proliferation and 
antibody regeneration  
193 
Sema4d Plexin B2 Monocytes  Secretion of TNFα 
and IL-6 
194,195 
Sema4d Plexin B2 Neutrophils  Prevent neutrophil 
activation 
196 
Sema6d  Plexin A1 T cells Contributes to CD4+ 
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Semaphorin 7a 
Semaphorin 7a (Sema7a, CD108) is the only semaphorin in class 7, as it is the only 
semaphorin to be linked the membrane via a GPI linker. Sema7a is located on  human 
chromosome 15 (25kb) and mouse chromosome 9B (22kb), both comprise of 14 
exons 209. The Sema7a protein in human and mice is composed of 666 and 664 amino 
acids respectively, with 89.5% sequence identity 210. The mouse Sema7a consists of 
a short 19 amino acid GPI linker, attached to a 602 amino acid extracellular domain, 
which contains the sema, PSI and Ig domains of Sema7a. Contained within  
Sema7a’s sema domain, is a RGD motif that facilitates binding to Integrin α -β1 dimers 
158. 
Sema7a expression is promoted in human endothelial cells (HMECs) by IL-6 and 
TNFα signalling or during hypoxia by Hypoxia-Inducible Factor 1α (HIF-1α) 211,212. 
These factors converge on Nf-κB signalling to promote Sema7a expression. 
Furthermore, Sema7a promotes IL-6 and TNFα expression in HMECs, indicating it is 
part of a positive feedback loop 212. Sema7a expression can also be repressed by 
Est2-repressor factor (ERF) 213. 
The Sema7a receptors are Integrin β1 and Plexin C1. Both Sema7a and Plexin C1 
have large extracellular domains which are highly glycosylated 158. The cytoplasmic 
domain of Plexin C1 contains a Rho-GTPase binding domain (RBD), and two GAP 
domains to facilitate downstream signalling.  
Typically, Plexin C1 signalling prevents cell adhesion and spreading, by preventing 
cofilin activation. Cofilin depolymerises F-actin at the slow growing end of the actin 
filament, providing new actin monomers for actin polymerisation. Phosphorylation by 
LIMK I and II inhibits cofilin 214,215. Sema7a - Plexin C1 - LMKII signalling inactivates 
cofilin and prevents melanocyte and dendritic cell spreading and adhesion 216–219.  
SemaVa (or A39R) synthesised by the vaccinia small pox virus, and SemaVb (or 
AHV-1) produced by alcelaphine herpes virus type 1, are structural mimics of 
Sema7a, and bind to Plexin C1 154. A39R has evolved to bind to Plexin C1 with a 10 
fold higher affinity 158. A39R and AHV-1 bind to Plexin C1 expressed by dendritic cells. 
This prevents cytoskeleton rearrangements required to phagocytose the virus, 
allowing the virus to thwart the immune system 218,219. Like all semaphorins, Sema7a 
was originally identified as an axon guidance molecule, it has since been shown to 
have roles in the immune response, angiogenesis and cancer.  
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Figure 1. 6 The structure of the Sema7a / Plexin C1 complex 
 
Figure 1. 6 
Ribbon models of the Sema7a / PlexinC1 complex.  
Sema7a (blue and cyan) is bound to the plasma membrane by a GPI linker. It forms 
a homodimer via its PSI and sema domains to bind two Plexin C1 (pink and magenta) 
receptors. Binding depends on a ‘loop in groove’ conformation.  
Plexin C1 is bound to the membrane by Ig domains.  
Sema7a and Plexin C1 are highly glycosylated. The N-linked glycans are shown 
(green). 
 
Black lines, position of cell membranes. Front view (left) and side view (right). Sema, 
sema domain; PSI, plexin-semaphorin- integrin domain.  
 
Adapted from Liu, H. et al. (2010) ‘Structural Basis of Semaphorin-Plexin Recognition 
and Viral Mimicry from Sema7A and A39R Complexes with Plexin C1’, Cell. Elsevier 
Ltd, 142(5), pp. 749–761 158  
Chapter 1 - Introduction 
38 
Sema7a as an axon guidance molecule  
Sema7a was first identified to promote axon outgrowth in the olfactory bulb in vitro 
and in vivo 176. Sema7a binds to Integrin β1 on the neurone, which phosphorylates  
FAK and ERK to promote outgrowth 176. Sema7a also promotes outgrowth of cortex 
and dorsal root ganglia axons in vitro 176. Since this discovery, Sema7a has been 
shown to promote neurone branching, migration and integration in both embryos and 
adults. For a summary, see Table 1. 4.  
Sema7a promotes axon branching of thalamocortical neurones by Integrin β1 220. Or 
branching of dendrites and cortical neurones by Arg (Abelson family non receptor 
tyrosine kinases related gene) mediated cytoskeletal rearrangements 177. Conversely, 
when Sema7a binds to Plexin C1 on dopaminergic neurones it restricts neurone 
growth. Sema7a KO mice had more Plexin C1+ axons extending dorsally into the 
dorsal striatum 221.  
To restrict Sema7a signalling during neural development, Sema7a is cleaved into an 
inactivate form by Caspase 9. Caspase 9 is activated by apoptotic protease factor -1 
(Apaf-1) and is independent of apoptosis and Caspase 3 activation. It has been 
proposed that the Apaf-1 /Caspase 9 signalling is part of a bigger developmental 
program which regulates axon wiring in the olfactory bulb. Mice deficient for Apaf-1 or 
Caspase 9 had abnormal olfactory sensory neurone axon trajectories, maturation and 
synapse formation 222,223.  
In the adult central nervous system, Sema7a- PlexinC1 signalling prevents 
proliferation of neural progenitors. Neurogenesis in the adult is tightly controlled and 
restricted to the subventricular zone and the subgranular zone (SGZ) of the dentate 
gyrus. Early progenitors in the SGZ express Plexin C1, this binds Sema7a which 
represses progenitor proliferation. At subsequent stages of neurogenesis, the new 
neurones must integrate into the existing neural network. Sema7a binds to Integrin  
β1 to facilitate dendrite outgrowth, spine development and the functional integration 
of the new born neurone 178.  
Sema7a also precisely guides new sweet taste receptor cells (TRCs) in the taste buds 
to its corresponding sweet ganglion, which relays the information to the CNS. TRCs 
are replaced every 5 – 20 days, but their corresponding ganglions last a lifetime. 
Therefore, Sema7a is constantly acting in the tongue to integrate new TRCs. Bitter 
TRCs are guided by Sema3a.  Misexpression of Sema3a in sweet TRCs causes bitter 
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ganglion neurones to bind to sweet TRCs, with the ganglion responding to both the 
sweet and bitter stimuli. Repeating the experiments with Sema7a gave the same 
results but in the sweet pathway 224. Therefore, Sema3a and Sema7a work 
independently of each other. Presumably, this specificity is receptor dependant, but 
receptor expression was not examined. It was not shown if Sema7a was secreted or 
membrane bound, which may also determine specificity. 
Following spinal cord injury, astrocytes become activated express Sema7a. The end 
feet of these astrocytes which highly express Sema7a bind to Integrin α1β1 on 
macrophages. It has been proposed that the activated macrophages and astrocytes 
prolong injury and fibrosis, to form a scar which prevent neurone regeneration 225.  
Sema7a directs Gonadotropin-releasing hormone (GnRH) neurones during 
development and regulate their actions in the adult. GnRH neurones are the master 
regulators of reproductive functions. They secrete GnRH into the bloodstream which 
carries GnRH to the anterior pituitary gland. This causes the release of reproductive 
hormones into the circulation including testosterone, luteinising hormone and follicle 
stimulating hormone. They also integrate olfactory sensory signals such as 
pheromones, to elicit attraction. The development and migration of GnRH neurones 
is tightly controlled by spatial-temporal expression of growth factors and adhesion 
molecules. In humans, defects in this system leads to hypogonadotropic 
hypogonadism (HH), a condition characterised by the reduction or failure of sexual 
competence 226. Patients with HH have mutations in the SEMA7A gene 227.  
Sema7a guides GnRH migration during development. GnRH neurones originate at 
the nasal placode. At the start of their migration, GnRH neurones only express Integrin 
β1. However, when the GnRH neurones enter the ventral forebrain, they only express 
Plexin C1 which hinders migration 179. This switch in receptor expression may be 
required for the precise guidance of GnRH neurones to their final location. 
The correct wiring of the GnRH neurones is required for reproduction in adult mice. 
Sema7a KO mice have less GnRH neurones and reduced fertility. Males have 
reduced testicular size and lower testosterone levels than WT mice. When exposed 
to male pheromones, the male Sema7a KO mice elicited the same attractional 
response, mediated by c-fos signalling, as female mice. Testosterone administration 
restored the typical male pattern response to male pheromones. These results imply 
the correct formation of GnRH neurones and testosterone circulation are required for 
male reproduction 180. 
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In female adult mice, progesterone causes cyclic Sema7a expression in tanycytes. 
Tanycytes cover the pituitary portal vessels to insulate them from GnRH nerve 
terminals during dioestrus. Progesterone binds to its receptor on the tanycyte which 
promotes TGF β expression. TGF-β upregulates Sema7a in the tanycyte. Autocrine - 
Sema7a – Integrin β1 – pFAK – pERK – pAKT signalling promotes the outgrowth and 
elongation of the tanycyte, so that it covers the portal vessel. In addition, Sema7a is 
secreted from the tanycyte, and binds to Plexin C1 expressed on GnRH neurones. 
Plexin C1 – pFAK – pERK causes GnRH neurone retraction. These mechanisms 
together prevent GnRH neurones from signalling into the vasculature at peak 
progesterone levels. Mice deficient for Plexin C1 or Sema7a have abnormal GnRH 
innervation, ovulation and cyclic fertility 227. 
In summary, Sema7a controls axon outgrowth and contraction by binding to 
structurally distinct receptors. When Sema7a binds to neural Integrin β1, FAK and 
ERK signalling activates axon outgrowth. When Sema7a binds to neural Plexin C1 
cofilin becomes inhibited; reducing migration and proliferation during neurogenesis, 
or neurone contraction. Sema7a receptor expression is often spatially and temporally 
controlled. This tight regulation is crucial for the correct neuronal wiring. 
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Table 1. 4 Roles of Sema7a in the nervous system 
Receiving 




Adult de novo 
neurones  
Integrin β1 
Dendrite outgrowth and 
functional integration of new 






Prevents proliferation of 
neural progenitors 
178 
Cortex and dorsal 
root ganglia 
axons 
Integrin β1 Axon outgrowth 176 
Dendrites and 
cortical neurones  
? 
Axon branching, mediated by 




Plexin C1 Restriction of neurone growth  221 
GnRH neurones 
Integrin β1 at 
the nasal 
placode  




Neurone migration 179 
GnRH neurones Plexin C1 
Neurone contraction during 
dioestrus, to prevent aberrant 
hormonal signalling  
227 
Olfactory bulb Integrin β1 
Axon outgrowth,  
By pERK-pFAK signalling  
176 
Tanycyte Integrin β1 
Tanycyte extension during 
dioestrus, to prevent aberrant 





Integration of new sweet 





Integrin β1 Axon branching 220 
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Roles of Sema7a in the immune system  
Sema7a has pro- and anti-inflammatory roles in the immune system. It is expressed 
by activated dendritic cells, T cells and macrophages; it attracts dendritic cells, 
monocytes and macrophages 228–230; and promotes monocyte activation. Most of the 
actions of Sema7a converge on the pFAK – pERK signalling pathway. Like all 
semaphorins, the receptor which receives Sema7a defines the overall outcome. For 
a summary see Table 1. 5. 
Sema7a is expressed by activated T cells. Sema7a on T cells binds to Integrin α1β1 
on macrophages to form a stable immunological synapse. This binding induces 
macrophage IL-6 and TNFα secretion (Figure 1. 7). This Sema7a expression on 
activated T cells was crucial for the effector phase of T cell mediated inflammation in 
vivo, as Sema7a KO mice were resistant to EAE 231. 
In rheumatoid arthritis, Sema7a forms a positive feedback loop to promote 
inflammation. Synovial monocytes secrete ADAM- 17, which cleaves Sema7a from 
the cell surface of T cells. This shed Sema7a promotes the differentiation of TH1 and 
TH17 cells. Shed Sema7a also binds to Integrin β1 on monocytes in the arthritic joint, 
this induces the monocytes to secrete pro-inflammatory IL-6, TNFα and more ADAM-
17, completing the pro-inflammatory feedback loop. In rheumatoid arthritis patients, 
Sema7a in the synovial fluid and serum correlates with the degree of arthritis. Blocking 
Sema7a in mice reduced inflammation in the joint in the collagen induced arthritis 
model 232. 
In human blood, Sema7a is expressed on human platelets 233 and erythrocytes where 
it carries John Milton Hagen (JMH) group antigens 234. In vitro studies suggest the 
JMH antigens activate T cell proliferation and secretion of the pro-inflammatory 
cytokines IL-8 and IFN-γ 235.   
In addition to the pro-inflammatory roles, Sema7a can have anti-inflammatory roles 
on macrophages. In a model of dextran sodium sulfate (DSS)-induced colitis, 
intestinal epithelial cells express Sema7a which binds directly to Integrin αvβ1 on 
intestinal macrophages. This induces the macrophages secrete the cytokine IL-10 
and reduces inflammation and injury (Figure 1. 7). Furthermore, Sema7a KO mice 
had severely reduced survival  compared to WT mice 236. 
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Figure 1. 7 Sema7a has pro- and anti-inflammatory effects on 
macrophages 
 
Figure 1. 7 
Left: Sema7a on activated T cells binds to Integrin α1β1 inflammatory macrophages 
to promote the secretion of IL-6 and TNFα. 
Right: Intestinal epithelial cells express Sema7a, which binds to Integrin αvβ1 on 
intestinal macrophages to promote the secretion of the anti-inflammatory cytokine IL-
10 
 
CX3CR1, CX3 C-chemokine receptor 1; TRC, T cell receptor. 
 
Adapted from: Kumanogoh, A. and Kikutani, H. (2013) ‘Immunological functions of 
the neuropilins and plexins as receptors for semaphorins.’, Nature reviews. 
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Sema7a also facilitates the transmigration of PMNs across an endothelial layer. 
Treating HMECs with a siRNA to knock down Sema7a reduced PMN transmigration, 
whereas HMEC transfection with a viral promoter enhanced transmigration 211. 
Sema7a KO mice had less myeloperoxidase (MPO) activity in the lungs after hypoxia, 
or LPS inhalation. Bone marrow transfer experiments indicated the effects are not 
mediated by immune cells 211,212.  
Follow up studies indicated that Plexin C1 on PMNs facilitates their transmigration 
into the lung during forced ventilation pulmonary injury. Plexin C1 KO mice, or WT 
mice with a Plexin C1 KO bone marrow transplant, had a reduced number of 
infiltrating cells in the bronchoalveolar lavage (BAL), and a lower expression of: IL-1β, 
TNFα, IL-6 and CXCL1 237.  
The same lab demonstrated Plexin C1 KO mice have less inflammation in a zymosan-
induced peritonitis model. Again, Plexin C1 expression on immune cells binds to 
Sema7a to facilitate infiltration and inflammation in the peritoneum 238. However, they 
did not show where Sema7a was expressed in relation to the peritoneum or 
characterise the peritoneal exudate cells.  
Sema7a is highly upregulated on mature DCs but is virtually absent on resting DCs. 
In Sema7a KO mice, DCs mature but have less actin based protrusions, lower 
adherence and cannot migrate in response to CCL21, a DC chemoattractant 230.  
Sema7a prevents DC phagocytosis. The herpes virus AHV-1 and the vaccinia 
poxvirus (A39R) produce a structural mimic of Sema7a, which binds to Plexin C1 
expressed by DCs 218,219. Sema7a - Plexin C1 signalling inhibits cofilin and prevents 
phosphorylation of FAK. This prevents the cytoskeletal rearrangements required for 
the DCs to adhere and to form the cellular protrusions required to perform 
phagocytosis of the virus. Thus the virus can thwart the immune system 218,219,239. 
Overall, Sema7a activates T cells, facilitates neutrophil migration across an 
endothelial barrier to promote acute pulmonary inflammation, and reduced DC 
adhesion, migration and phagocytosis. Sema7a also regulates if macrophages 
secrete pro- or anti-inflammatory cytokines, in a receptor dependant manner. If 
macrophages use Integrin α1β1 to bind to Sema7a on T cells, the macrophage 
secretes IL-6 and TNFα. Conversely, when macrophages use Integrin αvβ1 as the 
receptor for Sema7a expressed on intestinal epithelial cells, the macrophage secretes 
IL-10 (Figure 1. 7).   
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Roles of Sema7a in cancer 
Sema7a expression in breast cancer patients is associated with a poor prognosis.  
Sema7a is promotes mammary tumour cell motility and invasion via Integrin  β1 240. It 
also facilitates angiogenesis in mammary tumours 191. Inhibiting Sema7a with a short 
hairpin reduced tumour growth in vivo 241.  
Sema7a is expressed in human oral squamous cell carcinoma. In vitro, Sema7a -
pERK-pAKT signalling promotes cell growth and proliferation in human oral 
squamous cell carcinoma derived cells lines. In addition, Sema7a induced the 
expression of MMP2 and 9 which are required to breakdown the ECM during invasion. 
The authors also implied these effects were mediated by TGFβ signalling 242. It would 
be interesting to see if blocking Sema7a or TGFβ reduces oral squamous cell tumour 
growth in vivo.  
Together, Sema7a promotes tumour growth by promoting angiogenesis and 
metastasis. Sema7a often induces contrasting affects through its receptors Integrin 
β1 or Plexin C1. In breast cancer Integrin  β1 promotes cell invasion 240. In melanoma, 
Plexin C1 is expressed in primary tumours, and inhibits melanocyte proliferation and 
migration. Plexin C1 is downregulated during metastasis, which allows melanoma 
migration and proliferation, with depth of invasion inversely correlating with Plexin C1 
expression 217,243,244. Futures studies could examine if treatment with Plexin C1 
prevents Sema7a induced metastasis.  
 
Roles of Sema7a in the liver and TGFβ mediated lung fibrosis 
Very little known about the roles of Sema7a in the liver. Previous to this project 
Sema7a has been studied in the context of ischemia reperfusion injury 245 and chronic 
liver injury 246. In human liver samples, Sema7a is upregulated with either alcoholics 
liver disease or hepatitis C virus, possibly to promote fibrosis and inflammation 246.  
In a mouse model of chronic CCl4 and bile duct ligation injury, Sema7a is expressed 
by the hepatic stellate cells (HSCs), and is upregulated with its receptor Integrin β1 
(but not Plexin C1). Sema7a KO mice display less fibrosis and infiltration of F4/80+ 
macrophages than WT mice after CCl4 injection, with a down regulation of IL-6 and 
MCP-1. The authors indicate that these effects could be mediated through the TGFβ 
-pERK- pAKT pathway 246. However, they did not examine TGFβ signalling in vivo, or 
if the Sema7a KO mice had less activated HSCs.  
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In a model of ischemia reperfusion injury, Plexin C1 KO mice had less infiltrating 
PMNs lower serum ALT, AST, TNFα and IL-6. Rosenberger et al. demonstrate this is 
due to Plexin C1 expression on the immune cells through a bone marrow transfer. 
The effects are mediated by Sema7a, as blocking the Sema7a – Plexin C1 interaction 
reduced the measured injury parameters 245. However, there was very little necrosis 
in their model, reflected by the mild raise in ALT. The authors did not show where the 
Sema7a was being expressed, or if the PMNs were Ly6G+ neutrophils as they 
claimed, other immune cells were not examined.  
Other studies from the Rosenberger lab suggest Sema7a promotes pulmonary 
inflammation, by enabling Plexin C1 expressed by PMNs to bind onto endothelial 
Sema7a, enabling PMNs to transmigrate into the lungs 211,237. Sema7a KO mice had 
less pulmonary inflammation after LPS inhalation 212 and hypoxia 211. Plexin C1 KO 
mice, or blocking the Sema7a – Plexin C1 interaction, reduced PMN infiltration into 
the lungs a high pressure ventilation model 237 and into the peritoneum during 
zymosan A induced peritonitis 238. Together these studies show that Sema7a 
promotes inflammation by facilitating PMN endothelial transmigration.  
TGFβ is a critical mediator of bleomycin induced pulmonary fibrosis and is enhanced 
by Sema7a. To study the underlying mechanism, mice with pulmonary transgenic 
TGFβ expression (TGFβ+) were used. TGFβ+ mice had a higher expression of 
Sema7a, Integrin β1 and Plexin C1, than WT mice. Expression of Sema7a enhanced 
TGFβ induced cell death, myofibroblast accumulation, collagen deposition and ECM 
secretion, compared to TGFβ+ Sema7a KO mice. TGFβ induced injury was 
independent of the canonical SMAD2/3 signalling but required pPI3K – pAKT 
(phosphoinositide 3-kinase (PI3K) – protein kinase B (PKB, AKT)). The authors 
claimed there was no difference between pulmonary inflammation in Sema7a KO 
mice and Sema7a WT mice, but this data was not shown 247. The location of TGFβ 
induced Sema7a expression in the lung was not depicted. Together, this data shows 
Sema7a enhances TGFβ induced fibrosis by enhancing cells death and upregulating 
ECM synthesis.  
Overall, Sema7a signalling promotes TGFβ signalling to promote fibrosis in both lung 
and in the liver. In pulmonary fibrosis, TGFβ -Sema7a signalling did not promote 
inflammation.  However, in chronic liver injury, Sema7a KO mice had less CD45+ cells 
and F4/80+ cells infiltrating the liver this was associated with less IL-6 and MCP-1 
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signalling. In other in vitro and in vivo models, Sema7a promotes inflammation by 
activation of T cells, neutrophil transmigration, monocyte chemoattraction and 
macrophage activation. Sema7a may also be part of a positive feedback loop with IL-
6 and TNFα. Sema7a also has anti-inflammatory roles, when macrophages bind 
Sema7a through their Integrin ανβ1 receptor, they produce IL-10.  
 
The APAP mouse model  
The APAP mouse model closely mimics APAP overdose in human patients 3. To study 
the role of Sema7a during APAP injury and recovery, I used a 350 mg/kg mouse 
model using 9-12 week old male C57Bl6/J mice, or aged matched Sema7a KO male 
mice which are also on the C57Bl6/J background 176. Mice were starved for 12 hours 
before administering APAP intraperitoneally. This model was chosen for numerous 
reasons, discussed below. 
GSH is an antioxidant crucial for the detoxification of APAP (see Figure 1. 1) 3,4,14. 
GSH is readily synthesised from: L-cysteine, L-glutamic acid and glycine obtained 
from the diet 248. Starving mice for 12 hours prior to APAP injection normalises 
hepatocyte stores of GSH to basal levels. This sensitises the mice to APAP and 
reduces variability.  
Female mice are less susceptible to APAP injury. 2 hours after APAP administration, 
both male and female mice have increased ALT, depleted GSH stores 249,250, protein 
adduct formation and activation of the JNK pathway 249,251. However, 4 hours after 
APAP administration, female mice begin to restore their GSH stores 249,250, leading to 
lower ALTs and necrosis 249–251 and faster recovery compared to male mice 249,250.  
Immature 3 week old mice are also more susceptible to APAP injury, displaying higher 
ALTs and necrosis compared to 8 – 10 week old sex matched mice 251. To study 
APAP injury in adults we used 9- 12 week old male mice. 
The Sema7a KO mice obtained from Jackson labs are on a C57BL6/J background 
176. To match this background strain, I used C57BL6/J mice as WT controls. These 
C57Bl6/J mice have a moderate response to APAP injury. Harrill et al. treated 36 
different mice strains with 300 mg/kg APAP for 24 hours. Necrosis, ALT and GSH 
depletion all varied, with necrosis ranging from 0-80% with correlating ALT 252. The 
C57Bl6/J strain were median responders with 40% necrosis and around 2000 U/L 
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ALT 252. The C57Bl6/J (background) strain is therefore suitable for this moderate 
APAP study as adverse effects will be limited, and we can investigate the role of 
Sema7a during APAP injury and recovery.  
To study APAP injury and recovery, the dose must give reproducible levels of 
necrosis, injury and inflammation but low enough to allow recovery. Previously, our 
lab have used a 350 mg/kg APAP dose in C57Bl6/J mice to study APAP injury 32. The 
mice tolerated this dose well with reproducible levels of necrosis. Doses higher than 
350 mg/kg may cause too severe an injury in the mice and prevent recovery 147, or be 
lethal 23,53. Therefore, I used a 350 mg/kg APAP dose in C57Bl6/J male mice to study 
APAP injury and recovery. 
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Summary  
The only viable therapy for APAP overdose, NAC, is only effective in the first 12 hours 
following APAP ingestion. Outside of this window, patients require a liver 
transplantation. Patients with a moderate overdose can spontaneously recover 3. 
Understanding these mechanisms will lead to novel therapies.   
The innate immune system is present in both the injury and recovery phases of APAP 
injury. Initially, the innate immune system promotes APAP injury. During recovery, the 
macrophages switch to a restorative phenotype which phagocytose cellular debris, 
secrete anti-inflammatory cytokines such as IL-10, to reduce inflammation, and TNFα 
and IL-6 to prime the remaining hepatocytes to proliferate 4,35. Macrophages are also 
responsible for secreting Wnt and TGFβ, to induce regeneration or senescence 
respectively 144,150. Novel therapies may influence the immune system towards a 
restorative phenotype.  
Sema7a has diverse roles in the immune system. It can act as a chemoattractant for 
dendritic cells, monocytes and macrophages 228–230; activate T cells and macrophages   
225,232,235; and facilitate PMN endothelial transmigration into the lungs 211,212,237. During 
liver fibrosis, Sema7a KO mice have less inflammation compared to WT mice 212,246. 
Sema7a can also modulate macrophage secretion, depending on which receptor 
receives it. When macrophages bind to Sema7a on intestinal epithelial cells through 
Integrin αvβ1, macrophages secrete IL-10, an anti- inflammatory cytokine 236. 
Conversely, when Sema7a expressed on activated T cells binds to Integrin α1β1 on 
macrophages the proinflammatory cytokines IL-6 and TNFα are secreted 231. To date, 
there are more papers indicating Sema7a promotes inflammation than reduces 
inflammation. I therefore hypothesise Sema7a promotes inflammation during APAP 
injury. 
Sema7a can also enhance TGFβ signalling during liver and lung fibrosis 246,247. During 
APAP injury, macrophages secrete TGFβ to induce cell cycle arrest, marked by p21 
expression 144. Furthermore, Sema7a may be able to act as a barrier to APAP induced 
necrosis through modulation of the cytoskeleton.   
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Hypothesis and Aims  
Hypothesis: Sema7a promotes injury and inflammation during APAP injury 
Aims:  
1. Examine if Sema7a+ hepatocytes form a boundary to limit the spread of cell 
death 
2. Examine if Sema7a promotes p21 expression in hepatocytes 
3. Define if Sema7a delays proliferation during recovery from APAP injury 
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In vivo experiments  
Animal models 
The animals used in this study are male C57BL6/J or Sema7a KO mice, which were 
purchased from the Jackson Laboratory and bred on a C57BL6/J background. 
Animals were housed in a specific pathogen-free environment and kept under 
standard conditions with a 12 h day/night cycle and access to food and water ad 
libitum. All animal experiments were carried out under procedural guidelines, severity 
protocols and with ethical permission from the University of Edinburgh Animal Welfare 
and Ethical Review Body (AWERB) and the Home Office (UK), licence numbers 
70/7847 and P231C5F81.  
Genotyping 
Genotyping was performed by the commercial Transnetyx service. Mice were either 
homozygous knockouts for Sema7a-/- or homozygous WT (Sema7aWT/WT).  
For in house genotyping, ear clips were digested overnight with proteinase K in a 
shaking water bath at 55 °C. After heat inactivation at 95 °C, digests were centrifuged 
(10 min, 18,000 x g) and the supernatant collected. Genomic PCR was run using 
OneTaq DNA Polymerase kit (Biolabs) with 0.5 µM primers (Sigma): Common forward 
primer (GCA CAG CCC TGT AGT GTC TC), WT reverse primer (AGC CTC TTC ACT 
GCT CCA C), Sema7a KO reverse primer (CCG GGG GAT CCA CTA GTT CT). PCR 
products were run in a 0.5x TBE 2% agarose gel in with a 1 KB ladder. Bands were 
detected at: WT 182bp and Sema7a KO 249bp.  
APAP experiments  
9-12 week old male mice were fasted for 12 hours then intra-peritoneally (i.p.) injected 
with 350 mg/kg paracetamol (Acetaminophen, APAP (Sigma)) or sterile saline by 
injection. Mice were kept in a heat box at 28 °C, and closely monitored for the duration 
of the experiment. To measure proliferation, 100 µL 1 mg/ml 5-bromo-2'-deoxyuridine 
(BrdU, Sigma) was injected i.p. 1 hour before culling.  
Mice were humanely euthanised according to UK Home Office regulations. Blood was 
collected by cardiac puncture, clotted overnight at 4°C then centrifuged for 10 min, 
8,000 x g at 4 °C and serum removed. 
Chapter 2 – Materials and Methods  
55 
 
Livers were perfused via the inferior vena cava (IVC) with Phosphate Buffered Saline 
Solution (PBS). Samples of liver were embedded in optimal cutting temperature 
compound (OCT), or snap frozen, and stored at -80 °C. Liver, kidney, spleen and 
intestine were collected and fixed in formalin overnight, and paraffin embedded 
(FFPE). Embedding in paraffin blocks was performed by Shared University Research 
Facilities (SuRF) Histology, Queen’s Medical Research Institute (QMRI), University of 
Edinburgh.  
Serum liver function tests 
Serum analysis was performed by Dr Forbes Howie at the QMRI, University of 
Edinburgh. Serum Albumin, bilirubin, alanine aminotransferase (ALT), aspartate 
transaminase (AST), alkaline phosphatase (ALP) and glutamate dehydrogenase 
(GLDH) were measured in non-haemolysed serum samples according to 
manufacturer instructions (Alpha Laboratories). Kit instruction were adapted for use 
in the Cobas Fara or Cobas Mira analyser (Roche).  
In vivo phagocytosis assay  
100 µL PKH26PCL (10 µM in Diluent B; Sigma) or vehicle control was injected 
intravenously via the tail vein, 4 hours post APAP injection. Mice were sacrificed at 
12 h post APAP injection. For the 24 hours in vivo phagocytosis experiments, 
PKH26PCL was injected at 8 hours post APAP injections, and mice sacrificed at 24 
hours post APAP injections. Peripheral and cardiac blood, peritoneal lavage and liver 
tissue were collected for flow cytometry analysis (see ‘Tissue collection and staining 
for flow cytometry’)  
Tissue collection and staining for flow cytometry 
Peritoneal lavage collection and staining for flow cytometry   
The peritoneal cavity was washed with 1 ml PBS. The collected peritoneal lavage was 
centrifuged for 5 min, 300 x g at 4°C. The supernatant was stored at -80°C. The pellet 
was resuspended in PBS, filtered, and stained with L/D for 40 min at 4 °C. After 
blocking for 20 min 4 °C in 10 % mouse serum, samples were then stained for 20 min 
at 4°C with the ‘In vivo phagocytosis Flow Cytometry Panel for Peritoneal Lavage’. 
Cells were fixed and lysed with 200 µL 1x BD Phosflow Lyse/ Fix (BD Biosciences) 
for 15 min at RT.  Cells were kept in Fluorescent Activated Cell Sorting (FACS) wash 
(1%FCS, 2.5 mM Ethylenediaminetetraacetic acid (EDTA) in PBS). 
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Liver digestion and non-parenchymal cell isolation and staining for 
flow cytometry 
Isolation of hepatic non-parenchymal cells (NPCs), labelling and flow cytometry was 
performed by Jennifer Cartwright. The liver digestion protocol was based on the 
protocol previously published by Lynch et al 253. The staining protocol followed 
Campana’s 72 protocol, with minor modifications.  
0.5 g of perfused liver from the central lobe was mechanically homogenised with a 
scalpel, followed by enzymatic digestion: collagenase V (0.8 mg/ml; Sigma-Aldrich), 
collagenase D (0.625 mg/ml; Roche), dispase (1 mg/ml, Gibco), and DNase (30 
µg/ml, Roche) in RPMI 1640, for 20 min at 37 °C in a shaking incubator, with vigorous 
shaking every 5 min.  
Liver digests were filtered through a 100 μm filter, and enzymes inactivated by adding 
30 ml cold medium (RPMI,10% FCS, 4 °C). The NPC fraction of the liver was 
harvested by two centrifugations in 30 ml cold medium at 300 x g for 5 min at 4 °C, 
discarding the supernatant each time.  
NPC suspensions were passed through a 40 μm filter, stained with toluidine blue dye 
and live cells were counted with a BioRad analyser, then diluted to 7,000,000 cells/ml. 
NPCs were washed in PBS and stained with Live/Dead (L/D) for 40 min at RT, then 
blocked in 10% mouse serum. 1,000,000 cells/sample were stained with the Liver 
PKH Flow Cytometry Panel (Table 2. 6) for 40 min Room Temperature (RT) followed 
by two FACS buffer washes.  
Red blood cells were lysed, and NPCs were fixed with 1x BD Phosflow Lyse/ Fix (BD 
Biosciences) for 10 min at 4 °C. The NPC suspension was washed and kept in FACS 
buffer.   
Calculating the absolute number of NPCs per gram of liver 
The total number of live cells in the whole liver digest volume was calculated and 
divided by the weight of the liver lobe before digestion, providing the number of live 
cells per gram of liver. The specific NPC population count (selected in Figure 2. 10) 
was made into a percentage of the live cells count, as analysed by the BD LSR 
Fortessa SORP FACS. This was multiplied by the number of live cells per gram of 
liver, giving the absolute number of a specific NPC population per gram of liver. 
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Peripheral blood collection and staining for flow cytometry 
Peripheral blood was collected into anticoagulating EDTA tubes from untreated WT 
or Sema7a KO mice through a tail nick. Or from the IVC. of mice which had been 
starved for 12 hours prior to i.p. injection of saline, then left for 12 h before culling, to 
mimic an APAP experiment. 25 µL blood was stained for 20 min at RT in the required 
antibody cocktail (see ‘Flow cytometry on peripheral blood’).  
Cells were washed with PBS and stained with 1:1,000 Live/ Dead (L/D) e780 (L10120, 
Life technologies) for 40 min, followed by fixation and lysis with 200 µL BD Phosflow 
Lyse/ Fix (BD Biosciences) for 15 min RT. Cells were kept in FACS wash.   
 
Bone Marrow Derived Macrophage in vitro experiments  
Bone marrow derived macrophage (BMDM) isolation  
The femurs of 10-12 week old C57BL6/J males were flushed with BMDM medium 
(DMEM/F12 (gibco), 10% FCS, 1% L-Glut, 1% Penicillin/streptomycin (P/S) and 50 
ng/ml Macrophage colony stimulating factor-1 (M-CSF, Miltenyi Biotec)), to collect the 
bone marrow, which was cultured at a single cell suspension in Ultralow attachment 
flasks (Corning). BMDMs were kept for a week in BMDM medium. 
Apoptotic thymocytes (ApopTs) 
Thymi were isolated from 6 week old mice, pushed through a 100 μm filter, and then 
filtered through a 40 μm filter. Thymocytes were cultured at a single cell suspension 
in 10% FBS, 1:100 P/S, RPMI (gibco) for 2 h before adding 10 µg/ml hydrocortisone 
(Sigma) for 16 h, to make them apoptotic.  
BMDM staining for flow cytometry   
BMDMs were stained with 1:1,000 L/D, then blocked in 10% FCS, PBS for 30 min, 
followed by a 20 min stain with the required antibody cocktail.   
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Flow cytometry on BMDMs 
Compensation for all experiments was set up using eBioscience Ultracomp eBeads.  
BMDM phagocytosis assay 
ApopTs pre-stained with CMTMR (Life technologies) were cultured with BMDMs in 
BMDM medium for 1 or 2 hours. BMDMs were stained with 1:1,000 L/D, and CD11b 
BV650 (Biolegend). The experiment was run in triplicate. Phagocytosis was assessed 
on the ACEA Biosciences Novocyte and analysed (Figure 2. 1) using NovoExpress 
1.2.4 (ACEA Biosciences).  
Sema7a receptor expression on BMDMs 
BMDMs were incubated overnight with rmSema7a and integrin staining assessed by 
flow cytometry (Table 2. 1) and assessed using a BD LSR Fortessa SORP FACS. 
Results were analysed using FlowJo v10.0.07.2. For gating see Figure 2. 2.  
 
Table 2. 1 Sema7a receptor panel on BMDMs 
 
 
Marker Fluorophore Clone Channel Manufacturer Staining Conc. 
CD11b BV650 M1/70 V675/30 Biolegend 1:100 
Integrin α1 APC HMα1 R675/30 Biolegend 1:100 
Integrin αʋ PE RMV-7 B572/28 Biolegend 1:100 
L/D e780  R780/60 Life technologies 1:1,000 
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Figure 2. 1 Gating strategy to analyse BMDM phagocytosis 
 
Figure 2. 1  
BMDMs were isolated from healthy 10-12 week old WT and Sema7a KO mice. 
BMDMs were fed apoptotic thymocytes, pre-labelled with CMTMR, for 1 or 2 hours. 
BMDMs which have phagocytosed apoptotic T cells will be CD11b+ CMTMR+ 
The gating strategy to detect CD11b+ CMTMR+ BMDMs is as follows: 
A) Cells were gated for size, singlets, L/D -, and CD11b+. This CD11b positive 
population was assessed for CMTMR 
B) Gates were set using single colour controls, or unstained sample for CD11b. 
  
Chapter 2 – Materials and Methods  
60 
 
Figure 2. 2 Gating strategy to analyse Sema7a receptors on BMDMs 
 
Figure 2. 2 
BMDMs were isolated from healthy 10-12 week old WT and Sema7a KO mice, and 
assessed for the expression of: Integrin α1 and αν, the Sema7a receptors. To 
examine rector expression, the following gating strategy was used: 
A) BMDMs were gated for size, singlets, DAPI negative (live), and CD11b+. This 
CD11b+ population was assessed for Integrin α1 and αʋ expression.  
B) Gates in (A) were set using single colour controls, as indicated.   
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Flow cytometry on peripheral blood  
Peripheral blood was prepared as previously described (‘Peripheral blood collection 
and staining for flow cytometry’). Cells were gated on size, singlets, live, CD45+, and 
Lineage- (B and T cell exclusion). For this initial gating see Figure 2. 3.  
Figure 2. 3 Selecting live, CD45+, lineage- cells in peripheral blood 
 
Figure 2. 3 
Mouse blood was collected from healthy, and APAP injured, WT and Sema7a KO 
mice. CD45+ leukocytes were selected as follows:  
A) Cells in peripheral blood were gated for size, singlets, live (L/D-), CD45+, and 
Lineage- (B and T cell exclusion).  
B) FMOs were used to set the gates for L/D, CD45 and Lineage, as indicated.  
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Sema7a receptor expression on neutrophils 
Peripheral blood was stained for the ‘Sema7a receptor panel on peripheral blood‘(see  
Table 2. 2) and analysed on the Novocyte with NovoExpress 1.2.4 software (ACEA 
Biosciences). Cells were gated for size, singlets, L/D-, CD45+, and Ly6G+. The 
expression of the Sema7a receptors: Integrinα1 and Integrinαʋ, Plexin C1 were 
analysed on both the CD45+ population and the CD45+ Ly6G+ population (see Figure 
2. 4). 
 
 Table 2. 2 Sema7a receptor panel on peripheral blood  
Marker Fluorophore Clone Channel Manufacturer Staining 
Conc. 
CD11b BV650 M1/70 V675/30 Biolegend 1:100 
Integrin α1 APC HMα1 R675/30 Biolegend 1:100 
Integrin αʋ PE RMV-7 B572/28 Biolegend 1:100 
Plexin C1 Alexa 488 -  B530/30 R&D 1:50 
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Figure 2. 4 Gating for the Sema7a receptors on neutrophils 
 
Figure 2. 4 
Peripheral blood was isolated from healthy adult male WT and Sema7a KO mice. 
single, live, Lineage-, CD45+ leukocytes were selected as in Figure 2. 3.  
A) Ly6G+ cells were selected (right) from the CD45+ population. The gate was 
set using the FMO (left) 
B) To analyse expression of the Sema7a receptors on neutrophils, gates were 
set using the FMO (yellow). WT blood (cyan), Sema7a KO blood (magenta). 
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Numbers of neutrophils and monocytes in peripheral blood 
Peripheral blood was stained with the panel in Table 2. 3, and analysed on the 
Novocyte, (ACEA Biosciences), which can give the absolute count of cell populations.  
Data was quantified using NovoExpress 1.2.4 software (ACEA Biosciences). Cells 
were pre-gated as in Figure 2. 3, then neutrophils and monocytes were selected (see 
Figure 2. 5). 
 
Table 2. 3 Neutrophil and monocyte panel for peripheral blood 
Marker Fluorophore Clone Channel Manufacturer Staining 
Conc. 
CD45  BV650 30-F11 V675/30 Biolegend 1:100 
CD11b  Alexa Flour 
488 
M1/70 B530/30 eBioscience  1:100 
CD115 APC AFS98 R675/30 Biolegend 1:100 
Ly6G PE 1A8 B572/28 Biolegend 1:100 
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Figure 2. 5 Gating strategy to examine the presence of neutrophils and 
monocytes in blood 
 
Figure 2. 5 
Peripheral blood was isolated from 10-12 week old male WT and Sema7a KO mice. 
the neutrophil and monocyte population sin the blood was then examined using the 
following gating strategy.  
A) Cells were pre gated on: size, singlets, live, CD45+, and Lineage-. Ly6G+ 
neutrophils and Ly6G- monocytes were selected (left). Monocytes were further 
subdivided in to Ly6Chi and Ly6C lo (right).  
B) Gates were set using FMOs for Ly6G (left) and Ly6C (right). 
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Flow cytometry analysis for in vivo phagocytosis 
Peripheral blood, peritoneal lavage and liver was taken and stained as above. All 
tissues were analysed on the BD LSR Fortessa SORP FACS. Results were analysed 
using FlowJo v10.0.07.2 (Tree Star).  
Peripheral Blood 
30 µL blood was stained with the ‘PKH Blood Flow Cytometry Panel’ (see Table 2. 4), 
or FMO equivalent. Neutrophils and monocytes were selected as in Figure 2. 5.  
Phagocytosis (PKH+) was analysed using the gating strategy in Figure 2. 6.  
 
Table 2. 4 In vivo phagocytosis flow cytometry panel for blood  
Marker Fluorophore Clone Channel Manufacturer Staining 
Conc. 
CD45  BV650 30-F11 V660/20 Biolegend 1:100 
CD11b  Alexa Flour 
488 
M1/70 B530/30 eBioscience  1:100 
CD115 APC AFS98 R670/14 Biolegend 1:100 
Ly6G PB 1A8 V450/50 Biolegend 1:100 












L/D e780  R780/60 Life 
technologies 
1:1,000 





Sigma   
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Figure 2. 6 Gating strategy to analyse phagocytosis in the blood  
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Figure 2. 6 
 
10-12 week old WT and Sema7a KO mice were starved for 12 hours and injected with 
350 mg/kg APAP. Mice were then administered PKH, a phagocytic dye. At either 12 
or 24 hours post APAP injection, blood was collected from mice through a cardiac 
puncture. Single, live, CD45+, Lineage-, cells were selected as in Figure 2. 3.  
 
Ly6G+ neutrophils and Ly6G- monocytes were selected from the CD45+ Lineage- 
population. The Ly6G- monocytes were separated into Ly6Chi and Ly6Clo. Neutrophils 
and monocytes were subsequently (left column) analysed for frequency of 






The peritoneal lavage was stained with the panel in Table 2. 5 and was based on the 
staining panel described by Bain et al. 70. The neutrophil and macrophage 
compartments of the peritoneum were selected using the gating strategy in Figure 2. 
7. FMOs were used to set the gates for the different populations (Figure 2. 8). 
Phagocytosis of each population was analysed using a PKH FMO (Figure 2. 9).  
 
Correction: Bain et al. 70 used a lineage negative marker to remove B and T cells. 
This was not included in this analysis. Consequently, the ‘Ly6C monocyte’ gate 
includes B cells, T cells, monocytes and macrophages, and is therefore labelled 
incorrectly.  
To analyse the peritoneal macrophages, dendritic cells, B1 cells, T cells and 
neutrophils should have been excluded. This was not performed. Therefore, the MHC 
II + F4/80- gate will include dendritic cells and B1 cells 70,254. The MHC II + F4/80- gate 
will include T cells, monocytes and neutrophils. F4/80 can still be used to select 
mature peritoneal macrophages.  
These populations: Ly6C monocytes, Ly6Chi monocytes, MHC II + F4/80- and MHC 
II + F4/80- have been excluded from the analysis but are still shown on the flow 
cytometry plots.  
 
  




Table 2. 5 In vivo phagocytosis flow cytometry panel for peritoneal 
lavage  
Marker Fluorophore Clone Channel Manufacturer Staining 
Conc. 
CD11b Alexa Flour 
488 
M1/70 B530/30 eBioscience  1:100 
Ly6G PE Cy7 IA8 Y/G 
780/60 
Biolegend 1:200 
Ly6C PB HK1.4 V450/50 Biolegend 1:100 
F4/80 APC BM8 R670/14 eBioscience 1:100 
MHCII (I-
Ab) 
PerCP/Cy5.5 AF6-120.1 B710/50 Biolegend 1:200 




in the PE 
channel  
 Y/G586/15 Sigma   
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Figure 2. 7 
1ml peritoneal lavage was collected from adult WT and Sema7a KO mice at 12 or 
24 hours post APAP injury. Peritoneal exudate cells were analysed by flow 
cytometry as follows: 
A) Cells were gated for size, singlets, live (L/D-).  
B) After the gating in (A), the CD11b+ population was selected and divided into 
Ly6G+ neutrophils and Ly6G- cells. Ly6Chi monocytes were selected from 
Ly6G- cells.  
C) Peritoneal macrophages were separated from the live single cell population in 
(A), using F4/80.  
Gates were set using FMOs, as demonstrated in Figure 2. 8. 
 
Figure 2. 8 FMOs used to gate the Table 2. 5 In vivo phagocytosis flow 
cytometry panel for peritoneal lavage   
 
 
Figure 2. 8 
Populations of neutrophils, monocytes and macrophages in the peritoneal exudate, 
were analysed in WT mice at 12 and 24 hours post 350m/kg APAP. Gates were set 
using FMOS as shown.  
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Figure 2. 9 
Peritoneal exudate cells were collected from WT and Sema7a KO mice at 12 or 24 
hours post APAP injury. Mice were injected with PKH, a phagocytic dye, at 4 or 8 
hours APAP respectively, or Diluent B as a control. Neutrophils, Ly6Chi monocytes 
and macrophages were identified (left column, gating strategy Figure 2. 7). Each 
population was analysed for frequency of phagocytosis (PKH+, centre column). Gates 
to measure the frequency of phagocytosis were set using the mouse which had been 
injected with Diluent B, and therefore acted as an FMO (right column).  




The NPC fraction of the liver was stained with the ‘Liver PKH Flow Cytometry Panel’ 
(Table 2. 6) and gated as show in Figure 2. 10. Gates were set using FMOs, as shown 
in Figure 2. 12. Each NPC population was analysed for phagocytosis (PKH positivity), 
as shown in Figure 2. 13. To assess viability, NPC populations were selected as in 
Figure 2. 10, without the first Live/ Dead (L/D) gate. The NPC populations were 
assessed for viability by gating for L/D, on the individual populations. This viability 
gate was set using the respective NPC population, which had previously been gated 
for L/D as normal.  
 
Table 2. 6 In vivo phagocytosis flow cytometry panel for NPCs 




AF700 30-F11 R730/45 Biolegend 1:100 
CD11b BV650 M1/70 V670/30 eBioscience  1:100 
Ly6G  PB 1A8 V450/50 BD 
Pharmingen 
1:100 
CD62L FITC  B530/30  1:200 
F4/80 APC BM8 R670/30 Biolegend 1:100 










Biolegend  1:200 








Sigma   
Chapter 2 – Materials and Methods  
74 
 
Figure 2. 10 Gating strategy for NPCs of the liver at 24 hours post APAP 
injection  
 
Figure 2. 10  
WT and Sema7a KO adult mice were treated with 12 or 24 hours 350mg/kg APAP. 
The NPC fraction was isolated from the liver. Neutrophils, monocytes and 
macrophages were identified as follows:  
A) The NPC fraction was gated for cells, singlets, live (L/D-), CD45+, and 
Lineage– 
B) The lineage negative population was gated for Ly6G+ (neutrophils), and Ly6G- 
cells 
C) The Ly6G- cells were separated in to liver resident macrophages (Mϕ) 
(CD11blo, F4/80hi), and infiltrating Mϕ (CD11b+, F4/80lo).  
D) The infiltrating Mϕ were further subdivided to Ly6Chi and Ly6Clo 
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Figure 2. 11 Gating strategy for NPCs of the liver at 12 hours post APAP 
injection  
 
Figure 2. 11 
In the 12 hours post APAP injection in vivo phagocytosis experiment, Ly6G PB and 
Ly6C PB antibodies were accidentally used in the same antibody cocktail, which was 
used for all samples. Fortunately, the Ly6C PerCP Cy5.5 antibody was also included, 
so the Ly6G+ and Ly6G- populations could still be separated. Gates were set using 
an FMO. 
Single, live (L/D-), CD45+, and Lineage – ells were selected as in Figure 2. 10. 
A) The lineage negative population was gated for Ly6G+ (neutrophils), and Ly6G- 
cells 
B) The Ly6G- cells were separated in to liver resident Mϕ (CD11blo, F4/80hi), and 
infiltrating Mϕ (CD11b+, F4/80lo).  
C) The infiltrating Mϕ were further subdivided to Ly6Chi and Ly6Clo 
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Figure 2. 12 FMOs for the In vivo phagocytosis flow cytometry panel for 
NPCs 
 
Figure 2. 12  
To select neutrophils, monocytes and macrophages in the mouse NPC fraction of the 
liver in Figure 2. 10 and Figure 2. 11, FMOs were used, as indicated by their individual 
titles.  
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Figure 2. 13 Gating strategy to identify phagocytic NPCs in the liver.  
 
Figure 2. 13 
WT and Sema7a KO adult mice were treated with 12 or 24 hours 350mg/kg APAP. 
At 4 or 8 hours APAP respectively, mice were injected with PKH, a phagocytic dye. 
The NPC fraction was isolated from the liver. Neutrophils, monocytes and 
macrophages were identified as in Figure 2. 10. Each NPC population (left) was 
analysed for phagocytosis (PKH+, centre). Gets were set using an FMO (right).  




4 µm-thick FFPE sections were dewaxed and rehydrated before 15 min heat mediated 
antigen retrieval in Sodium Citrate pH 6 or Tris-EDTA pH 8, depending on the antibody 
used (see Table 2. 7). Sections were permeabilised in PBS 0.1% Tween 20 (PBST) 
for 5 min, washed in PBS, and treated with Protein Block (Spring Bio) for 30 min at 
RT, and stained  with the primary antibody overnight at 4 °C. Frozen sections were 
fixed for 20 min in ice cold Methanol: Acetone (1:1) before a 30 min Protein Block at 
RT, followed by overnight incubation with the primary antibody at 4 °C. Secondary 
antibodies were applied for 1 h RT. Sections were stained with DAPI (1:1,000) and 
mounted with fluromount (Southern Biotech). All primary antibodies used in the 
current study are provided together with method of antigen retrieval and working 
dilution in Table 2. 7. Fluorescent secondary antibodies are detailed in Table 2. 8. 
Isotype controls were used for all stains, see Figure 2. 14.  
For 3,3'-diaminobenzidine (DAB) stains, slides were sequentially blocked with Bloxall 
(Vector) for 15 min, then Avidin and Biotin (Invitrogen) for 10 min each, followed by 
30 min Protein Block at RT. Sections were stained overnight at 4 °C with the primary 
antibody, followed by the secondary antibody for 1 h at RT (see Table 2. 8). Slides 
were blocked with R.T.U. VECTASTAIN Elite ABC reagent (Vector) for 30 min, before 
detection with DAB (DAKO). Slides were counterstained with haematoxylin before 
dehydration and mounting. Isotype controls were used for all DAB stains (Figure 2. 
15).  
Haematoxylin and Eosin (H&E) staining and block processing was performed by 
SuRF Histology at the QMRI, University of Edinburgh. 
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Manufacturer Cat. Number Host 



















CD45 1:200 Formalin 15min TE R&D MAB114 Rt 










N/A Abcam ab6640 Rt 




Abcam ab18256 Rb 










N/A Abcam ab119871 Rt 
Integrin β1 1:200 
Methanol: 
Acetone 
N/A Millipore MAB1997 Rt 
K19 1:200 Formalin 15min TE DSHB Troma III Rt 
Ly6G 1:500 Formalin 15min TE Biolegend 127601 Rt 
p21 1:200 Formalin 15min TE Abcam ab188224 Rb 




Sema7a 1:100 Formalin 15min TE Abcam ab23578 Rb 
Vimentin 1:500 Formalin 15min TE Abcam ab92547 Rb 
 
TE, Tris ETDA pH 8; Ms, Mouse; Rb, Rabbit; Rt, Rat; Shp, Sheep. 
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Mouse  Fluorescent Alexa 488 1:200 Invitrogen A21202 Donkey 
Rabbit Biotinylated - 1:200 Vector BA-1000 Goat 
Rabbit Fluorescent Alexa 555 1:200 Invitrogen A31572 Donkey 
Rat Biotinylated - 1:200 Vector BA-9400 Goat 
Rat Fluorescent Alexa 488 1:200 Invitrogen A21208 Donkey 
Sheep Biotinylated - 1:200 Vector BA-6000 Rabbit 
Sheep Fluorescent Alexa 555 1:200 Invitrogen A21436 Donkey 
Sheep Fluorescent Alexa 488 1:200 Invitrogen A11015 Donkey 
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Figure 2. 14 Controls for immunofluorescent stains  
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Figure 2. 14 
A) Immunofluorescent isotype control images. Image labels indicate which 
immunostain the isotype control corresponds too. DNA is stained with DAPI, 
in these images the fluorescent signal has been coloured green. 20x 
magnification 
B) Negative (left) and positive (right) controls for the TUNEL assay. The negative 
control used a 24h APAP injured tissue section, but without the enzyme 
required to label double stranded DNA breaks. Positive control used a healthy 




Figure 2. 15 Isotype controls for DAB stains 
 
Figure 2. 15 
Brightfield images of isotype controls for DAB stains. Image labels indicate which 
immunostain the isotype control corresponds too. DNA is stained with haematoxylin. 
Scale bars 100 μm 
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Microscopy and Image Analysis  
Fluorescent and brightfield images were acquired using a Nikon Eclipse e600 
microscope fitted with a Retiga 2000R camera (Q-Imaging, Image Pro premier 
software). Images were contrasted and analysed using Fiji ImageJ on 6 random non-
overlapping fields per mouse. (ImageJ version 1.52e software for Windows (ImageJ 
Software, National Institutes of Health, USA, available at: http://rsb.info.nih.gov/ij/). 
Confocal microscopy was performed with an inverted Leica TCS SP8 Confocal 
microscope with 3 detectors. High magnification images used the Nyquist criterion to 
give the maximum resolution using 60x objective lens. Images were converted from 
Z- stacks to Maximum Intensity Projections, and contrast adjusted using Fiji ImageJ  
In immunofluorescence studies, necrotic areas were identified by background auto-
fluorescence, and a lack of intact hepatocyte nuclei. On DAB stains, necrotic areas 
were identified through a lack of intact hepatocyte nuclei, hepatocyte ballooning, 
disrupted tissue architecture and background DAB staining.  
Numbers of different single cell populations were counted manually; Jennifer 
Cartwright counted the number of Ly6G+ in necrotic areas. Pixel density, and the 
number of F4/80+ cells per 20x field of view during the APAP time course, was 
quantified using a macroinstruction.  
The number of F4/80+ cells per area was calculated by categorising the input image 
into three zones: healthy, central and out necrotic (Figure 2. 16). The number of 
F4/80+ macrophages was counted in each zone and divided by the area.  
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Figure 2. 16 Quantification of the number of F4/80+ cells per area  
 
Figure 2. 16 
Tissue sections from WT and Sema7a KO mice were stained for F4/80 and imaged 
using a 20x lens.  
The central necrotic zone was selected using Fiji ImageJ and removed from the input 
image. The out necrotic zone was then selected. F4/80+ macrophages were counted 
in the healthy parenchyma, central and outer necrotic zone and dived by the area 
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Necrotic areas on H&E stains were quantified using the inForm 2.4 (Perkin Elmer) 
software. H&E stained sections were scanned using the Polaris multispectral slide 
scanner. The Polaris uses a brightfield scan to identify the tissue, then eight 10x fields, 
at 1 μm resolution, were selected per mouse. Selected fields underwent multispectral 
imaging (MSI) by the Polaris. The resulting images were segmented and analysed 
with the inForm trainable tissue segmentation software, to identify necrotic areas (see 
Figure 2. 17). Polaris and inForm software were also used to count numbers of Ly6G+ 
cells in liver tissue. For this analysis, 8 20x fields are selected for MSI by the Polaris. 
The inForm software segmented the tissue into single cells. Haematoxylin was used 
to identify nuclei, then DAB positive cells (Ly6G+) were identified by setting a 
threshold, which remained constant in each experiment.  
Fluorescent stains were imaged and quantified using the Perkin Elmer Operetta high 
content imaging system. Images were acquired using a 20x objective lens. Images 
were analysed using Columbus software. All parameters and variables remained 
constant in each experiment. Background fluorescence in 488 and 546 channels was 
reduced using the sliding parabola module, with a defined curvature. DAPI positive 
nuclei were detected using method ‘C’. The DAPI intensity, morphology and size of 
these nuclei were used to exclude any artefacts (see Figure 2. 18).  Selected nuclei 
were then assigned as positive or negative based on the pixel intensity in the 
normalised 488 or 546 channels. Depending on the experiment, positivity was 
detected in either the nucleus (e.g. BrdU, TUNEL, Hnf4a) or in the cytoplasm using a 
15-pixel ring surrounding the nuclei (e.g. F4/80, CD45, Sema7a). For each 
experiment, identical thresholds were set to assign nuclei to their respective 
population. For an example analysis pipeline see Figure 2. 18.  
 
  
Chapter 2 – Materials and Methods  
86 
 
Figure 2. 17 Necrosis analysis using the inForm software 
 
 
Figure 2. 17  
 
Example pipeline to analyse necrosis using the Polaris and the inForm software 
A) 8 10x fields of HnE stained tissue are selected to be multispectral imaged by the 
Polaris. Scale bar 2 mm. 
B) The inForm software was trained to identify: necrosis (cyan), healthy parenchyma 
(purple), vessels (yellow) and red blood cells (RBCs, red).  
C) After training, the inForm software can reliably segment tissue into the defined 
areas, which can then be used to calculate %necrosis.  
 
 
Chapter 2 – Materials and Methods  
87 
 
Figure 2. 18 Single cell analysis pipeline using Colombus software 
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Figure 2. 18  
Example pipeline to identify Hnf4α+, Sema7a+ hepatocytes in liver sections from WT 
mice at 24 hours post APAP injury.  
A) DAPI+ nuclei are identified with ‘Method C’, a built in algorithm in the 
Columbus software. Artefacts are excluded based on morphology and 
intensity of the nuclei, to give the ‘selected nuclei’ population. 
B) The image is filtered using the sliding parabola algorithm, which removes 
background fluorescence. Hnf4α expression is then examined in the selected 
nuclei’ population  
C) A 15 pixel ring is drawn around the selected nuclei and tested for Sema7a 
expression. 
D) Dual positive Sema7a+ Hnf4α cells are identified.  
Scale bars 100 um 
 
TUNEL assay  
4 µm FFPE tissue was dewaxed, rehydrated and permeabilised for 5 min in Sodium 
citrate. DNA fragments and breaks were labelled using the Terminal deoxynucleotidyl 
transferase–mediated biotinylated deoxy-uridine triphosphate nickend labelling 
(TUNEL) assay, according to manufacturer instructions (In Situ Cell Death Detection 
Kit, TMR Red, Roche). TUNEL+ nuclei were quantified using the Perkin Elmer 
Operetta high content imaging system. 
 
Protein quantification 
Protein extraction  
60 mg liver tissue was homogenised with a Tissue Tearor (Biospec Products) in cold 
Meso Scale Diagnostics (MSD) lysis buffer (150mM NaCl, 20mM Tris pH7.5, 1 mM 
EGTA, 1mM EDTA, 1% Triton X-100, 1X Halt Protease inhibitor Cocktail (Thermo 
Scientific)). Homogenates were slowly mixed for 30 min, then centrifuged for 10 min 
20,000 x g at 4 °C. The aqueous supernatant was removed, and the protein 
concentration was determined using a Pierce BCA Protein Assay Kit (Thermo 
Scientific).  
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Quantification of cytokines in mouse serum and liver 
10 pro-inflammatory cytokines were multiplexed (IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, 
IL-4, IL-5, IL-6, CXCL1, TNF-α) in mouse serum and liver using the V-PLEX Pro-
inflammatory Panel 1’ mouse plate (MSD), following the manufacturer instructions.  
100 µg of liver homogenate, or 25 µL serum, were assayed in single wells in a 96 well 
V-PLEX plate. The provided standards were run in duplicate. Each well was made to 
50 µL in diluent 41 and placed in a shaking incubator (600rpm) for 2 hours at RT. 
Wells were washed in PBST then incubated with ‘Detection Antibody Solution’ for 2 
hours in a shaking incubator. After washing in PBST, 2x ‘Read Buffer’ was added. 
The plate was read on the QuickPlex SQ 120 analyser (MSD). Concentrations of each 
cytokine was quantified using the standard curve for the respective cytokine.  
Sema7a enzyme-linked immunosorbent assay (ELISA) 
Mouse liver protein homogenate was diluted to 0.5 mg/ml and mouse serum was 
diluted 1:5 in sample diluent.  Samples were assayed in duplicate using the Mouse 
LS Bio sandwich ELISA kit according to manufacturer instructions (Manufacturer; LS-
F6958) 
Healthy human serum was collected by Fiona Chapman and Dan Pugh. Participants 
provided written consent according to the NRS BioResource generic consent form.  
Human serum from was taken from APAP overdose patients on day 1 of admission. 
Ethical approval from the Scotland ‘A’ Research and Ethics Committee had been 
previously gained for a previous study 255. Serum was diluted 1:1 in sample diluent 
from the LS Bio sandwich ELISA kit (LS-F21047), and run in duplicate, following the 
kit instructions.  
 
Quantitative reverse transcriptase PCR (qRT-PCR) 
40 mg of liver tissue was homogenised in 500 µL Qiazol (Qiagen). Homogenates were 
mixed with 100 µL chloroform, incubated at RT for 3 min, and then centrifuged at 4 
°C 1,200 x g, for 15 min. The aqueous supernatant was removed and mixed in an 
equal volume of 70% ethanol. BMDMs were lysed in Buffer RLT.  RNA was extracted 
using an RNAeasy Kit according to manufacturer instructions (Qiagen). Reverse 
Transcription and Real Time-qPCR was performed using Qiagen Quantitect and 
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Quantifast reagents on a LightCycler 480 II (Roche). Commercial primers from 
Qiagen’s Quantitect range were used. Gene expression was normalised to the 
housekeeping gene peptidylprolyl isomerase A (PPIA). Samples were run in triplicate. 
Primers: AKT1, QT00114401; CCL2, QT00167832; CXCL1, QT00115647; IL-1β, 
QT01048355; IL-6, QT00098875; ITGα1, QT01559138; ITGB1, QT00155855; 
MAPK1, QT00133840; Plxnc1, QT00145418; PPIA, QT00247709; PTK2, 
QT01059891; Sema7a, QT00173488; TGFB1, QT00145250; TGFBR1, 
QT00135828; TGFRB2, QT00135646; 
 
Statistics  
GraphPad Prism 8 Software was used for all statistical analysis. Data are presented 
as mean ± s.e.m. n refers to biological replicates. A Shapiro-Wilk test was used to 
determine whether data fitted a normal distribution. Anomalies were only removed if 
they were identified using a Grubbs test (alpha=0.05). Each dot represents a mouse. 
A two-tailed unpaired t-test, with a Welch correction applied if required, or Mann 
Whitney test was used to compare two sample parametric or non-parametric data 
respectively. A one-way ANOVA with Tukey’s multiple comparison test or a Kruskal-
Wallis test with Dunn's Multiple Comparison Test was used for multi-sample 
parametric or non-parametric data respectively.  
Two-way ANOVA with Sidak’s multiple comparison test was used to analyse 
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APAP overdose causes 46% of acute liver failure in the UK and the USA, with 200 
deaths annually in the UK 1,2. The only therapy for APAP overdose, NAC, is effective 
in the first 12 hours following APAP ingestion. After this timepoint, 22% of patients 
require a liver transplant, which are often not found in time 3. Research is needed to 
find a suitable therapy to prevent liver failure and promote recovery after the initial 12 
hour time window. One potential therapeutic avenue could be to manipulate the innate 
immune system to promote recovery and avoid multi-organ failure.  
The innate immune system is present in both the injury and recovery phases of APAP 
injury. Dying hepatocytes release danger-associated-molecular patterns (DAMPs), 
which are detected by and activate Kupffer cells, the liver resident macrophage 4. 
Activated Kupffer cells secrete a plethora of cytokines including: TNFα, IL-6, CXCL1, 
IL-1β and IL-18 to trigger and recruit the innate immune system 4,44. During the initial 
stages of APAP injury, inflammation enhances injury. For example, secreted TNFα 
primes hepatocytes to apoptose, enhancing hepatocyte loss 4,35.  
During recovery, the innate immune system is beneficial as macrophages and 
neutrophils remove cellular debris through phagocytosis 35. Phagocytosis causes 
macrophages to switch from a pro-inflammatory to an anti-inflammatory phenotype 
72,256. The restorative macrophages secrete anti-inflammatory cytokines such as IL-
10  to reduce inflammation 256, and TNFα and IL-6 to stimulate the remaining 
hepatocytes to proliferate 17. Novel therapies may influence the immune system 
towards a restorative phenotype.  
Semaphorin 7a (Sema7a) has diverse roles in the immune system. It promotes 
monocytes to release pro-inflammatory cytokines 231, and can act as a 
chemoattractant for dendritic cells monocytes and macrophages 228–230, or induce the 
transmigration of neutrophils into hypoxic tissue 211. Sema7a can also modulate 
macrophage secretion of pro- or anti- inflammatory cytokines, depending on which 
receptor receives it. For example, when Sema7a on activated T cells is received by 
Integrin α1β1 on macrophages, pro-inflammatory cytokine production is induced 231. 
Conversely, when macrophages receive Sema7a from intestinal epithelial cells 
through αvβ1 integrin, anti-inflammatory cytokines are secreted 236.  
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In chronic liver and lung injury, Sema7a forms a positive feedback loop with the TGFβ 
to promote fibrosis 246,247.  In the liver, Sema7a KO mice injured with chronic CCl4 
administration, or bile duct ligation, display less infiltrating CD45+ leukocytes and 
F4/80+ macrophages, lower transcription of IL-6 and MCP-1 246, a key 
chemoattractant for monocytes 63. In APAP injury, infiltrating macrophages secrete 
TGFβ to induce hepatocyte senescence, marked by p21 expression. This senescence 
prevents hepatocyte proliferation and recovery, and patients are more likely to 
undergo liver failure 144. In acute APAP injury, Sema7a may have a role in 
inflammation, which is key during both injury and recovery from APAP injury.  
This chapter aims to characterise the expression of Sema7a and its receptors Plexin 
C1 and Integrin β1, in healthy mice and during APAP injury. I will also examine if 
Sema7a is simply a marker for cells about to undergo cell death, senescence, or if 
Sema7a has a direct role in promoting recovery from APAP injury. Finally, I will 








Sema7a is expressed on peri-necrotic cells at peak APAP injury 
 
To investigate if Sema7a expression is regulated in APAP injury or recovery, Sema7a 
protein expression was assessed during a time course of APAP overdose (Figure 3. 
1A). In this model, centrilobular necrosis and inflammation begins to develop by 4 
hours post-APAP administration. Necrosis spreads into the parenchyma as the injury 
develops, until 24 hours post APAP. From 36 hours post APAP overdose, necrosis 
resolves, and the mice recover from APAP injury (Figure 3. 1B & C).  
Sema7a expression is absent in healthy mice and the early stages of APAP injury (4-
8 hours). As necrosis and inflammation continues from 12 to 24 hours post APAP 
injury, Sema7a expression is induced in cells surrounding the necrotic areas, peaking 
at 24 hours. During the recovery phase (36 - 60 hours post APAP) Sema7a 
expression diminishes as necrosis resolves (Figure 3. 1B & D). Since peak injury and 
Sema7a expression coincide at 24 hours APAP, further studies were focussed on this 
time point.   
 
 
Figure 3. 1  
A) Schematic overview of the APAP injury time course experiment 
(performed by Philip Starkey Lewis).   
B) Sema7a expression during a time course of 350 mg/kg APAP. Scale bars 
100 µm. Black dashes outline necrotic areas. Yellow dashes outline 
Sema7a positive peri-necrotic cells.  
C) Polaris analysis of necrotic area during APAP injury (performed by Philip 
Starkey Lewis).   
D) Percentage area of Sema7a positivity. 
 
Scale bars 100 µm. CV, central vein; PT, Portal tract. The APAP injury mouse 
experiment was performed once.  
 
Each dot represents an individual mouse. Data was checked for normality and equal 
variance. This applies to every figure henceforth.  
Chapter 3 – Results  
97 
 
Figure 3. 1 Peri-necrotic cells express Sema7a during APAP injury 
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Sema7a cells are viable, and surround the necrosis 
At 24 hours post APAP there is ongoing necrosis, the predominant mode of 
hepatocyte death during APAP injury 17,27,257. Since Sema7a is expressed by cells 
adjacent to the necrotic area during APAP injury, I undertook studies to determine 
whether Sema7a identifies cells about to undergo necrosis, or if Sema7a+ cells form 
a boundary around the necrosis.  
A Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay was 
performed to label dying cells (Figure 3. 2A). Healthy mice were TUNEL-negative. At 
24 hours APAP, the characteristic necrotic (TUNEL+) pattern is seen. Comparing 
Sema7a stained serial section indicates the Sema7a+ hepatocytes lie outside the 
TUNEL+ area, with three cells on average being dual positive for Sema7a and TUNEL 
(Figure 3. 2B).  
To ensure Sema7a cells were not undergoing apoptosis, serial sections were stained 
for active Caspase 3, an apoptosis marker, and Sema7a (Figure 3. 2C). In healthy 
mice, Caspase 3+ cells were absent. At 24 hours APAP, an average of 29 Caspase 
3+ cells are observed at the edge of necrotic areas. Comparing the Caspase 3 and 
Sema7a stains shows that the Sema7a+ hepatocytes lie adjacent to Caspase 3+ cells 
(Figure 3. 2C), with an average of two Caspase 3+ cells being dual positive for 
Sema7a per field (Figure 3. 2D). 
Therefore, Sema7a is expressed by viable cells, and is not a marker for cell death. 
Due to the position of Sema7a+ cells, they may act as a boundary to necrosis, which 
will be investigated in Chapter 4.   
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Figure 3. 2 Sema7a+ cells are viable 
 
Figure 3. 2 
A) Serial staining of Sema7a (top) and TUNEL (bottom) in mice treated with saline 
(left) or 24 hours 350 mg/kg APAP (right). The identified Sema7a+ region is 
encircled in white; this region was overlaid on the TUNEL serial image. Green 
arrows indicate cells dual positive for TUNEL and Sema7a (Sema7a+ TUNEL+).  
B) Average number of Sema7a+, TUNEL+ or dual + cells, in mice treated with 24 
hours 350 mg/kg APAP.  
C) Serial staining of active Caspase 3 (top) and Sema7a (bottom) in mice treated 
with saline (left) or 24 hours 350 mg/kg APAP (right). Identified active Caspase 3+ 
nuclei are labelled in black; these labels were overlaid on the Sema7a serial 
image. Cells dual positive for active Caspase 3 and Sema7a (Sema7a+ Caspase 
3+) are highlighted in red.  
D) Average number of Sema7a+, Caspase 3+ or dual + cells, in mice treated with 24 
hours 350 mg/kg APAP.  
Scale bars 100 µm. The APAP injury mouse experiment was performed once. 





Sema7a is expressed by hepatocytes 
To define which cells express Sema7a, dual immunohistochemistry (IHC) was 
performed with markers for the main liver cell types including: Hnf4α for mature 
hepatocytes 258, CK19 for ductular cells 259 and ICAM-1 for endothelial cells 260. Dual 
staining of Sema7a with Hnf4α reveals that during APAP injury, Sema7a becomes 
expressed on peri- necrotic hepatocytes, from here on referred to as Sema7a+ 
hepatocytes (Figure 3. 3A).  
Sema7a expression during APAP injury was further examined in whole liver. 
Quantitative reverse transcription PCR (qRT-PCR) revealed a 9.5 fold increase of 
Sema7a mRNA in the whole liver at 24 hours post-APAP injection, compared to 
healthy controls (Figure 3. 3B). This was not reflected by an increase in Sema7a 
protein levels in the whole liver, as measured by an ELISA (Figure 3. 2C). However, 
Sema7a was significantly elevated in mouse serum at 12 and 24 hours post APAP 
injection (P=0.0127 & P=0.007, respectively) (Figure 3. 3D). This increase of Sema7a 
in the serum correlates (Pearson coefficient (r) = 0.728) with an increase in ALT, a 
serum biomarker used clinically to detect hepatocellular damage 261.  
As serum Sema7a correlated with ALT in our murine APAP injury model, we 
investigated if Sema7a could be used as a serum marker to indicate the degree of 
hepatocellular injury in human paracetamol overdose (POD) patients. To assess 
correlation sera with a range of ALT levels, from a previous POD study 255, was 
selected and separated into a Mid ALT (1000 < 4600 u/L) or high ALT (>5,000 u/L) 
group. The levels of Sema7a in this POD sera and sera from healthy patients was 
measured using an ELISA. In human POD, Sema7a does not correlate with ALT and 
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Figure 3. 3 Sema7a is expressed by hepatocytes during APAP injury 
 




Figure 3. 3 
A) Confocal images of Hnf4a (green) and Sema7a (red), merged (right), in WT mice 
treated with 24 hours saline (top), or 24 hours 350 mg/kg APAP (bottom). Yellow 
arrows indicate Sema7a+ Hnf4a+ hepatocytes. Scale bars 100 µm. 
B) Sema7a expression in whole liver lysate measured by qRT-PCR, Unpaired t-test 
with Welch's correction. 
C) ELISA for Sema7a in whole liver lysate from mice treated with saline or 24 hours 
350mg/kg APAP. Unpaired t-test with Welch's correction. 
D) ELISA for Sema7a in serum from healthy mice or mice treated with 12, 24 or 42 
hours 350mg/kg APAP. Brown-Forsythe ANOVA test, with Games-Howell's 
multiple comparisons test.  
E) Linear regression of Sema7a and ALT in mouse serum.  
F) ELISA for human Sema7a in serum from healthy or paracetamol overdose 
patients. Mid ALT, 1000 < 4600 u/L; High ALT, >5000 u/L. One-way ANOVA.  
G) Linear regression of Sema7a and ALT in human serum. 
 
 * p<0.05, ** p<0.01. ms, mouse; hu, human. The APAP injury mouse experiment was 
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Sema7a is not expressed by other liver cells 
 
To examine if Sema7a is expressed by the other main cell types of the liver, dual IHC 
of Sema7a was performed with the CK19 and the endothelial cell marker ICAM-1. 
This IHC shows Sema7a is not expressed on ductular cells (Figure 3. 4) or endothelial 
cells (Figure 3. 5). Hepatic stellate cells (HSCs) were also negative for Sema7a 
(inferred from Figure 3. 7 & Figure 3. 9). Therefore, Sema7a is expressed by 
hepatocytes during APAP injury. 
 
 
Figure 3. 4 Sema7a is not expressed on ductular cells  
 
 
Figure 3. 4 
 
Sema7a (red) is not expressed by ductular cells (K19, green) in WT mice treated with 
saline (top, n=4) or 24 hours 350mg/kg APAP (bottom, n=5).  
Nuclear stain DAPI (blue). Scale bars 100 µm. The APAP injury mouse experiment 
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Figure 3. 5 Sema7a is not expressed on endothelial cells  
 
 
Figure 3. 5 
 
Sema7a (red) is not expressed on ICAM-1+ (green) endothelial cells in mice treated 
with 24 hours saline (top), or 24 hours 350 mg/kg APAP (bottom). Nuclear stain DAPI 
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The Sema7a receptors Plexin C1 and Integrinβ1 are stable during 
APAP injury 
Plexin C1 and Integrin β1 are the Sema7a receptors 231,262. To examine if they are 
affected by APAP injury, their expression was assessed. Plexin C1 expression 
remained constant during APAP injury, but Integrin β1 was more highly expressed at 
24 hours APAP (P=0.0344) (Figure 3. 6A & B).  In healthy mice, Plexin C1 and Integrin 
β1 have similar expression patterns. Proteins levels of Integrin β1 are unaltered by 
APAP injury, but Plexin C1 is more widely expressed covering an average of 10% of 
each 20x field, compared to 7.7% in healthy mice (P=0.0208) (Figure 3. 6C & D).  
Dual immunofluorescence and confocal imaging was utilised to determine the extent 
of co-localisation between Sema7a and Plexin C1. At 24 hours APAP injury, Plexin 
C1 was expressed on cells lying between the Sema7a+ hepatocytes, and on cells 
dispersed across the healthy parenchyma (Figure 3. 7A). These cells are not Hnf4a+ 
hepatocytes (Figure 3. 7B), or CK19+ ductular cells (Figure 3. 8). In the liver, vimentin 
labels the type III intermediate filaments contained in HSCs and the smooth muscle 
cells of arterioles and veins 263,264. Plexin C1 was exclusively expressed by a subset 
of vimentin+ HSCs, but not vimentin+ arterioles or venules (Figure 3. 9).  
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Figure 3. 6 Plexin C1 and Integrin β1 expression during APAP injury  
 
 
Figure 3. 6 
Expression of the Sema7a receptors, Plexin C1 and Integrin β1 were examined in WT 
mice which were treated with saline (left), or 24 hours 350 mg/kg APAP (right).  
A) PlexinC1 mRNA expression, relative to PPIA1 in whole liver lysate.   
B) Integrin β1 mRNA expression, relative to PPIA1 in whole liver lysate (Welch’s 
correction applied).  
C) Protein expression of Plexin C1 in the liver. Area of Plexin C1 positivity is 
quantified (right) 
D) Protein expression of Integrin β1 in the liver. Area of Integrin β1 positivity is 
quantified (right)  
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Figure 3. 7 Plexin C1 is not expressed by hepatocytes 
 
Figure 3. 7 
A) Confocal images of Sema7a (red), and its receptor Plexin C1 (green) with 
DAPI (blue) in the liver of WT mice treated with saline (top) or 24 hours 350 
mg/kg APAP (bottom).  
B) Plexin C1 (green) expression with Hnf4α (red) and DAPI (blue) in the liver of 
WT mice treated with saline (top) or 24 hours 350 mg/kg APAP (bottom).  
20 x image (left). White inset indicates areas examined at a higher magnification.  
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Figure 3. 8 Plexin C1 is not expressed by ductular cells 
 
Figure 3. 8 
Expression of Plexin C1 (red) and K19 (ductular marker, green) and DAPI (blue) in 
WT mice treated with saline (top, n=3) or 24 hours post APAP injection (bottom, n=4). 
Representative images are shown. Scale bars 100 µm 
 
Figure 3. 9 Plexin C1 is expressed by Hepatic Stellate Cells 
 
Figure 3. 9 
Plexin C1 (green) is expressed by hepatic stellate cells (vimentin, red), dual 
expression in yellow, with DAPI (blue). Mice were treated with saline (top) (n=5) or 24 
hours 350 mg/kg APAP (bottom) (n=5). Inset on 20x images (left) shows location of 
60x images. Scale bars 100 µm. Data is shown from two APAP mouse experiments.  
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Integrin β1 is widely expressed in the liver 
To define where Integrin β1 is expressed in the liver, in relation to the Sema7a+ 
hepatocytes, dual IHC was utilised. Integrin β1 outlines the Sema7a+ hepatocytes 
and appears to be expressed by cells lying between the Sema7a+ hepatocytes 
(Figure 3. 10A). This was confirmed with a dual stain of Integrin β1 and Hnf4α, where 
Integrin β1 is seen outlining the hepatocytes, as indicated by the white arrows in 
(Figure 3. 10B). Integrin β1 is also expressed by vimentin+ HSCs (Figure 3. 11), which 
interject between the Sema7a+ hepatocytes. Unlike Plexin C1, Integrin β1 is also 
expressed by the vimentin+ smooth muscle cells of the arterioles and veins, and the 
vimentin negative bile ducts (Figure 3. 11). Together, these IHC images show Integrin 
β1 is widely expressed in the liver, as previously reported 265. As HSCs express both 
Plexin C1 and Integrin β1, and lie between the Sema7a+ hepatocytes, they are most 
likely to receive Sema7a signalling. Due to the ubiquitous expression of Integrin β1, 
Sema7a could interact with Integrin β1 expressed by many cell types, including other 
hepatocytes or immune cells.   
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Figure 3. 10 Integrin β1 is expressed by hepatocytes 
 
Figure 3. 10 
A) Confocal images of Integrin β1 (green) and Sema7a (red) with DAPI (blue) in 
mice treated with saline (top) or 24 hours 350 mg/kg APAP (bottom). Scale 
bars 100 µm, or 50 µm on 60x inset images. 
B) Integrin β1 (green) and Hnf4α (red) expression with DAPI (blue), dual Hnf4α 
and DAPI (magenta) in mice treated with saline (top) or 24 hours 350 mg/kg 
APAP (bottom). White arrows indicate Integrin β1 and Hnf4α positive cells. 
Scale bars 100 µm. 
White dashes and asterix indicate necrotic areas.  
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Figure 3. 11 Integrinβ1 is expressed by hepatic stellate cells 
 
Figure 3. 11 
Expression of Integrin β1 (green), vimentin (red), dual expression yellow, with DAPI (blue) in WT mice treated with saline (top) or 24 hours 
350 mg/kg APAP (bottom row). Inset on 20x images indicate areas taken for 40x images. Inset on 40x images shows Integrin β1 expression 
at the portal triad (green surrounding the duct nuclei), independent of vimentin.  
Representative images from n= 5 mice (two APAP experiments). White dashes and asterix indicate necrotic areas. Scale bars 100 µm. PT, 
portal triad; CV, central vein. 




Sema7a does not mark proliferating cells in APAP injury 
One of my aims is to investigate if Sema7a promotes hepatocyte proliferation, and 
therefore promotes recovery from APAP injury. As Sema7a expression reduces 
during recovery (36 – 60 hours APAP, Figure 3. 1), it is unlikely to be directly involved 
in proliferation. To test this theory, proliferative cells were labelled with BrdU. At 42h 
post APAP overdose 5% of all nuclei are BrdU+ (Figure 3. 12C), with less than 1% of 
BrdU+ cells expressing Sema7a (Figure 3. 12B &E).  
To confirm that Sema7a is not involved proliferation, Sema7a expression was 
examined in a highly proliferative model - partial hepatectomy (PHx). 70% of the liver 
mass is removed surgically, and the remaining liver mass enters hyperplasia to 
replaced lost tissue. Peak proliferation occurs at 48 hours, and mice recover their liver 
mass by 1 week post-surgery. Both sham (control) and PHx surgeries were performed 
by Sofia Ferreira-Gonzalez.  
At 48 hours post 70% PHx, 7.8% of all nuclei are positive for Ki67, a proliferation 
marker, compared to 0.6% of sham operated mice, as expected (P=0.004) (Figure 3. 
13A & B). However, Sema7a was not expressed in these mice, suggesting it is not 
involved in proliferation (Figure 3. 13C). To conclusively prove Sema7a has no direct 
role in hepatocyte proliferation, Sema7a KO mice could undergo 70% PHx and 












Figure 3. 12 Sema7a hepatocytes are not proliferative  
 
Figure 3. 12 
A) Representative images of Hnf4α (red) (n=6), or B) Sema7a (red) (n=5), with BrdU 
(green) and DAPI (blue), in mice recovering from 350 mg/kg APAP injury at 42 
hours. Scale bars 100 µm.  
C) Quantification of BrdU expression at 42 hours APAP 
D) Quantification of proliferating hepatocytes at 42 hours APAP 
E) Quantification of proliferating Sema7a+ cells at 42 hours APAP  
Data is shown from three APAP mouse experiments. 













Figure 3. 13 
A) Ki67 (red) and Hnf4α (green) with DAPI (blue) in mice with a sham surgery 
(control) or 48h post 70% PHx (right). White arrow heads indicate 
proliferating nuclei. Images are representative of n=8 PHx or n=4 sham 
mice. Experiment was performed once.  
B) The percentage of Ki67+ proliferating nuclei is raised at 48 hours post 70% 
PHx. Mann Whitney test **p<0.01. 
C) Sema7a is not expressed during proliferation. Sham (left) or 48 hours post 
70% PHx (right). Images are representative of n=5 PHx or n=2 Sham mice. 
Representative images are shown. Scale bars 100 µm. Both the partial hepatectomy 
(PHx) and sham surgeries were performed by Sofia Ferreira-Gonzalez. 
 
 
A proportion of Sema7a+ cells are in cell cycle arrest 
Senescence is induced in times of cellular stress. It is detected by the lack of 
proliferation and the presence of key markers such as p21. As Sema7a is absent from 
proliferating cells, and p21+ hepatocytes can be found surrounding the necrotic 
region, during APAP injury 144, in a similar location to the Sema7a positive 
hepatocytes, I investigated whether the Sema7a+ hepatocytes were undergoing 
senescence.  
Serial sections were stained for Sema7a and p21 (Figure 3. 14A). In healthy mice, 
p21 expression is negligible, as expected. At 16 hours APAP an average of five p21 
positive hepatocytes could be detected in the parenchyma and the peri- necrotic 
hepatocytes. At 24 hours post APAP overdose, an average of 16 p21+ hepatocytes 
could be detected per field of view, as injury progressed from 16 to 24 hours APAP 
post overdose (Figure 3. 14B, Saline vs 24 hours P=0.0002. 16 vs 24 hours 
P=0.0041).  
Comparing p21 and Sema7a serial IHC, shows that the number hepatocytes dual 
positive for both p21 and Sema7a (Sema7a+ p21+) increase from two on average per 
field at 16 hours to eight at 24 hours post APAP overdose (Figure 3. 14C, Saline vs 
24 hours P=0.0004. 16 vs 24 hours P=0.0051). At 24 hours APAP 18% of the 
Sema7a+ also express p21 (P=0.0059, Figure 3. 14D). These results demonstrate 
that a fifth of the Sema7a positive hepatocytes are in cell cycle arrest. Bona fide 
senescence should be confirmed using other senescence markers such as p16 and 
DCR2. In Chapter 4, I will investigate if a lack of Sema7a influences p21 expression.  
 




Figure 3. 14 p21 increases with injury and is expressed by Sema7a+ 
cells  
 
Figure 3. 14 
A) Serial staining of p21 (top) and Sema7a expression (bottom) in saline (left), or 
16 (centre) and 24 hours (right) 350mg/kg APAP. Black encircles cells with 
p21+ nuclei. Red, indicates p21+ Sema7a+ cells.  
B) Number of p21+ cells. One-way ANOVA. Tukey's multiple comparisons test.  
C) Number of p21+ Sema7a+. One-way ANOVA. Tukey's multiple comparisons 
test. 
D) Percentage p21+Sema7a+ cells in Sema7a+ cells. Kruskal-Wallis test, Dunn's 
multiple comparisons test.  
Data is shown from two APAP mouse experiments. Scale bars 100 µm. *p<0.05, 
**p<0.01, ***p<0.001.  
  




The relationship between Sema7a+ hepatocytes and immune cells 
The innate immune system is essential during APAP injury and recovery, and is 
recruited by DAMPs and cytokines released by activated Kupffer cells and dying 
hepatocytes 44. Sema7a has been reported to regulate the expression of the pro-
inflammatory factors MCP-1, TGFβ, IL-6 and IL-1β 212,246,247.  The expression of these 
factors was examined using qRT-PCR at 24 hours when Sema7a expression is 
highest. MCP-1 was upregulated 18 fold, and TGFβ1 was upregulated two fold higher 
than healthy mice (p=0.0061, P=0.0295, respectively), but the expression of the TGFβ 
receptors remained constant (Figure 3. 15). The possibility that Sema7a signalling 
could influence these genes will be investigated in Chapter 5. 
To examine the localisation of the CD45+ immune cells, in relation to Sema7a+ 
hepatocytes, confocal imaging was performed. CD45+ cells are predominantly 
located within the necrotic area during APAP injury. Some CD45+ cells are closely 
associated with the Sema7a+ hepatocytes (Figure 3. 16A). For an interaction to occur, 
CD45+ cells must express the Sema7a receptors Plexin C1 or Integrin β1, in a dimer 
with either Integrin α1 or αv. This was examined with flow cytometry (Figure 3. 16B). 
20-30% of CD45+ cells express Plexin C1, Integrin β1 and αv, but only 2.3% of CD45+ 
cells expressed Integrin α1 (Figure 3. 16C). Suggesting that immune cells bind to 
Sema7a through either Plexin C1 or the Integrin β1- αv dimer. 
  




Figure 3. 15 mRNA expression of pro-inflammatory factors 
 
Figure 3. 15 
mRNA expression of the indicated genes in whole liver lysate from WT mice treated 
with saline or 24 hours 350 mg/kg APAP, relative to saline treated mice. 
Unpaired t-test except for: MCP-1, IL-6; TGFβR2, which required a Mann Whitney 
test. *p<0.05, **p<0.01. Data is shown from three APAP mouse experiments. 
 




Figure 3. 16 Circulating CD45 + Cells express the Sema7a Receptors  
 
Figure 3. 16 
A) Confocal images of CD45+ cells (green) and Sema7a cells (red), with 
DAPI (blue) at 24 hours 350 mg/kg APAP. Scale bars 100 µm.  
B) Expression of Sema7a receptors (blue) on single, live, CD45+ cells 
isolated from peripheral blood of healthy mice. Gates were set using the 
relative FMO (grey) 
C) Quantification of (B)  








A proportion of the CD45+ sitting close to the Sema7a+ hepatocytes are F4/80+ 
macrophages, as shown by confocal imaging in Figure 3. 17A. The F4/80+ 
macrophages did not appear to express Sema7a, ideally this should be confirmed by 
flow cytometry, but at the time of analysis there wasn’t a suitable antibody available. 
However, isolated bone marrow derived macrophages (BMDMs) had negligible levels 
of Sema7a relative to the housekeeper, PPIA-1, suggesting macrophages do not 
express Sema7a (Figure 3. 17B).  
To assess if macrophages could receive Sema7a, expression of the Sema7a 
receptors was examined. mRNA expression of PlexinC1, Integrin β1, α1 and αν was 
detected in BMDMs (Figure 3. 17B) and at the protein level by IHC for Integrin β1 
(Figure 3. 17C), and flow cytometry for Integrin α1 and αν (Figure 3. 17D & E). 
Together, during APAP injury, pro-inflammatory cytokines including MCP-1 are 
synthesised in the liver to activate the innate immune system. F4/80+ macrophages 
and other CD45+ leukocytes are attracted to the necrotic area. Some of these cells 
become marginalised to the edge of necrosis, in close association with the Sema7a+ 
hepatocytes. As macrophages express the Sema7a receptors there may be a 
signalling interaction occurring during APAP injury. The relationship between Sema7a 








Figure 3. 17 F4/80+ Macrophages are adjacent to Sema7a+ 
hepatocytes 
 





Figure 3. 17 
A) Confocal images of F4/80+ macrophages (green) and Sema7a (red), in mice 
treated with 24 hours saline solution (top), or 24 hours 350 mg/kg APAP 
(bottom). Scale bars 100 µm. 
B) mRNA expression of Sema7a and its receptors: Plexin C1 (PlxC1), Integrin 
(ITG) β1, α1 and αν in BMDMs 
C) Integrin β1 (red) is expressed by bone marrow derived macrophages 
(BMDMs) (left), right shows the isotype control 
D) Frequency of Live, CD11b+ BMDMs which express Integrin α1, measured by 
flow cytometry.  
E) Frequency of Live, CD11b+ BMDMs which express Integrin αν, measured by 
flow cytometry.  
Each dot represents a single BMDM experiment.  
 
  





Novel treatments for APAP injury may promote the pro-restorative arm of the innate 
immune system. Sema7a has been previously reported as an important 
immunomodulator, it can act as a chemoattractant for both monocytes and dendritic 
cells 151, and stimulate the production of both pro- 231 and anti- inflammatory236 
cytokines from macrophages. Furthermore, Sema7a KO mice have less inflammation 
in both liver 246 and lung 212 injuries. I questioned if Sema7a had a role during APAP 
injury or recovery. 
At 12- 24 hours post APAP administration, Sema7a becomes expressed in peri - 
necrotic Hnf4α+ hepatocytes. These Sema7a+ hepatocytes are viable and encircle 
the Caspase 3+ and TUNEL+ cells. Sema7a+ hepatocytes may act as a physical 
boundary to prevent the spread of necrosis and may further prevent injury by acting 
as a barrier between the necrosis and the healthy parenchyma. In Chapter 4 I will 
investigate this in more detail using Sema7a KO mice.  
At 24 hours post APAP administration, Sema7a expression is increased at the 
transcript, but not the protein level. The elevated Sema7a may replace Sema7a 
detected in the serum, which was significantly increased at 12 and 24 hours APAP, 
and correlated with the hepatocellular injury marker ALT. 
Sema7a may be cleaved or secreted during APAP injury to promote inflammation. In 
rheumatoid arthritis, ADAM17 cleaves Sema7a from T cells and monocytes in the 
synovial fluid. This shed Sema7a binds to Integrin β1 on monocytes and 
macrophages causing them to secrete IL-6 and TNFα, promoting inflammation in the 
arthritic joint 232. In human blood, Sema7a is expressed on human platelets 233 and 
erythrocytes where it carries John Milton Hagen (JMH) group antigens 234. In vitro 
studies suggest the JMH antigens activate T cell proliferation and secretion of the pro-
inflammatory cytokines IL-8 and IFN-γ 235.  In contrast to the mouse data, POD 
patients did not express Sema7a more highly in the serum during injury. This may 
reflect a difference in species, or when the time the blood samples were taken. Serum 
samples were taken on day one of hospital admission, but the time between overdose 
and admission will vary hugely, unlike our time-controlled mouse experiments. To 
confirm clinical relevance Sema7a expression in human POD liver should be 
examined, unfortunately, I could not find a working antibody for Sema7a in human 
liver.  




In both humans and mice, peri-necrotic p21 expression correlates with the degree of 
APAP injury 144. p21 is a key cell cycle arrest marker, which can be induced by TGFβ 
signalling in times of cellar stress 143,144. As Sema7a has previously been shown to 
promote TGFβ signalling 246,247, and Sema7a hepatocytes are also located in the peri-
necrotic area I investigated if the Sema7a hepatocytes express p21. 18% of the 
Sema7a+ hepatocytes expressed p21, suggesting that some of the Sema7a+ 
hepatocytes are in cell cycle arrest. The possibility that Sema7a is involved with p21 
expression will be investigated using Sema7a KO mice in Chapter 4.  
APAP injury is both enhanced and resolved by the innate immune system 35. A 
multitude of DAMPs released by dying hepatocytes, and cytokines released by 
activated Kupffer cells, recruit leukocytes to the liver during APAP injury 44. At 24 
hours post APAP administration, these CD45+ cells can be seen infiltrating to the 
necrotic area. A portion of these cells are F4/80+ macrophages, which were closely 
associated with Sema7a+ hepatocytes. BMDMs express the Sema7a receptors. 
Therefore, Sema7a+ hepatocytes may modulate macrophage behaviour or 
localisation during APAP injury. Previously, Sema7a been shown to stimulate 
macrophages to produce both pro 231- and anti- 236 inflammatory cytokines via Integrin 
β1. The effects of Sema7a on macrophages during APAP injury will be explored in 
Chapter 5. 
The Sema7a receptors Plexin C1 and Integrin β1 are both expressed by HSCs. 
Integrin β1 is also expressed by most cell types of the liver, as shown here and 
previously reported 265. HSCs secrete cytokines and growth factors which are 
protective against APAP induced necrosis 266,267. However, later timepoints from 
APAP overdose were not examined in these mice to ensure resolution of necrosis, 
and an absence of inflammation and activation of native HSCs. 
At 24 hours post APAP overdose, Plexin C1 expression was increased. As this is the 
timepoint for peak Sema7a expression, it may promote the expression of Plexin C1. 
In melanocytes, Sema7a promotes Plexin C1 217 to induce melanocyte spreading in 
vitro 216,217. However, PlexinC1 was reduced in HSCs isolated from mice treated with 
chronic CCl4 and bile duct ligation 246. If Sema7a promotes Plexin C1 in our acute 
APAP model, I expect Plexin C1 expression to decrease in Sema7a KO mice during 
APAP injury. This will be examined in Chapter 4. 




After APAP injury, the hepatocytes must proliferate to replace lost cells. To see if 
Sema7a has a role in recovery, its expression from 36h – 60h post APAP 
administration was examined. During this recovery period, the expression of Sema7a 
reduces. Proliferative BrdU+ cells were also negative for Sema7a. Together, these 
results indicate that Sema7a has no direct role in proliferation after APAP injury. This 
was confirmed in the PHx model, at peak proliferation there was an absence of 
Sema7a+ hepatocytes. However, Sema7a may have an indirect role in promoting 
recovery from APAP injury. By preventing the spread of necrosis, Sema7a may 
indirectly promote regeneration by allowing healthy cells to proliferate. This will be 
investigated in Chapter 4.  
To conclude, Sema7a becomes expressed on peri-necrotic hepatocytes during APAP 
injury. These hepatocytes are viable, non-proliferative and may form a boundary 
between the necrosis and the remaining healthy cells. The Sema7a+ hepatocytes 
may also interact with macrophages or other immune cells during APAP injury. Using 
Sema7a KO mice I will confirm if Sema7a+ hepatocytes are required as a barrier to 
prevent the spread of necrosis, which may indirectly aid recovery. I will also explore if 























Chapter 4 - Sema7a prevents the 
spread of necrosis into the 
parenchyma during APAP injury 
   





In Chapter 3, viable Sema7a+ hepatocytes were discovered encircling the necrosis 
at peak APAP injury. HSCs lie in between the Sema7a+ hepatocytes and express the 
Sema7a receptors Plexin C1 and Integrin β1. This chapter aims to investigate if 
Sema7a+ hepatocytes act as a barrier, to prevent the spread of necrosis. 
Cell cycle arrest or senescence is induced during times of oxidative stress or DNA 
damage to prevent damaged cells from replicating. Senescent cells also secrete 
factors to recruit the immune system and reinforce senescence 143,268. It can be 
beneficial to prevent the spread of damage and mass cell death during tissue insult 
145, or detrimental if senescence persists and prevents tissue regeneration 143,144,146.  
During APAP injury, TGFβ signalling is upregulated 144,269 and induces cell cycle arrest 
in peri-necrotic hepatocytes, and prevents hepatocyte proliferation required for APAP 
recovery 144. In chronic liver and lung injury models, Sema7a forms a positive 
feedback loop with TGFβ, independent of SMAD 2/3, to promote noncanonical TGFβ 
signalling 246,247. In Chapter 3, TGFβ1 mRNA expression was significantly upregulated 
at 24 hours post APAP administration, at the same time point of peak Sema7a 
expression.  
As Sema7a can promote TGFβ signalling, and modulate the immune system, 
Sema7a may be part of a stress response with p21 to recruit the immune system and 
limit the spread of damage. Moreover, Sema3a is now recognised as a senescence 
marker 145. To be in cell cycle arrest, cells must be non-proliferative and express 
several cell cycle arrest markers. In Chapter 3, none of the Sema7a+ hepatocytes 
expressed the proliferation marker BrdU. Furthermore, a fifth of the Sema7a+ 
hepatocytes express the cell cycle arrest marker p21.  
To investigate the role of Sema7a during APAP injury and recovery in more detail, 
mice with Sema7a constitutively deleted 176 (Sema7a knock out (KO) mice) were 
treated with 350 mg/kg APAP, and compared to WT mice of the same genetic 
background. This chapter characterises the Sema7a KO mice during homeostasis, 
APAP injury and recovery. Specifically, I examine the following: firstly, if Sema7a+ 
hepatocytes prevent APAP injury by acting as a barrier to contain the spread of 
necrosis. Secondly, whether Sema7a promotes the expression of its receptors, 
Integrin β1 and Plexin C1. Thirdly, I investigate if Sema7a promotes expression of the 




cell cycle arrest marker p21. Lastly, I explore if Sema7a promotes hepatocyte 
proliferation after APAP injury. The effects of Sema7a on inflammation during APAP 
injury will explored in detail in Chapter 5.   
 
All data presented was assessed for normality. If required, a Welch test was applied 





Sema7a is absent in Sema7a KO mice 
To ensure the Sema7a KO mice were deficient for Sema7a, I assessed their 
expression of Sema7a at the genomic, mRNA and protein level (Figure 4. 1). 
Sema7a was absent at all levels, confirming Sema7a KO mice are deficient for 
Sema7a. In comparison, mRNA expression in WT mice was significantly 
upregulated (P= <0.0001) at 24 hours post APAP administration, compared to 
healthy WT and Sema7a KO mice, or Sema7a KO mice at 24 hours post APAP 
administration. 
  





Figure 4. 1 Sema7a is absent in Sema7a KO mice 
 
 
Figure 4. 1 
Sema7a is absent in Sema7a KO mice, as confirmed by:  
A) Genomic DNA PCR. The WT band for Sema7a is detected at 182bp, and the 
Sema7a KO band at 250bp. 1KB ladder on a 2% agarose gel.  
B) mRNA expression of Sema7a in whole liver lysate, relative to the housekeeper 
PPIA1. N=8. One-way ANOVA. WT mice have significantly upregulated 
Sema7a at 24 hours post APAP injury, compared to healthy WT mice and 
Sema7a KO mice, and Sema7a KO mice treated with 24 hours APAP.  
****p<0.0001.   
C) Sema7a protein expression at 24 hours 350 mg/kg APAP. Scale bars 100 µm. 
 
Data is shown from three APAP mouse experiments. 
 
Each dot represents an individual mouse. Data was checked for normality and equal 
variance. This applies to every figure henceforth. 
 
  




Sema7a KO mice do not have a baseline phenotype  
Before treating the Sema7a KO mice with APAP, I ensured healthy mice did not have 
a baseline phenotype which could alter their response to APAP treatment. 
Histologically, the livers of Sema7a KO mice appear normal (Figure 4. 4B).  
To examine liver function, liver function tests (LFTs) were performed. LFTs measures 
a panel of serum biomarkers associated with liver function: alanine transaminase 
(ALT), alkaline phosphatase (ALP), aspartate transaminase (AST), bilirubin and 
albumin. In the clinic raised LFTs indicate disease aetiology.  For details on each LFT 
biomarker, please see Table 4. 1. There was no significant difference between any of 
the biomarkers between the healthy WT and Sema7a KO mice, suggesting that liver 
function is unaltered by a deficiency of Sema7a (Figure 4. 2).  
To ensure APAP metabolism is unaffected in the Sema7a KO mice, Cyp2e1 
expression was examined. Cyp2e1 is restricted to zone 3 (Figure 4. 3), and converts 
APAP into the hepatotoxic metabolite NAPQI, giving APAP injury its characteristic 
centrilobular necrosis pattern. In the Sema7a KO mice, Cyp2e1 is still restricted to 
zone 3 and the area of expression is not significantly different to the healthy WT mice 
(Figure 4. 3). 
As the serum liver function tests, histology and Cyp2e1 expression are equivalent 
between the healthy WT and Sema7a KO mice, any differences seen during APAP 
injury will be due to a lack of Sema7a expression.   
 
  




Table 4. 1 Serum biomarkers used to assess liver function 
Biomarker Function Indications 
ALT ALT is a cytoplasmic enzyme found 
in high concentrations of the liver.  
 
In gluconeogenesis ALT catalyses 
the transfer of amino groups from 
alanine to ketoglutaric acid to 
produce pyruvic acid  




Extremely high levels are seen 
during: Hepatitis, APAP injury, 
ischemia reperfusion injury   
AST AST is located in the mitochondria 
and cytoplasm of: liver, cardiac and 
skeletal muscle, kidneys, brain and 
pancreas. 
 
In gluconeogenesis AST catalyses 
the transfer of amino groups from 
aspartic acid to ketoglutaric acid to 
produce oxaloacetic acid  
Released into the serum upon 
cellular injury. Not specific to 
the liver 
 
High levels: liver necrosis, 
cirrhosis or myocardial 
infarction  
ALP ALP is concentrated to the bile 
canaliculus. ALP can also be 
detected in bones and the intestines 
 
ALP is a zinc metalloenzyme which 
perform lipid transportation.   
Increased levels: Biliary 
disease or injury, hepatitis or 
bone disease  
Bilirubin Bilirubin is a breakdown product of 




Unconjugated bilirubin is insoluble. 
Conjugating bilirubin to albumin 
makes it water soluble  
Inability of hepatocytes to clear 
bilirubin  
 




Moderate levels: biliary 
obstruction   
Albumin Albumin is a globular protein 
synthesised in the liver 
 
It regulates the oncotic pressure of 
the blood and can act as a carrier 
protein  
Synthetic function test 
predominantly used to detect 
chronic liver disease.  
 
Low levels: decreased 
synthesis in the liver  
 
High levels: during APAP injury 
may indicate dehydration  
 
Information was gathered from: 270,271  




Figure 4. 2 Liver function is unaltered in healthy Sema7a KO mice  
 
Figure 4. 2 
To assess baseline function of the liver in Sema7a KO mice, serum biomarkers which 
indicate liver function were examined in saline treated WT and Sema7a KO mice.  
Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase 
(ALP), bilirubin and albumin.  
Unpaired t-test. Data from three APAP mouse experiments is shown.  
 
  




Figure 4. 3 Cyp2e1 areas are the same in WT and Sema7a KO mice 
 
Figure 4. 3 
A) Cyp2e1 DAB staining in healthy WT and Sema7a KO mice, representative 
images shown. 10x magnification. Scale bars 100 µm. 
B) Average percentage area of Cyp2e1 positivity in healthy WT and Sema7a KO 
mice.  
Data from three APAP mouse experiments is shown. 
  




Sema7a KO mice are more susceptible to APAP injury 
To investigate the role of Sema7a during APAP injury, WT and Sema7a KO mice 
were treated with 350mg/kg APAP at the following time points: i) 12 hours, when 
hepatocyte Sema7a expression is first detected, with ongoing inflammation and 
necrosis; ii) 24 hours, the time point of peak injury and Sema7a expression; iii) 42 
hours, to compare recovery of the Sema7a KO and WT mice. For a schematic of the 
experiment see Figure 4. 4A.  
The histology of WT and Sema7a KO mice was compared using H & E staining. 
Healthy WT and Sema7a KO mice have similar histology. At 12 hours post APAP 
injection, both WT and Sema7a KO mice have centrilobular necrosis with a faint 
boundary between the centrilobular necrosis and healthy tissue. Tissue necrosis was 
quantified using the Polaris and trainable inForm software. At 12 hours post APAP 
injury the Sema7a KO mice have significantly more necrosis (P= 0.0391) than WT 
mice. At 24 hours APAP, the boundary between the centrilobular necrosis and healthy 
tissue becomes defined in the WT mice, but not the Sema7a KO mice. The Sema7a 
KO mice also appear to have more infiltrating small mononucleated cells (identified 
by the presence of small blue nuclei) in the necrotic area (Figure 4. 4B). At 42 hours 
APAP the WT and Sema7a KO mice are histologically similar and are recovering from 








Figure 4. 4 Sema7a KO mice have more necrosis than WT mice 
 




Figure 4. 4 
 
A) Schematic of the APAP injury time course experiment  
B) H&Es of WT (left) or Sema7a KO mice (centre) treated with saline (top row), 12 
hours (second row), 24 hours (third row), or 42 hours (bottom row) 350mg/kg APAP. 
Area of necrosis (right) was quantified using the Polaris. Unpaired t-test. 
C) Area of necrosis over the time course of APAP injury. Two-way ANOVA with 
Sidak's multiple comparisons test. WT, blue; Sema7a KO, red.  
 
Data from eight APAP mouse experiments is shown.*p<0.05. Scale bars 100 µm. 
 
 
To further assess the extent of APAP injury in the WT and Sema7a KO mice, LFTs 
were performed. The increased necrosis at 12 hours APAP in the Sema7a KO mice 
is accompanied by raised ALT (P=0.0095), AST (P= 0.0107) and albumin (P= 
0.0212), confirming increased hepatocellular damage. Elevated albumin during acute 
liver injury may be due to dehydration, mice are less likely to eat or drink with a sore 
abdomen (Figure 4. 5). Necrosis at 24 hours and 42 hours post APAP injection was 
not significantly different in the WT and Sema7a KO mice. However, the Sema7a KO 
mice still had more ongoing damage as they had higher bilirubin (P= 0.0109) at 24 
hours APAP (Figure 4. 6) and higher ALP (P= 0.0306) at 42 hours APAP (Figure 4. 
7). These result show that throughout the APAP time course, Sema7a KO mice are 
more injured than WT mice. 
During all the APAP experiments, the mice were watched closely and culled if they 
approached the moderate severity threshold. Figure 4. 8 shows the numbers of WT 
and Sema7a KO mice which were humanely culled during the APAP experiments. 
Although not significant, the Sema7a KO mice reached the severity limit more often 
than WT mice. Indicating that Sema7a KO mice succumb to APAP injury more easily 
than WT mice. To confirm this, a survival experiment should be performed. This was 
not practically possible due to a lack of Sema7a KO mice.  
 
  




Figure 4. 5 Sema7a KO mice have elevated serum transaminases at 12 
hours post APAP injury 
 
Figure 4. 5 
Serum biochemical markers for liver function in WT and Sema7a KO mice treated 
with 350mg/kg APAP for 12 hours.  
Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase 
(ALP), bilirubin and albumin.  
Data from three APAP mouse experiments is shown. Unpaired t-test. *p<0.05, 
p<0.01** 
  




Figure 4. 6 Sema7a KO mice have raised bilirubin at 24 hours post APAP 
injury  
 
Figure 4. 6 
Serum biochemical markers for liver function in WT and Sema7a KO mice treated 
with 350mg/kg APAP for 24 hours  
Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase 
(ALP), bilirubin and albumin.  
Unpaired t-test. p*<0.05. Data from three APAP mouse experiments is shown. 
 
  




Figure 4. 7 Sema7a KO mice have raised ALP levels at 42 hours post 
APAP injury  
 
Figure 4. 7 
Serum biochemical markers for liver function in WT and Sema7a KO mice treated 
with 350mg/kg APAP for 42 hours  
Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase 
(ALP), bilirubin and albumin.  
Unpaired t-test. Data from three APAP mouse experiments is shown.  




Figure 4. 8 Sema7a KO mice are more sensitive to APAP injury  
 
Figure 4. 8 
Percentage of WT (blue) and Sema7a KO (red) mice reaching the severity threshold 
during 350mg/kg APAP experiments. Please not the x axis scale is different on the 
three graphs.  
A) All mice to from all experiments to 12 hours APAP 
B) Only mice taken to 24 hours and beyond, plus those humanely culled during 
the 12 hours APAP experiments  
C) Only mice taken to 42 hours APAP, plus those humanely culled in the 12 hours 
and 24 hours APAP experiments.   
Data from eight APAP mouse experiments is shown. 





ICAM-1+ expression is unaltered with APAP injury 
Microvasculature damage during APAP overdose further enhances injury 272,273. 
APAP toxicity directly targets the LSECs, causing them to swell, with gaps in the 
sinusoidal wall being detected from two hours post APAP overdose 18,19. This results 
in  microvascular permeability, and extravagation of erythrocytes 20,21. These changes 
can be detected before a rise serum ALTs and hepatocyte necrosis 18,272. The 
breakdown and congestion of the centrilobular microvasculature causes ischemic 
injury and enhances oxidant stress in the liver 19.  
In our APAP experiments, the Sema7a KO mice’s livers are harder to perfuse. To 
assess if the increased susceptibility of the Sema7a KO mice to APAP injury was due 
to increased vascular damage, ICAM-1 expression was assessed. There was no 
significant difference in the number of ICAM-1+ cells between healthy WT and 
Sema7a KO mice or at 24 hours APAP injury. ICAM-1+ expression is upregulated by 
pro-inflammatory cytokines during injury to aid neutrophil and monocyte recruitment 
260,274. However, the number of ICAM-1+ cells remained constant between the WT 
and Sema7a KO saline and APAP treated mice (Figure 4. 9).  
To assess if ICAM-1 expression is being upregulated during APAP injury, a 
quantitative test should be used. IHC is used to describe the location of protein 
expression with in a tissue, and the number of cells which express the protein of 
interest. However, fluorescence intensity does not directly correlate with the number 
of proteins expressed by a cell. Fluorescence can vary within a tissue and within a 
staining batch. Sources of variation within IHC include: tissue perfusion, the extent of 
injury (necrotic areas are always more auto-fluorescent), tissue fixation, antigen 
retrieval and edge effects. To quantify an upregulation in ICAM-1 expression, a 
quantitative analysis i.e. an ELISA for ICAM-1 should be performed. However, it will 
not directly answer the question of: Do Sema7a KO mice have increased vascular 
damage? As a loss or gain of ICAM-1+ could be contributed to a loss of ICAM-1+ 
LSECs, or a change in expression of ICAM-1 to recruit immune cells. Alternative 
methods to assess vessel permeability are the Evans blue assay, which detects 
extravagated albumin, or electron microscopy to assess the damage to the sinusoidal 
wall.  
 




Figure 4. 9 ICAM-1 is unaffected by APAP injury or Sema7a deficiency. 
 
Figure 4. 9 
A) ICAM-1 (green) expression on cryosections in WT (left) and Sema7a KO mice 
(right) treated with saline (top) and 24 hours APAP 350mg/kg treated mice 
(bottom). 20x images. Scale bars 100μm. 
B) Number of DAPI+ ICAM-1+ cells were counted using the Perkin Elmer 
Operetta. Each dot represents the average number of ICAM-1+ cells per 20x 
field of view, per individual mouse. One-way ANOVA. No significance was 
detected between any of the samples.  
 
  




Sema7a acts as a physical barrier during APAP injury 
In the above section, I demonstrated that Sema7a deficiency resulted in increased 
APAP injury. In WT mice, Sema7a+ hepatocytes surround the necrosis, which 
suggests Sema7a acts as a barrier against the spread of necrosis. To test this, a 
TUNEL assay was performed to identify the localisation of necrotic and apoptotic 
cells.  
TUNEL assays were performed on WT and Sema7a KO at 24 hours post APAP 
administration, when Sema7a expression is highest. Sections were scanned using 
the Perkin Elma Operetta. DAPI+ nuclei were identified using the Colombus software. 
Necrotic TUNEL+ nuclei were identified in this DAPI+ population to avoid auto-
fluorescent false positives. The percentage of TUNEL+ nuclei in the DAPI+ population 
was then calculated.  
WT and Sema7a KO mice had the same percentage of TUNEL+ nuclei, confirming 
the necrosis H&E analysis in Figure 4. 4.  In WT mice, TUNEL+ nuclei are confined 
to the necrotic area. However, Sema7a KO mice had TUNEL+ nuclei in the 
surrounding healthy parenchyma (P= 0.0151). This data supports that peri-necrotic 
Sema7a+ hepatocytes act as a barrier to limit the spread of necrosis (Figure 4. 10C).  
Cellular damage or stress can induce senescence. In Chapter 3, a fifth of Sema7a+ 
hepatocytes expressed the senescence marker p21. To test if Sema7a promotes p21 
expression, or if a lack of Sema7a causes more stress induced cell cycle arrest, p21 
expression was examined in WT and Sema7a KO mice. At 24 hours post APAP 
administration, there was no difference in the number of p21+ nuclei (Figure 4. 11A).  
To assess if a lack of Sema7a+ hepatocytes causes more cell stress in the 
parenchyma, the frequency of p21+ nuclei in the peri-necrotic hepatocytes and 
healthy parenchyma was assessed. Again, there was no significant difference 
between the WT and Sema7a KO mice (Figure 4. 11C & D). These results 
demonstrate that during APAP injury, Sema7a has no influence on p21 expression, 
and if Sema7a is induced as part of a stress response, it is independent from p21 
signalling. These results do not rule out that Sema7a influences p21 expression at 
another time point. Bird et al. performed most of their experiments at 48 hours post 
APAP injection 144. In our model, Sema7a expression decreases after 24 hours post 
APAP administration, so it is unlikely to play a role in p21 expression at later time 
points.   




Figure 4. 10 Sema7a limits the spread of necrosis 
 
Figure 4. 10 
A) TUNEL assay for necrosis (top, yellow), in WT (left) and Sema7a KO (right) 
mice at 24 hours 350 mg/kg APAP. Lower panels show the merged TUNEL 
and DAPI (blue) images. Dotted lines indicate the edge of necrosis. * label 
areas of necrosis. Red arrows indicate TUNEL+ nuclei outside the necrotic 
area. Scale bars 100 µm 
B) Percentage of TUNEL+ nuclei in WT and Sema7a KO mice. N=8 for each 
group  
C) Average number of TUNEL+ nuclei outside the necrotic area, per 10 x20 fields 
of view. N=8 for each group. p*<0.05 
Data from three APAP mouse experiments is shown. 




Figure 4. 11 Sema7a does not influence p21 expression during APAP 
injury 
 
Figure 4. 11 
A) p21 expression in WT (left) and Sema7a KO mice (right) at 24h 350mg/kg 
APAP.  
B) Average number of p21 nuclei. Unpaired t test. 
C) Average percentage of p21+ cells found in the peri-necrotic area (outlined in 
black dashes). Mann Whitney test.  
D) Average percentage of p21+ cells detected outside the necrotic and peri-
necrotic area. Mann Whitney test. 
Percentages are of the total p21+ nuclei population, averaged from six 20x fields of 
view. Peri-necrotic area outlined with black dashes. * indicates necrotic area. Scale 
bars 100μm. Data from two APAP overdose experiments is shown. 
  




High Mobility Group Box 1 (HMGB1) is a highly conserved protein and known DAMP. 
In the steady state, HMGB1 is retained in the nucleus, where it acts as a DNA 
chaperone to facilitate DNA transcription and binding. A lack of nuclear HMGB1 is a 
sign of cell stress. During injury, HMGB1 is passively released upon necrotic, but not 
apoptotic, cell death. In this setting HMGB1 acts as a DAMP to recruit more 
inflammatory cells. HMGB1 function is modulated by several post-translational 
modifications. Acetylated HMGB1 is actively secreted by macrophages as a cytokine, 
contributing to the recruitment of macrophages and dendritic cells to the site of injury 
275–277. In APAP injury, HMGB1 is released from necrotic cells as a DAMP, with serum 
levels of HMGB1 correlating with severity of APAP injury 278. Neutralizing HMGB1 with 
an antibody or deleting hepatic HMGB1, reduces APAP induced necrosis and 
inflammation 53,279.  
As Sema7a KO mice have more injury, and appear to have more infiltrating 
mononuclear cells, I questioned if HMGB1 was being released from the nucleus to 
promote inflammation. At 24 hours post APAP overdose, HMGB1 remains in the 
nuclei of hepatocytes in WT mice. In the Sema7a KO mice, the peri-necrotic 
hepatocytes which would express Sema7a consist of significantly more HMGB1 
negative nuclei (P= 0.0058) (Figure 4. 12). This suggests without Sema7a, the peri-
necrotic hepatocytes are more stressed or injured, and possibly secrete HMGB1 to 
promote inflammation.  
Further work is needed to define the role of HMGB1 in this setting. For example, 
serum levels of HMGB1 could be measured in the WT and Sema7a KO mice during 
APAP injury.  Oxidation and acetylation states of HMGB1 in the liver could be 
examined using mass spectrometry. In vitro, hepatocytes could be isolated from WT 
and Sema7a KO mice, and treated with APAP and the media analysed for HMGB1 
secretion. The effects of this conditioned media on macrophages could then be 
explored. In vivo, mice with a hepatic deletion for HMGB1 could be bred with the 
Sema7a KO mice to see if the non-nuclear HMGB1 promotes inflammation.  However, 
these experiments are outside the scope of my project.  
  




Figure 4. 12 HMGB1 becomes cytoplasmic in peri-necrotic hepatocytes 
in Sema7a KO mice  
 
Figure 4. 12 
A) HMGB1 staining in saline (left, 20x) or 24 hours APAP (right, 20x and 40x) treated 
WT (top) and Sema7a KO (bottom) mice. 40x images taken from inset yellow 
boxes. Yellow arrows indicate HMGB1 negative nuclei.  
Representative images shown.  
B) Average number of HMGB1 negative nuclei in saline treated mice. 
C) Average number of HMGB1 negative nuclei in WT and Sema7a KO mice at 24 
hours post APAP administration. 
Scale bars 100 µm. Unpaired t-test. *p<0.05. **p<0.01. Data from two APAP overdose 
experiments is shown. 
  




Sema7a receptor expression in Sema7a KO mice 
To examine if Sema7a expression on hepatocytes regulates receptor expression, the 
expression of Integrin β1 and Plexin C1 was assessed in the liver. Integrin β1 mRNA 
expression was not significantly different between WT and Sema7a KO mice treated 
with saline or at 24 hours post APAP injury. However, Integrinβ1 was elevated in 
Sema7a KO mice at 24 hours APAP injury compared to their healthy counterparts 
(P=0.0427), suggesting a slightly increased Integrin β1 transcription at 24 hours post 
APAP injection compared to healthy Sema7a KO mice (Figure 4. 13A).  At the protein 
level, WT and Sema7a KO had the same ubiquitous Integrin β1 expression pattern, 
and the same area of Integrin β1 positivity in both healthy mice and at 24 hours post 
APAP administration (Figure 4. 13).  
Plexin C1 is expressed at comparable levels in the WT and Sema7a KO mice, in 
healthy mice and 24 hours post APAP injury. At the protein level, Plexin C1 has the 
same morphological pattern, and area of Plexin C1 positivity in saline, 12 hours and 
42 hours APAP treated WT and Sema7a KO mice. At 24 hours post APAP overdose, 
there is significantly less Plexin C1 in Sema7a KO mice (P= 0.0208, Figure 4. 14). 
This data implies that Sema7a promotes PlexinC1 expression in HSCs at 24 hours 
post APAP administration. 
In Chapter 3, I showed that Plexin C1 is expressed on vimentin+ HSCs. To ensure 
the reduction in Plexin C1 expression is not due to a reduction in HSCs, I compared 
vimentin expression in WT and Sema7a KO mice. In healthy mice and at 24 hours 
post APAP overdose, the area of vimentin expression is the same in WT and Sema7a 
KO mice (Figure 4. 15). Therefore, the reduction in Plexin C1 expression is due to a 
deficiency of Sema7a. This should be confirmed with a quantitative assay.  
During this analysis, I observed that mice with less necrosis at 42 hours post APAP 
administration had visibly more intact elongated Plexin C1+ HSCs in the remaining 
necrotic area. This should be quantified by analysing the morphology of vimentin+ 
HSCs at 42 hours post APAP overdose and correlating it with necrosis. Potentially, 
these elongated HSCs are secreting ECM factors to aid tissue regeneration. 
Additional analysis could compare the production of ECM factors. Sema7a has been 
shown to promote collagen deposition and during chronic liver and lung injury 246,247. 
It would be interesting to see if ECM remodelling that is required for tissue 
regeneration is altered in the Sema7a KO mice.   




Figure 4. 13 Integrin β1 expression is unaffected in Sema7a KO mice 
 
 
Figure 4. 13 
A) mRNA expression of Integrin β1 in WT and Sema7a KO in whole liver lysate, 
treated with saline or at 24 hours post APAP administration, relative to WT 
saline treated mice. Kruskal-Wallis test, Dunn’s multiple comparison test. 
Sema7a KO saline vs, Sema7a KO 24 hours post APAP P=0.0427 
B) Integrin β1 staining in saline treated (top) and at 24 hours post APAP 
administration (bottom) treated WT (left) and Sema7a KO (right) mice. 
Representative images shown.  
C) Average area of Integrin β1 positivity in saline treated mice. 
D) Average area of Integrin β1 positivity in WT and Sema7a KO mice at 24 hours 
post APAP administration  
Scale bars 100 µm. Data from three APAP overdose experiments is shown Unpaired 
t-test, unless otherwise stated. *p<0.05 
  




Figure 4. 14 Plexin C1 expression is reduced in Sema7a KO mice at 24 









Figure 4. 14 
A) PlexinC1 mRNA expression in whole liver lysate from WT and Sema7a KO 
mice treated with saline or at 24 hours post APAP overdose. Kruskal-Wallis 
test.  
B) Plexin C1 expression in WT (left) or Sema7a KO mice (centre) treated with 
saline (top row), 12 hours (second row), 24 hours (third row), or 42 hours 
(bottom row) post APAP injection.  
Scale bars 100 µm. Data from eight APAP experiments is shown. Unpaired t-test, 
unless otherwise stated. *p<0.05   




Figure 4. 15 Vimentin expression is unchanged in Sema7a KO mice 
 
Figure 4. 15 
A) Confocal images of Vimentin (red, HSC marker), and Plexin C1 (green) 
expression with DAPI (blue) in WT and Sema7a KO mice treated with saline (top 
two rows) or 24 hours APAP (bottom two rows). Left column shows a 
representative 20x image. White boxes indicate where the 60x images on the right 
were taken from. Scale bars 100 µm. 
B) Average percentage area of vimentin expression in saline treated mice 




C) Average percentage area of vimentin expression in WT and Sema7a KO mice 
treated at 24 hours post APAP administration 
Unpaired t-test. Data from two APAP experiments is shown. 
 
Sema7a signalling pathways are not upregulated 
Sema7a signalling is predominantly mediated by the p-FAK, p-AKT and p-ERK 
pathway 209,217,218,246. In a model of rheumatoid arthritis, ADAM-17 cleaves Sema7a to 
promote the secretion of pro-inflammatory cytokines from macrophages 232. Sema7a 
can also promote TGFβ signalling and expression through a SMAD2/3 independent 
pathway 246,247. I questioned if a lack of Sema7a and the subsequent downregulation 
of Plexin C1 in HSCs was accompanied by a reduction in downstream Sema7a 
signalling in Sema7a KO mice. These signalling factors were examined in whole liver 
lysate at 24 hours APAP post overdose with qRT-PCR, but no significant difference 
was detected between the WT and Sema7a KO mice (Figure 4. 16).  
Ideally protein expression of TGFβ and TGFβR1 and protein phosphorylation states 
of FAK, AKT and ERK should be examined by a western blot to compare the activation 
of signalling pathways in the WT and Sema7a KO mice. However, due to the technical 
challenges in detecting temporary phosphorylation states of proteins at a low 
concentration in the whole liver lysate, I was unable to obtain a clean western blot. I 
tried to detect both TGFβ and TGFβR1 by IHC. Unfortunately, there is not a working 
antibody for TGFβ, and I could not optimise the TGFβR1 stain on my sections.  
 









Figure 4. 16 
mRNA expression of the indicated genes in whole liver lysate from WT and Sema7a 
KO mice at 24 hours post 350 mg/kg APAP administration, relative to WT mice. Data 
from three APAP experiments is shown. Unpaired t-test. 
 
  




Sema7a does not directly promote proliferation  
To recover from APAP injury, the remaining hepatocytes must proliferate to restore 
the parenchyma. To see if Sema7a had a role in recovery from APAP injury, 
proliferating cells were labelled with BrdU. At 42 hours post APAP overdose, Sema7a 
KO mice had the same levels of proliferation as the WT mice (Figure 4. 17) and area 
of necrosis (Figure 4. 4), indicating that hepatocyte proliferation from APAP injury is 
not affected by a Sema7a deficiency.  
In Chapter 3, I assessed Sema7a expression in the highly proliferative partial 
hepatectomy (PHx) model. In this model 70% of the liver is surgically removed. The 
remaining liver mass enters hyperplasia, so that by one week post PHx, the liver mass 
is restored 146. Sema7a was not detected in this model, confirming Sema7a is not 
required for hepatocyte proliferation. Sema7a may indirectly promote liver 
regeneration after APAP injury by preventing the spread of damage, or by influencing 
immune cells to phagocytose or to release anti-inflammatory cytokines, which 
promote recovery. 
To be completely certain that Sema7a does not have a role in recovery from APAP 
injury, necrosis and inflammation in Sema7a KO mice should be assessed at 72 hours 
and at one week post APAP injection, in comparison to WT mice. By one week post 
APAP overdose, WT mice will have recovered from APAP injury. Any lingering 
necrosis or inflammation will indicate that Sema7a KO mice have not recovered, and 
Sema7a is therefore required for the resolution of APAP injury. These experiments 










Figure 4. 17 WT and Sema7a KO mice have the same frequency of 
proliferation 
 
Figure 4. 17 
A) Dual stain for BrdU (red) and Hnf4a (green), dual positive yellow, in WT (left) 
and Sema7a KO (right) mice at 42 hours post APAP injection 
B) Percentage of BrdU+ nuclei in WT and Sema7a KO mice  
C) Percentage of dual positive Hnf4α and BrdU hepatocytes  
Images were quantified using the Columbus software. Scale bars 100μm. Data from 
three APAP experiments is shown.  





Centrilobular necrosis is a hallmark for APAP injury. In severe APAP injury, the 
necrosis spreads across the liver and results in acute liver failure. In our moderate 
APAP injury model, Sema7a is expressed on peri-necrotic hepatocytes, which contain 
TUNEL+ nuclei to the centrilobular necrotic area. In Sema7a KO mice TUNEL+ nuclei 
were detected in the healthy parenchyma. This demonstrates Sema7a+ hepatocytes 
act to limit the spread of necrosis. 
The Sema7a KO mice had more necrosis at 12 hours post APAP injection, elevated 
LFTs throughout the APAP time course and were more susceptible to APAP injury, 
compared to WT mice. In addition, Sema7a KO mice had peri-necrotic hepatocytes 
with non-nuclear HMGB1 expression, indicative of increased cellular stress at 24 
hours post APAP injury. Together, this data shows that Sema7a acts to prevent the 
spread of necrosis and reduces APAP injury. 
To the best of our knowledge, this is the first study investigating the role of Sema7a 
during APAP injury.  To ensure the mice with Sema7a constitutively removed did not 
have an underlying defect, which would affect their response to APAP, I compared 
healthy WT and Sema7a KO mice. Histology and liver function were similar. In 
addition, expression of: Cyp2e1, vimentin, HMGB1, ICAM-1 and the Sema7a 
receptors Plexin C1 and Integrin β1 were the same in healthy Sema7a KO and WT 
mice. Therefore, any differences between the WT and Sema7a KO mice during APAP 
injury are due to a lack of Sema7a+ hepatocytes, or possibly Sema7a on infiltrating 
immune cells, as Sema7a is constitutively removed 176.  
TUNEL+ cells were detected in the healthy parenchyma of Sema7a KO mice. The 
exact mechanism of how this occurs requires further investigation. One possible 
reason is that Sema7a on hepatocytes binds to Plexin C1 and Integrin β1 on the HSCs 
to form a physical barrier against the spread of ROS. Without this barrier the integrity 
is compromised allowing toxic solutes and ROS to spread into the surrounding 
parenchyma. To test this theory, I tried to compare the location and spread of 
oxidative stress in the WT and Sema7a KO mice. Due to the instability of ROS, it is 
difficult to assess their exact location in tissue using IHC.  Nitric oxide formed during 
APAP injury reacts with superoxide to form peroxynitrite, which nitrates tyrosines 
found in proteins, DNA and lipids to form 3-nitrotyrosine (3-NT) 16. 3-NT can therefore 
be used to assess oxidative stress during injury. I attempted to assess the localisation 




of 3-NT in Sema7a KO mice, compared to WT mice. Unfortunately, I could not get a 
successful 3-NT IHC stain.  
APAP toxicity has also been suggested to spread through decreased tight junctions 
or gap junctions. Integrin β1 forms tight junctions with collagen on the ECM and 
controls epithelial polarity 280. During APAP injury these tight junctions become 
disrupted in a dose dependant manner 127,128. Although the authors did not 
demonstrate if this could lead to enhanced APAP injury or the spreading of toxicity. 
Connexions (Cx) form gap junctions which allow the passage of solutes between cells. 
In the liver the main Cx is Cx32 136. During APAP injury, Cx32 can transmit toxic APAP 
solutes between cells, increasing liver injury in mice. Genetic deletion or using a the 
2-ABP small inhibitor of Cx32 prevents the spread of APAP induced necrosis 137. In 
vitro, deletion of the Cx32, Cx26 gap junction in coupled hepatocytes prevented 
synchronised necrotic cell death. Furthermore, coupling female hepatocytes which 
are naturally resistant to APAP toxicity, to male hepatocytes, which are more 
susceptible to APAP toxicity, prevented cell death of the male hepatocyte 140. Cx43 is 
upregulated during APAP injury, and Cx43 +/- mice had elevated ALT and increased 
IL-1β and TNFα secretion at 24 hours post APAP injury, suggesting Cx43 protects 
against APAP injury 141. Semaphorins are known actin modulators. The actin 
cytoskeleton transports de novo Cx43 channels from the Golgi to the plasma 
membrane 281, and stabilises the gap junction formation 131. Potentially, Sema7a 
mediates the formation of Cx43 channels to reduce the spread of necrosis during 
APAP injury.  
My second aim for this chapter is that Sema7a promotes the expression of its 
receptors. In Sema7a KO mice, Plexin C1 expression was significantly reduced at 24 
hours post APAP administration. This suggests that Sema7a upregulates Plexin C1 
expression in HSCs at peak APAP injury, although this is not seen at the transcript 
level. Integrin β1 and Plexin C1 expression were unaltered at other time points of 
APAP injury.  
Sema7a signalling regulates the cytoskeleton through Plexin C1 and Integrin β1 to 
control a delicate balance between cellular adhesion and deadhesion 209. Cofilin 
depolymerises F-actin at the slow growing end of the actin filament, providing new 
actin monomers for polymerization, facilitating cell motility. Cofilin is inhibited by 
phosphorylation by LIMK I and II 214,215. In melanocytes, Sema7a signalling through 




Integrin β1 and p-FAK causes actin polymerisation and melanocyte spreading 209,217.  
Whereas Sema7a - Plexin C1 - LMKII signalling results in the inactivation of cofilin 
and prevents melanocyte and dendritic cell spreading and adhesion 216–219.  
Potentially, Sema7a - Plexin C1 prevents HSCs actin remodelling and spreading 
during APAP injury. If this were true, Sema7a KO mice would have more elongated 
HSCs than WT mice, at 24 hours APAP injury.  However, as the area of vimentin 
remained the same in the WT and Sema7a KO mice, this is unlikely to be the 
mechanism of action. 
Sema7a signalling via Plexin C1 and Integrin β1 modulates the actin cytoskeleton, or 
cytokine secretion from immune cells through p-FAK, p-AKT and p-ERK 209,217,218. 
Sema7a can also promote TGFβ signalling and expression through p-FAK and p-AKT 
in activated HSCs during chronic liver injury 246. There was no significant difference in 
the mRNA expression of FAK, AKT, ERK, TGFβ1 or TGFβR1 between WT and 
Sema7a KO mice at 24 hours post APAP administration. Mechanistic studies which 
examine the protein expression and phosphorylation states of these signalling factors 
are needed to elucidate the actions of Sema7a signalling during APAP injury. 
Sema7a KO mice may have elevated HMGB1 signalling. At 24 hours post APAP 
overdose, Sema7a KO mice had peri-necrotic hepatocytes with non-nuclear HMGB1 
expression, which is indicative of increased cell stress. Active secretion of acetylated 
HMGB1, or the passive release of HMGB1 by necrotic cells as a DAMP, promotes 
inflammation 275,276. In APAP injury, serum HMGB1 correlates with injury 278 and 
hepatocyte HMGB1 signalling promotes neutrophil infiltration 53. As Sema7a KO mice 
have more injury, it is likely they will have elevated serum levels of HMGB1, but this 
remains to be examined. Sema7a KO mice appeared to have more infiltrating immune 
cells during APAP injury. A potential theory is that without Sema7a+ hepatocytes to 
limit the spread of necrosis, the peri-necrotic hepatocytes become more stressed, 
which results in the secretion of HMGB1, which promotes neutrophil infiltration. The 
effects of Sema7a in the innate immune system will be investigated in Chapter 5.   
Cell cycle arrest, or senescence, is induced in times of cellular stress 143. Previously, 
TGFβ signalling been shown to induce cell cycle arrest in peri-necrotic hepatocytes 
144. Sema7a has previously been shown to promote non-canonical TGFβ signalling 
through a positive feedback loop 246,247. In Chapter 3, a fifth of the Sema7a+ 
hepatocytes also expressed p21. Sema3a is now recognised as a senescence marker 




145. To see if Sema7a could induce cell cycle arrest during APAP injury, p21 
expression was examined, however, there was no significant difference WT or 
Sema7a KO mice. This implies Sema7a does not promote p21 expression. If Sema7a 
is part of a cell stress response, it is an independent mechanism to the cell cycle 
arrest pathway.  
The final aim for this chapter is that Sema7a promotes hepatocyte proliferation. 
Proliferative cells were labelled with BrdU. The frequency of BrdU+ nuclei and BrdU+ 
hepatocytes were not significantly different in the Sema7a KO mice compared to WT 
mice at 42 hours post APAP administration, showing Sema7a does not have a role in 
proliferation. The area of necrosis at 42 hours was also the same in the WT and 
Sema7a KO mice, but Sema7a KO mice have raised ALP levels, suggesting some 
ongoing damage. Therefore, Sema7a may have an indirect effect in recovery by 
limiting the spread of damage or by influencing the immune system. To investigate 
this further Sema7a KO mice should be compared at later time points e.g. 72 hours 
and one week post APAP administration, to ensure the Sema7a KO mice are 
completely recovered with no lingering necrosis or inflammation. 
To summarise, I have shown a novel role of Sema7a to act as a barrier to necrosis. 
At 24 hours post APAP overdose, Sema7a is expressed by peri-necrotic hepatocytes, 
and upregulates Plexin C1 expression. In Sema7a KO mice TUNEL+ necrotic cells 
are detected in the healthy parenchyma. In addition, a deficiency of Sema7a in the 
peri-necrotic hepatocytes caused them release HMGB1 from their nuclei, presumably 
as a stress signal to enhance inflammation. The expression of the cell cycle arrest 
marker, p21, was not affected in Sema7a KO mice. At 12 hours post APAP overdose 
Sema7a KO mice have more necrosis. Throughout the APAP time course, Sema7a 
KO mice had elevated LFTs and were more likely to succumb to APAP injury. 
Signifying Sema7a has a protective role during APAP injury. During recovery from 
APAP injury, Sema7a does not have a role in hepatocyte proliferation. However, 
Sema7a may indirectly influence recovery from APAP injury by preventing the spread 
of necrosis or influencing inflammation. The next chapter investigates the role of 
Sema7a in inflammation during APAP injury.  
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Introduction   
Sema7a deficiency resulted in increased susceptibility to APAP toxicity. Sema7a KO 
mice had raised LFTs and necrosis at both 12h and 24h post APAP administration, 
compared to WT mice (Chapter 4). At 24 hours post APAP overdose, TUNEL+ nuclei 
were detected outside the necrotic area, and HMGB1 negative nuclei were detected 
in peri-necrotic hepatocytes in Sema7a KO mice. Both events were absent in the WT 
mice. This suggests that Sema7a+ hepatocytes act as a barrier to contain the spread 
of necrosis. In Sema7a KO mice, there was an observed increase in the number of 
small mononuclear cells infiltrating the necrotic area (Chapter 4). This chapter 
examines the role of Sema7a in inflammation during APAP injury.  
Inflammation has both beneficial and detrimental roles during APAP injury. 
Neutrophils are the first responders to injury in the innate immune system 91. They are 
recruited to the liver during APAP injury by DAMPs including HMGB1 and formylated 
peptides, and cytokines including CXCL1 52,53,111,282. The exact role of neutrophils in 
APAP are unknown. It was originally suggested that neutrophils are detrimental during 
APAP, as they can release hydrolytic and oxidative enzymes, ROS and NETs, which 
can cause collateral damage to the tissue 91,110. However, studies which depleted 
neutrophils, or blocked their recruitment 60,116, or genetically prevented their ability to 
release ROS 59,60 showed no protection against APAP injury. Recently, neutrophils 
have been shown to promote recovery from APAP by secreting ROS to switch 
monocytes and macrophages to from the Ly6Chi pro-inflammatory phenotype to the 
Ly6Clo restorative phenotype 60.    
Macrophages are professional phagocytes, responsible for phagocytosing cellular 
debris. Kupffer cells (KCs) become depleted during APAP injury 48,49. Monocytes 
infiltrate the injured liver and mature into monocyte derived macrophages and become 
the dominant hepatic macrophage 48. Resident and infiltrating macrophages initially 
have a pro-inflammatory phenotype and release TNFα, IL-6, IL-1a and IL-18 to 
activate and recruit the innate immune system 4,45. TNFα also acts to prime 
hepatocytes for apoptosis, enhancing hepatocyte loss 4. To reduce the initial wave of 
inflammation, macrophage depletion studies with liposomal clodronate 61,62 or 
gadolinium chloride have been performed 55,56. Macrophage depletion was initially 
beneficial, but delayed or prevented recovery 21,51. During recovery, macrophages 
switch to an anti-inflammatory, pro-restorative phenotype. What initiates this switch is 
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unknown. Pro-restorative macrophages phagocytose debris, secrete cytokines 
including IL-10, to reduce inflammation, and promote hepatocyte proliferation by 
secreting IL-6 and TNFα 34,72,81,84,85. 
There is potentially a third macrophage population in the liver during injury. In a model 
of sterile thermal injury, F4/80+ GATA6+ peritoneal macrophages infiltrated the liver, 
dismantled necrotic nuclei and promoted regeneration 71. It is so far unknown how 
peritoneal macrophages contribute to APAP injury and recovery.  
Sema7a has been previously shown as a chemoattractant for monocytes, 
macrophages and dendritic cells 228–230, mediates neutrophil transmigration across an 
endothelial barrier 211 and modulates macrophage behaviour in a receptor dependant 
manner. If macrophages bind to Sema7a on intestinal epithelial cells through their 
Integrin αvβ1 receptor, they secrete the anti-inflammatory cytokine IL-10 236. Equally, 
if macrophages bind to Sema7a on T cells via their Integrin α1β1 receptor, they 
secrete the pro-inflammatory cytokines TNFα and IL-6 231. In vivo, Sema7a KO mice 
have less PMNs infiltrating the lungs in an acute LPS inhalation model 212, and less 
CD45+ cells  and F4/80+ macrophages in the liver after chronic CCl4 liver injury 246. 
However, after in TGFβ induced pulmonary fibrosis, inflammation was not effected in 
Sema7a KO mice 247.  
In dendritic cells, Sema7a- Plexin C1 signalling prevents cytoskeletal rearrangements 
required for dendritic cell adhesion, spreading, migration and phagocytosis 218,230. The 
herpes and vaccinia poxvirus use this to their advantage. They produce structural 
Sema7a mimic, which binds to Plexin C1 on dendritic cells. This prevents the dendritic 
cell from phagocytosing the virus, allowing the virus to thwart the immune system 
218,219,239.  
It is currently unknown how Sema7a regulates the immune system during APAP 
injury. Given previous findings, that Sema7a can facilitate neutrophil transmigration 
across an endothelial barrier, act as a chemoattractant for monocytes and modulate 
macrophage cytokine secretion. I hypothesise that Sema7a promotes inflammation 
during APAP injury.  
In Chapter 3, F4/80+ macrophages were detected adjacent to the Sema7a+ 
hepatocytes at 24 hours post APAP overdose, suggesting an interaction between 
these cells. Specifically, this chapter aims to describe how a deficiency of Sema7a 
affects the number of F4/80+ macrophages and neutrophils present in the liver, and 
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their localisation. I will also compare the relative frequencies of macrophages, 
monocytes and neutrophils systemically, by assessing these population in the blood 
and peritoneal lavage. Lastly, we examine if Sema7a is required for phagocytosis 
during APAP injury.  
 
Some of the in vivo experiments performed in this chapter required a collaborative 
effort. The use of ‘we’ indicates a team effort, with the deserved recognition in the 
respective figure legend. I performed all IHC staining, imaging and quantification; 
RNA isolation from the liver and subsequent qRT-PCR; BMDM isolation, 
differentiation and analysis; protein extraction and quantification; flow cytometry 
staining and analysis on blood, BMDMs and peritoneal exudate cells. Rhona Aird 
performed the F4/80 IHC. Jennifer Cartwright helped with staining the APAP time 
course for Ly6G and the subsequent counting of Ly6G+ cells. The MSD V-Plex was 
run in conjunction with Philip Starkey Lewis. Tail nicks were performed by Janet Man. 
APAP experiments were either performed solely by myself, or with help from Jennifer 
Cartwright or Lara Campana. Jennifer Cartwright performed the liver digest, staining 
and sample analysis for flow cytometry. Fiona Rossi helped set up the flow cytometry 
panels and checked the compensation. I performed the subsequent analysis on all 
flow cytometry data, with technical advice from Lara Campana. Lara Campana also 
provided technical advice for the in vitro and in vivo phagocytosis experiments. 
Technical assistance for confocal imaging was obtained from Matthieu Vermeren.  
 
All data presented was assessed for normality. If required, a Welch test was applied 
to correct for unequal variances between samples. Each dot represents an individual 
mouse.  
  




In Chapter 4, Sema7a KO mice appeared to have more small mononuclear cells 
infiltrating the APAP induced necrotic areas. To test this, the expression of CD45+, a 
leukocyte marker, was analysed in WT and Sema7a KO mice by flow cytometry and 
immunofluorescence at 24 hours post APAP overdose. In Figure 5. 1A, CD45+ cells 
are seen gravitating towards the necrotic area. In both analyses, the frequency of 
CD45+ cells is the same in the WT and Sema7a KO mice at 24 hours post APAP 
overdose (Figure 5. 1).  
Sema7a KO mice have less F4/80+ macrophages at 12 hours 
APAP overdose 
The CD45+ population examined in Figure 5. 1 consists of neutrophils, monocytes, 
macrophages, eosinophils and lymphoid cells. I questioned if a deficiency of Sema7a 
altered the composition of the CD45+ population in the liver during APAP injury. 
Specifically, we examined the localisation and population dynamics of F4/80+ 
macrophages during a time course of APAP injury, in WT and Sema7a KO mice.  
F4/80 is expressed by the resident KCs. During APAP injury, KCs become depleted. 
They are replaced by self-renewal 48, or by infiltrating CD11b+ F4/80lo macrophages 
which express F4/80+ 65. 
Healthy WT and Sema7a KO mice have similar levels of F4/80+ macrophages in the 
liver. At 12 hours post APAP overdose, the F4/80+ macrophage population becomes 
depleted. WT mice had an average of 71 F4/80+ macrophages per 20x field of view. 
Sema7a KO mice had visibly less F4/80+ macrophages (P=0.0483), with only 42 per 
20x field of view, suggesting an enhanced depletion of macrophages in the Sema7a 
KO mice (Figure 5. 2A).  
At 24 hours post APAP overdose, the F4/80+ population drastically increases, to 
levels above healthy mice as the infiltrating macrophages enter the liver and mature 
into F4/80+ macrophages (Figure 5. 2B). By this time point, the F4/80+ macrophage 
population in Sema7a KO mice has been restored to similar levels of WT mice, with 
155 and 150 F4/80+ macrophages, per 20x field of view, respectively. During 
recovery, at 42 hours post APAP injury, the number of F4/80+ macrophages is the 
same in WT and Sema7a KO mice (Figure 5. 2A). As the mice recover, the number 
of F4/80+ macrophages in the liver decreases (Figure 5. 2B).   
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Figure 5. 1  WT and Sema7a KO mice have the same frequency of 
CD45+ cells at 24 hours post APAP injury 
 
Figure 5. 1 
A) Localisation of CD45+ (green) cells in the liver, in relation to Sema7a (red) at 
24 hours post APAP administration in WT (top) and Sema7a KO (bottom) 
mice. DAPI nuclear stain. Quantification shows the percentage of CD45+ 
nuclei, out of the total nuclei, per field of view.  
Unpaired t-test. Scale bars 100µm. 
B) Flow cytometry analysis of live, CD45+ cells in the liver at 24 hours post APAP 
administration in WT (left) and Sema7a KO (centre) mice, quantified (right). 
Mann Whitney test. Data from three experiments is shown 
 
Each dot represents an individual mouse. Data was checked for normality and equal 
variance. This applies to every figure henceforth.   
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This dynamic response of macrophages to APAP injury has been previously reported 
in mice 48,49,51, and confirms that our model corresponds to those used in the literature. 
To the best of our knowledge, this is the first time Sema7a KO mice have been shown 
to have an enhanced depletion of F4/80+ macrophages, at 12 hours post APAP 
overdose. 
During APAP injury, infiltrating macrophages are recruited by CCL2/CCR2 49,63, and 
macrophages are directed to the necrotic area by DAMPs and cytokines. Sema7a is 
a  monocyte chemoattractant 228. In Chapter 3, F4/80+ macrophages were seen in 
close association with Sema7a+ hepatocytes, suggesting an interaction. To examine 
if a deficiency of Sema7a prevented the recruitment of F4/80+ macrophages to the 
necrotic area, the number of F4/80+ macrophages per necrotic area was analysed. 
Throughout the APAP time course, there was no significant difference between WT 
and Sema7a KO mice. Interestingly, the number of F4/80+ macrophages in the 
necrotic area correlates with both the number of F4/80+ macrophages in the liver, and 
the stage of injury. With the number of F4/80+ macrophages per necrotic area peaking 
at the height of APAP injury at 24 hours post APAP overdose and decreases as injury 
resolves (Figure 5. 2C). 
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Figure 5. 2 Sema7a KO mice have less F4/80 macrophages at 12 hours 
post APAP administration  
 




Figure 5. 2 
A) F4/80 staining for macrophages in WT (left column) and Sema7a KO mice 
(centre column) over a time course of APAP.  Number of F4/80+ macrophages 
per 20x field of view is quantified (right). In saline treated (top) or APAP treated 
mice at 12 (second row), 24 (third row) and 42 (bottom row) hours post 
administration. Unpaired t-test. Staining was performed by Rhona Aird.  
B) Average number of F4/80+ macrophages per 20x field of view, during the 
APAP injury time course. Two-way ANOVA, n.s.  
C) Average number of F4/80+ macrophages in the necrotic area during the time 
course of APAP injury. Two-way ANOVA, n.s.  
Data from eight APAP mice experiments is shown. WT mice, blue. Sema7a KO mice, 
red. Scale bars 100μm. *p< 0.05.  
 
 
In Figure 5. 2A, F4/80+ macrophages are detected next to the peri-necrotic 
hepatocytes, the same location of Sema7a+ hepatocytes at 24 hours post APAP 
administration. In Sema7a KO mice, the F4/80+ macrophages do not appear to be 
marginalised to the edge of necrosis. To examine if Sema7a+ hepatocytes cause 
F4/80+ macrophages to be marginalised to the edge of the necrotic area I separated 
the necrotic area into two zones, the central necrotic zone and the edge of the necrotic 
zone, and assessed how many F4/80+ macrophages were present per area (Figure 
5. 3B). Sema7a KO mice had significantly less macrophages in the central necrotic 
zone (P=0.0366), but the same number of F4/80+ macrophages at the edge of 
necrosis (Figure 5. 3C). This suggests that the Sema7a+ hepatocytes do not 
marginalise F4/80+ macrophages to the edge of necrosis. However, a Sema7a 
deficiency either directly or indirectly, prevents F4/80+ macrophages from infiltrating 
into the central necrotic zone. This could be due to a lack of Sema7a chemoattraction 
signals, or an inability for the F4/80+ macrophages to migrate through the tissue. 
Alternatively, as there were less F4/80+ macrophages at 12 hours post APAP 
overdose in Sema7a KO mice, the reduced number of F4/80+ macrophages in the 
central necrotic zone many reflect a delay in Sema7a KO F4/80+ macrophages being 
able to respond to APAP injury.  
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Figure 5. 3 F4/80+ macrophage localisation at 24 hours post APAP injury  
 
Figure 5. 3 
A) F4/80 staining in WT (left) and Sema7a KO mice (right) at 24 hours post APAP 
overdose.  
B) Method used to define areas of necrosis using ImageJ software. The central 
necrotic zone (centre) and outer necrotic zone (right) was delineated from the 
input image (left). The number of F4/80+ cells per necrotic area was 
calculated.  
C) Average number of F4/80 macrophages per defined necrotic zone (central, 
outer or total) in WT and Sema7a KO mice.   
Data from three APAP mice experiments is shown. Scale bars 100μm. Unpaired t-
test. *p< 0.05 
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Sema7a KO mice have more neutrophils in the necrotic area at 24 
hours post APAP injury  
 
Neutrophils are the first responders of the innate immune system, and are identified 
by the expression of Ly6G 283. During sterile injury, neutrophils adhere to ICAM on the 
LSECs and crawl along the sinusoids towards an increasing concentration of 
cytokines and DAMPs 52,91. To leave the sinusoid, neutrophils can exit via a fenestrae, 
or transmigrate 284. In a forced ventilation model of lung injury, neutrophils express 
Plexin C1 which binds to endothelial Sema7a to facilitate transmigration into the 
alveolar space 211,237. If Sema7a KO mice have a delay in their innate immune system 
response to APAP injury, it may be reflected in the neutrophil population.  
Neutrophils were examined in WT and Sema7a KO mice during a time course of 
APAP injury. Healthy WT and Sema7a KO mice had on average two patrolling 
neutrophils per field of view. By 12 hours post APAP administration, the neutrophil 
population dramatically increases. Neutrophils continue to accumulate in the liver until 
24 hours post APAP administration to a peak of 148 and 132 neutrophils per field of 
view in WT and Sema7a KO mice respectively. After this time point, the neutrophil 
population decreases in both the WT and Sema7a KO mice, as seen by the decrease 
in the number of neutrophils by 42 hours post APAP overdose.  Throughout the APAP 
time course, no statistical difference was detected between the WT and Sema7a KO 
mice (Figure 5. 4A). Combining this data and comparing it to the F4/80+ macrophage 
time course (Figure 5. 2B), clearly depicts neutrophils acting as the first responders 
to injury. At 12 hours post APAP overdose, there is mass infiltration of neutrophils 
(Figure 5. 4B), before the infiltrating macrophages replenish the F4/80+ macrophage 
population at 24 hours (Figure 5. 2B). Both the neutrophil and the F4/80+ macrophage 
population peak at 24 hours post APAP administration, and decrease by 42 hours 
post APAP administration, as injury resolves. 
During APAP injury, neutrophils can be seen homing towards the necrotic area. Whilst 
analysing the population during the time course in Figure 5. 4, we observed that the 
Sema7a KO mice had more neutrophils present in the necrotic area. This is confirmed 
in Figure 5. 5, where Sema7a KO mice have significantly more neutrophils per 
necrotic area (P= 0.0182), but not per field of view at 24 hours post APAP 
administration.  




The increased neutrophil population in the necrotic area could be due to several 
factors: an increased infiltration of neutrophils into the liver during APAP injury in 
Sema7a KO mice; a delay in neutrophils and macrophages infiltrating into the necrotic 
area; a defect in the neutrophils ability to reverse migrate back into the vasculature; 
or reduced phagocytosis of neutrophils by macrophages. The rest of this chapter 
investigates why there are more neutrophils in the necrotic area at 24 hours post 












Figure 5. 4 
A) Ly6G staining for neutrophils in WT (left column) and Sema7a KO mice (centre 
column).  Number of neutrophils per 20x field of view quantified (right column). 
In saline treated (top) or APAP treated mice at 12 (second row), 24 (third row) 
and 42 hours (bottom row) post administration. Unpaired t-test.  The 12 hours 
and 24 hours timepoints required a Welch correction.  
B) Average number of neutrophils per 20x field of view, during the APAP injury 
time course. Two-way ANOVA, n.s.  
WT mice, blue. Sema7a KO mice, red. Scale bars 100μm. Data from eight APAP mice 
experiments is shown. Staining and analysis was performed in collaboration with 
Jennifer Cartwright.  
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Figure 5. 4 Neutrophils infiltrate the liver during APAP injury 
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Figure 5. 5 Sema7a KO mice have more neutrophils in the necrotic area 
at 24 hours post APAP overdose 
 
Figure 5. 5 
A) Ly6G staining to detect neutrophils in WT (left) and Sema7a KO mice (right) 
at 24 hours post APAP overdose. 
B) Number of Ly6G+ neutrophils per 10x field of view. Unpaired t-test with 
Welch's correction.  
C) Number of Ly6G+ cells per necrotic area. Unpaired t-test. 
Data from three APAP mice experiments is shown. *p< 0.05. Scale bars 100μm. 
Analysis was performed by Jennifer Cartwright.   
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Healthy Sema7a KO and WT mice have similar numbers of 
circulating neutrophils and monocytes  
 
Neutrophils and monocytes originate from the bone marrow and circulate the body in 
search of pathogens or cytokines 48,51,91. To ensure the increased number of 
neutrophils in the necrotic area and depleted F4/80+ macrophage population was not 
due to difference in the frequency of circulating neutrophils or monocytes, these 
populations were analysed in the peripheral blood of healthy mice.  
Peripheral blood was collected by either a tail nick from naive mice, or 12 hours after 
a saline injection to mimic an APAP experiment. In both scenarios, the frequency of 
circulating Ly6C+ monocytes (Figure 5. 6B) and neutrophils (Figure 5. 6C) were 
statistically the same between the WT and Sema7a KO mice. This implies the 
differences seen during APAP injury are not due to an increase or decrease in the 
number of available circulating neutrophils or monocytes.  
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Figure 5. 6 Healthy WT and Sema7a KO mice have the same frequency 
of circulating neutrophils and monocytes  
 
Figure 5. 6  
The frequency of blood monocytes and neutrophils in healthy WT and Sema7a KO 
mice. Blood was obtained via a tail nick, or from mice which had been starved for 12 
hours, injected with saline, and sacrificed 12 hours later to mimic an APAP 
experiment. The experiment was performed twice.  
A) Ly6G+ neutrophils and Ly6C+ monocytes populations in blood, from healthy 
WT (left) and Sema7a KO mice (right). Plots were previously gated for Cells, 
singlets, live, CD45+, and Lineage-.  
B) Frequency of monocytes in blood obtained via a tail nick (left), or cardiac 
puncture (right). Mann Whitney test. 
C) Frequency of neutrophils in blood obtained via a tail nick (left), or cardiac 
puncture (right). Mann Whitney test.   
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Neutrophils do not express Sema7a, but both neutrophils and 
macrophages express the Sema7a receptors  
Sema7a is constitutively deleted in the Sema7a KO mice 176. To ensure the 
differences seen between the WT and Sema7a KO mice are not due to an intrinsic 
defect in the neutrophils from a Sema7a deficiency, I examined protein expression of 
Sema7a in neutrophils with confocal imaging. Neutrophils do not express Sema7a in 
WT mice (Figure 5. 7A).  
The main receptors for Sema7a are: Plexin C1 and Integrin β1, which dimerises with 
either Integrin α1 or αν. To examine if the changes seen could be due to a lack of 
Sema7a signalling from other cell types, I examined the expression of the Sema7a 
receptors on neutrophils.  Neutrophils express Plexin C1, as seen by confocal imaging 
(Figure 5. 7B), and flow cytometry (Figure 5. 8A), as previously reported 218. 
Neutrophils also express Integrin β1 and αν, but not Integrin α1 (Figure 5. 8B-D). A 
deficiency of Sema7a did not affect the frequency of neutrophils which expressed the 
Sema7a receptors, or the intensity at which the receptors were expressed (Figure 5. 
8).  
In Chapter 3 Figure 3.17, F4/80+ macrophages were closely associated with 
Sema7a+ hepatocytes but did not express Sema7a at the protein or transcription level 
(Figure 3.17). WT BMDMs did express the receptors Integrin β1, α1 and αν (Figure 
3.17). To examine if Sema7a KO BMDMs expressed the Sema7a receptors at a 
similar level to the WT BMDMs, receptor expression was analysed by flow cytometry. 
Plexin C1, Integrin β1 and α1 were detected at a similar frequency on BMDMs from 
WT and Sema7a KO mice, and at a similar intensity (Figure 5. 9).  
Together, these results imply the differences seen in the neutrophil and F4/80+ 
macrophage populations during APAP injury is due to a lack of external Sema7a 
signalling in the Sema7a KO mice, and not an intrinsic defect due to a Sema7a 
deficiency within these innate immune cells.  
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Figure 5. 7 Neutrophils express Plexin C1 but not Sema7a  
 
Figure 5. 7 
A) Confocal imaging of neutrophils (Ly6G, cyan) and expression of Sema7a (magenta). Scale bars: 40 µm 
B) Confocal imaging of neutrophils (Ly6G, cyan) and expression of Plexin C1 (magenta). Scale bars: 50 µm 
Images are from WT mice at 24 hours post APAP injection. Nuclear stain, DAPI (yellow). White inset indicates area used for high power 
images.  
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Figure 5. 8 Neutrophils express the Sema7a receptors  
 
Figure 5. 8 
Expression of Sema7a receptors on Live, Lin-, CD45+, Ly6G+ neutrophils from 
peripheral blood of healthy WT and Sema7a KO mice 
A) Plexin C1. Mann Whitney test for %Plexin C1/ Ly6G+.  
B) Integrin β1. Mann Whitney test for both quantification graphs.  
C) Integrin αν 
D) Integrin α1 
Left, representative histogram showing neutrophil receptor expression. WT, cyan; 
Sema7a KO, magenta; FMO, yellow.  Centre, frequency of receptor expression. 
Right, receptor intensity on Ly6G+ cells, assessed by Mean fluorescent intensity 
(MFI).  Unpaired t-test, unless stated otherwise. Data is shown from one experiment.  
Chapter 5 - Results  
182 
 
Figure 5. 9 BMDMs express the Sema7a receptors 
 
Figure 5. 9 
WT and Sema7a KO BMDMs were selected for: singlets, live, then analysed for 
Integrin β1 (CD11b) expression (A). CD11b+ BMDMs were analysed for the other 
Sema7a receptors (B&C): 
A) Integrin β1 
B) Plexin C1  
C) Integrin α1 
Left, representative histogram showing BMDM receptor expression. WT, cyan; 
Sema7a KO, magenta; FMO, yellow.  Centre, frequency of receptor expression on 
BMDMs. Right MFI of receptor on BMDMs.  
Each dot represents one BMDM sample, with each colour representing a single 
experiment. Data from four experiments is shown. A higher power is needed for 
statistical analysis.  
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Sema7a KO mice have elevated serum levels of IL-6 and CXCL1 
 
During APAP injury, cytokines attract and activate the innate immune system. To 
examine if the expression of inflammatory cytokines were altered in the Sema7a KO 
mice, qRT-PCR was utilised. At 24 hours post APAP administration, there was no 
significant difference in mRNA expression of IL-1β, IL-6, CXCL1 (mouse homolog to 
IL-8), MCP-1 or IL-10 (Figure 5. 10) in whole liver lysate.  
To assess protein cytokine expression, the MSD V-Plex system was employed. IL-6 
(P=0.0078), and CXCL1 (P=0.0459) were significantly increased the serum of 
Sema7a KO mice at 24 hours post APAP administration, compared to WT mice 
(Figure 5. 11). In the whole liver, there was no significant difference between the WT 
and Sema7a KO mice in any of the cytokines tested (Figure 5. 11). These results 
indicate Sema7a KO mice have more systemic inflammation than WT mice. CXCL1 
is a neutrophil chemoattractant 52,91. It may enhance recruitment during APAP injury 




Chapter 5 - Results  
184 
 
Figure 5. 10 mRNA expression of pro-inflammatory cytokines in whole 
liver lysate is similar in WT and Sema7a KO mice 
 
Figure 5. 10 
mRNA expression of pro-inflammatory genes at 24 hours post 350 mg/kg APAP 
injection in WT and Sema7a KO mice, relative to WT mice.  
IL-6, IL-10, Mann Whitney test.  
Unpaired t-test unless otherwise indicated. Data from three APAP mouse experiments 
is shown. The ELISA was performed twice.  
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Figure 5. 11 Sema7a KO mice have elevated IL-6 and CXCL1 in serum 
at 24 hours post APAP injury 
 
Figure 5. 11 
Serum (left column) and whole liver lysate (right column) from WT and Sema7a KO 
mice at 24 hours post APAP injection, were analysed for the following cytokine 
expression, with the MSD V-Plex: 
A) IL-6. Serum: Unpaired t-test with Welch's correction. 
B) CXCL1. Serum and whole liver lysate: Unpaired t-test with Welch's correction. 
C) IL-1β. Whole liver lysate Mann Whitney test. 
D) IL-10. Whole liver lysate Mann Whitney test. 
Unpaired t-test unless otherwise indicated. *p< 0.05, ** p<0.01. Data from three APAP 
mouse experiments is shown. The ELISA was performed twice   
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Macrophages and neutrophils are viable during APAP injury  
Neutrophils apoptose at the site of injury, and release ‘find me’ signals that attract 
monocytes, which then phagocytose the apoptotic neutrophil 91,121,149. A possible 
reason for more neutrophils in the necrotic area of Sema7a KO mice is that they are 
dying and not being cleared by phagocytosis. In our model, the number of neutrophils 
in the liver decreases after 24 hours post APAP administration (Figure 5. 4B).  
To examine if the neutrophils were undergoing apoptosis at 24 hours post APAP 
injury, a dual stain of Ly6G and active Caspase 3, an apoptosis marker, was 
performed. In WT mice 1.6% of Ly6G+ neutrophils are dual positive for active caspase 
3. Sema7a KO mice had significantly less apoptotic neutrophils (P =0.0129), with only 
0.8% of Ly6G+ neutrophils expressing active caspase 3 (Figure 5. 12). This data 
suggests neutrophils are not undergoing apoptosis at 24 hours post APAP 
administration. However, it is unknown how long neutrophils maintain their Ly6G 
expression for when they apoptose. So, we may not be detecting all the apoptotic 
neutrophils present at 24 hours post APAP overdose. Alternatively, the neutrophils 
could be being engulfed immediately after they apoptose, making them difficult to 
detect. 
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Figure 5. 12 Sema7a KO mice have less apoptotic neutrophils at 24 
hours APAP injury 
 
Figure 5. 12 
A) Staining for Ly6G+ neutrophils (green) and active Caspase 3 (aCsp3, red), in 
WT and Sema7a KO mice at 24 hours APAP overdose. Scale bars µm.  
B) Percent of apoptotic neutrophils (aCsp3+, Ly6G+) in the total Ly6G population. 
Unpaired t-test with Welch's correction, p<0.05.  
aCsp3, active Caspase 3. Data from three APAP mouse experiments is shown. 




Resident macrophages become depleted during APAP injury 48,49, as they succumb 
to APAP toxicity 50. Sema7a KO mice have less F4/80+ macrophages in the liver at 
12 hours post APAP administration. To examine if Sema7a KO F4/80+ macrophages 
have increased cell death at 12 hours post APAP administration, F4/80+ macrophage 
viability was examined by flow cytometry.  
The non-parenchymal cell (NPC) fraction was isolated from the livers of WT and 
Sema7a KO mice at 12 hours post APAP administration. Viability was assessed using 
the Live/Dead (L/D) e780 viability dye. L/D is impermeable to healthy cells. Dying and 
dead cells have permeable or damaged cell membranes, allowing L/D to covalently 
bind to intracellular amines. Therefore, dead cells are L/D+, which can be easily 
separated from viable L/D- cells during flow cytometry 285.  
The following populations were examined for viability at 12h post APAP injury: Ly6G+ 
neutrophils; Ly6G-, F4/80hi CD11blo resident macrophages; and Ly6G-, F4/80lo 
CD11bhi infiltrating macrophages, which further subdivided into Ly6Clo macrophages 
and Ly6Chi monocytes. There was no significant difference in viability in any of these 
populations between WT and Sema7a KO mice. Resident macrophages and 
neutrophils both had around 95% viability in WT and Sema7a KO mice (Figure 5. 13). 
Collectively, resident F4/80+ macrophages and neutrophils are not undergoing cell 
death at 12 hours post APAP administration. At 24 hours post APAP administration, 
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Figure 5. 13 Hepatic neutrophils and macrophages are viable at 12 hours 
post APAP injury 
 
Figure 5. 13 
Liver NPCs were isolated from WT (left) and Sema7a KO mice (centre), at 12 hours 
350mg/kg APAP. Viability was assessed in the following populations: Neutrophils, 
resident macrophages, and infiltrating cells, which was separated into Ly6C hi and 
Ly6C lo. Data shown is from one experiment. Gates were set using FMOs. Percentage 
viability is quantified right. Data from three APAP mouse experiments is shown.   
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Investigating the composition of leukocytes in WT and Sema7a KO 
mice during APAP injury 
 
Sema7a KO mice have more neutrophils in the necrotic areas at 24 hours APAP post 
overdose (Figure 5. 5) and a higher expression of CXCL1 in the serum (Figure 5. 11).  
Could this systemic CXCL1 recruit neutrophils from other compartments in the 
Sema7a KO mice?  
In the IHC analysis, Sema7a KO mice had less F4/80+ macrophages at 12 hours post 
APAP administration. Whilst at 24 hours APAP, the F4/80+ macrophage population 
was equivalent to WT mice (Figure 5. 2). Do Sema7a KO mice have more 
macrophages infiltrating into the liver to restore the F4/80+ macrophage population?  
To investigate these questions, flow cytometry was used to analyse specific subsets 
of neutrophils, monocytes and macrophages, isolated from the liver, blood and 
peritoneum of WT and Sema7a KO mice, at 12 and 24 hours post APAP 
administration. For a schematic of the experiment please see Figure 5. 14A and 
Figure 5. 19A respectively.   
 
At 12 hours post APAP overdose, Sema7a KO mice have a higher 
frequency of infiltrating macrophages 
 
We first analysed the liver at 12 hours post APAP administration, to see if we could 
detect an early accumulation of Ly6G+ neutrophils and the enhanced depletion of 
F4/80+ macrophages in the Sema7a KO mice. Neutrophils were defined as CD45+, 
lineage (CD3, CD19 & NK1.1) -, Ly6G+. Resident macrophages (Mϕ) were defined 
as CD45+, lineage-, Ly6G-, F4/80hi CD11blo. Infiltrating macrophages were defined 
as CD45+, lineage-, Ly6G-, F4/80lo CD11bhi 72. This infiltrating macrophage 
population was further subdivided into Ly6Clo macrophages and Ly6Chi monocytes, 
which have yet to mature into Ly6Clo macrophages.  For the full gating strategy, for all 
the flow cytometry, please see Chapter 2. 
In the liver, the frequency of neutrophils was significantly lower in Sema7a KO mice 
(P=0.0178) than WT mice at 12 hours post APAP administration (Figure 5. 14B). WT 
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and Sema7a KO mice had the same frequency of resident macrophages with 3.6% 
and 3.2% of the NPC CD45+ fraction, respectively (Figure 5. 14C). Infiltrating 
macrophages were significantly higher (P=0.036) in Sema7a KO mice with 29.0% of 
CD45+ cells compared to 19.2% of CD45+ cells in WT mice. 86.3% and 86.8% of the 
infiltrating macrophages are freshly infiltrated Ly6Chi monocytes in WT and Sema7a 
KO mice, respectively (Figure 5. 14D). This data implies that Sema7a KO mice have 
a lower frequency of neutrophils but a higher frequency of macrophages infiltrating 
the liver at 12 hours post APAP administration. 
Examining the percentage frequency of a population can be misleading. Large 
changes in the abundance of a specific population will affect the frequency of other 
populations cells, but this may not be reflected in the absolute quantity of cells 286. To 
examine if the lower frequency of Ly6G+ neutrophils and increased frequency of 
infiltrating macrophages is reflected in cellular number in the liver, the absolute counts 
of each population were assessed per gram of liver. At 12 hours post APAP 
administration, WT and Sema7a KO mice had the same absolute count of neutrophils 
and resident macrophages per gram of liver. However, Sema7a KO mice had a higher 
quantity of infiltrating macrophages (P=0.0472) than WT mice, per gram of liver. 
Consistent with this, Sema7a KO mice had significantly more Ly6Chi monocytes, per 
gram of liver (P=0.0456) compared to WT mice (Figure 5. 15).  
These absolute counts per gram of liver confirms that Sema7a KO mice have more 
infiltrating macrophages at 12 hours post APAP administration than WT mice, with a 
greater proportion being Ly6Chi. However, WT and Sema7a KO mice have the same 
quantity of neutrophils. This implies that a Sema7a deficiency does not affect total 
neutrophil infiltration at 12 hours post APAP administration. The absolute quantity of 
resident macrophages was also equal in WT and Sema7a KO mice. The different 
results obtained by flow cytometry and IHC are obtained via different methods and 
these variations will be considered in the discussion.  
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Figure 5. 14 Sema7a KO mice have less neutrophils infiltrating the liver than WT mice at 12 hours post APAP injury  
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Figure 5. 14 
A) Experimental design. After a 12 hour fast, mice were administered with 350 
mg/kg APAP. 4 hours later a phagocytic dye (PKH) was injected i.v. Mice were 
humanely sacrificed at 12 hours APAP.  
NPCs were isolated from the livers of WT (left) and Sema7a KO mice (centre). 
Representative plots from three experiments are shown. The frequency of the 
following NPC populations in the CD45+ fraction, is quantified (right): 
B) Neutrophils  
C) Resident macrophages (Mϕ) (quantified left); and infiltrating macrophages 
(quantified right) 
D) Infiltrating macrophages subdivided by Ly6Chi and Ly6Clo (Mann Whitney) 
expression 
Liver digestion and staining was performed by Jennifer Cartwright. Unpaired t-test, 
unless otherwise stated. *p< 0.05. Data shown is from one experiment. 
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Figure 5. 15 Absolute counts of NPCs at 12 hours post APAP injury 
 
Figure 5. 15 
Absolute counts of neutrophils, resident macrophages (Mann Whitney), infiltrating 
macrophages, Ly6Chi monocytes, and Ly6Clo macrophages per gram of liver in WT 
and Sema7a KO mice at 12 hours post APAP overdose. *p<0.05 
Unpaired t-test unless otherwise stated. The experiment was performed once.  
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Infiltrating neutrophils and monocytes originate from the bone marrow and are 
delivered to the liver by the circulation 51,52,111,287. I considered if the increase in 
infiltrating macrophages and higher neutrophil population was due to an increase in 
circulating neutrophils and monocytes at 12 hours post APAP administration.  
Using flow cytometry, the frequency of circulating: CD45+, lineage + (CD3+, CD19+) 
B and T cells; CD45+, lineage-, Ly6G+ neutrophils; and CD45+, linage-, Ly6G- 
monocytes were analysed in WT and Sema7a KO mice at 12 hours post APAP 
administration. WT and Sema7a KO mice had the same frequency of circulating B 
and T cells, Ly6G+ neutrophils and Ly6G- monocytes (Figure 5. 16 A & B). Yet, 
Sema7a KO mice had a significantly higher frequency (P= 0.0297) of Ly6Clo 
monocytes with 2.3% of CD45+ cells compared to 0.7% of CD45+ cells in WT mice 
at 12 hours post APAP administration (Figure 5. 16C). Collectively, Sema7a KO mice 
have more circulating Ly6Clo monocytes, which contribute to the higher levels of 
infiltrating macrophages of Sema7a KO mice at 12 hours post APAP administration.  
 
GATA6+ peritoneal macrophages infiltrate the liver and promote recovery in a model 
of sterile thermal injury 71. If and how these macrophages contribute to inflammation 
during APAP is currently unexplored. To examine if peritoneal exudate cells (PEC) 
contribute to enhanced neutrophil or macrophages infiltration, the composition of PEC 
from WT and Sema7a KO were compared at 12 hours post APAP administration. WT 
and Sema7a KO mice had the same frequency of: CD11b+ cells, CD11b+ Ly6G+ 
neutrophils, CD11b+ Ly6G- cells, Ly6Chi monocytes (Figure 5. 17) and F4/80+ mature 
macrophages, (Figure 5. 18), which have been previously reported to be GATA6+ 70.  
Due to time restraints, this experiment was only performed once, and is currently 
underpowered. With a sample number of 8, there may be a significantly more 
neutrophils and Ly6Chi monocytes in Sema7a KO mice in the PEC at 12 hours post 
APAP administration (Figure 5. 17B & C). Therefore, the current conclusion of no 
significant difference between WT and Sema7a KO mice would be incorrect.  
 
Correction: In the original analysis, the CD11b+ Ly6G- gate was examined as Ly6C 
monocytes, which was subdivided into the Ly6Chi and Ly6Clo populations. However, 
this CD11b+ Ly6G- population will include monocytes, macrophages, T cells and B1 
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cells 70,254. A lineage negative step should have been included to exclusively examine 
the peritoneal monocytes. 
The MHCII+ F4/80- and MHCII- F4/80- macrophage populations were also examined 
in live PECs. Again neutrophils, monocytes, T and B1 cells should have been 
excluded prior to analysis of the macrophage populations. The analysis of: Ly6C 
monocytes, Ly6Clo monocytes, MHCII+ F4/80- and MHCII- F4/80- macrophages has 
been removed but are still shown on the flow cytometry plots. As mature macrophages 
are exclusively F4/80+, they are still included in the analysis 70,254. 
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Figure 5. 16 Sema7a KO mice have a higher frequency of circulating Ly6Clo monocytes at 12 hours post APAP injury 
 




Figure 5. 16 
Peripheral blood was collected from WT (left) and Sema7a KO mice (right) at 12 hours 
post 350mg/kg APAP administration. Representative plots from three experiments are 
shown. Quantification (right) shows the frequency of CD45+ cells for the following 
populations: 
A) B & T cells (Lin + (CD3+ & CD19+)) 
B) Neutrophils (quantified left) and monocytes (quantified right) 
C) The monocyte population was analysed for Ly6Chi (quantified left); and Ly6Clo 
monocytes (quantified right).  
For the gating strategy see Chapter 2. Unpaired t-test, unless otherwise stated. *p< 




Figure 5. 17 
PECs were collected from WT (left) and Sema7a KO (centre) mice at 12 hours post 
350mg/kg APAP administration.  
Quantification (right) shows the frequency of: 
A) CD11b+ cells, in live cells 
B) Neutrophils (CD11b+, Ly6G+, quantified left,) and CD11b+ Ly6G- cells as a 
percentage of live cells  
C) Ly6Chi in the Ly6G- fraction.  
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Figure 5. 17 Sema7a KO mice have the same frequency of neutrophils in the peritoneal exudate as WT mice at 12 
hours post APAP overdose  
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Figure 5. 18 WT and Sema7a KO mice a similar frequency of F4/80+ 
macrophages in the peritoneal exudate at 12 hours post APAP injury 
 
Figure 5. 18 
A) Live, Peritoneal macrophages were isolated from WT (left) and Sema7a KO 
(right) mice, at 12 post hours APAP overdose, and separated by the 
expression of F4/80 and MHC Class II 
B) Frequency of F4/80+. Mann Whitney test 
Data shown is from one experiment.  
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At 24 hours post APAP administration, WT and Sema7a KO mice 
have similar frequencies of immune cells  
Sema7a KO mice have more neutrophils in the necrotic area at 24 hours post APAP 
injury (Figure 5. 5).  Histological analysis also revealed the lower F4/80+ macrophage 
population at 12 hours post APAP administration is restored by 24 hours (Figure 5. 
2).  In the flow cytometry experiments, Sema7a KO mice had significantly more Ly6Clo 
monocytes in the blood and infiltrating macrophages in the liver, but the resident 
macrophage population was equivalent to WT mice (Figure 5. 14 & Figure 5. 15).  
To investigate if the increased neutrophil population in the necrotic areas of Sema7a 
KO mice was due to an increased neutrophil depletion from other tissues, or a higher 
or prolonged infiltration of neutrophils, the neutrophil population in the liver, blood and 
PEC was examined in WT and Sema7a KO mice at 24 hours post APAP 
administration. The composition of the monocyte/ macrophage populations were also 
examined in these tissues.  
In the NPC CD45+ fraction of the liver, WT and Sema7a KO mice have the same 
frequency of: neutrophils, resident macrophages, and infiltrating macrophages, which 
were composed of the same proportions of Ly6Chi and Ly6Clo monocytes (Figure 5. 
19). To ensure that this was reflected in the quantity of cells present in the liver, the 
absolute count was calculated.  No significant differences were detected, confirming 
that WT and Sema7a KO have similar frequencies and abundance of each population 
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Figure 5. 19 WT and Sema7a KO mice have the same frequency of neutrophils and macrophages in the liver at 24 
hours post APAP injury  
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Figure 5. 19 
A) Experimental design. After a 12 hour fast, mice were administered with 350 
mg/kg APAP. 8 hours later a phagocytic dye (PKH) was injected i.v. Mice were 
humanely sacrificed at 24 hours APAP.  
NPCs were isolated from the livers of WT (left) and Sema7a KO mice (centre). 
Quantification shows the frequency in CD45+ cells for the following NPC populations: 
B) Neutrophils  
C) Resident macrophages (quantified left, Mann Whitney test); Infiltrating 
macrophages (quantified right).  
D) Infiltrating macrophages were examined for Ly6Chi and Ly6Clo expression 
For a gating strategy see Chapter 2. Data from three experiments is shown. Liver 
digestion and staining was performed by Jennifer Cartwright. Unpaired t-test, unless 
otherwise stated.  
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Figure 5. 20 Absolute counts of hepatic immune cells are the same in 
WT and Sema7a KO at 24 hours post APAP administration 
 
Figure 5. 20 
Absolute counts of neutrophils, resident macrophages, infiltrating macrophages, 
Ly6Chi monocytes, and Ly6Clo macrophages per gram of liver in WT and Sema7a KO 
mice at 24 hours post APAP overdose. Data from three experiments is shown.  
Mann Whitney test. 
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Next the frequency of monocytes and neutrophils were examined in the blood from 
WT and Sema7a KO mice at 24 hours post APAP administration. WT and Sema7a 
KO mice have similar frequencies of B and T cells, neutrophils, and monocytes in the 
live, CD45+ population in the blood at 24 hours APAP. In addition, the infiltrating 
monocytes had the same proportions of Ly6Chi and Ly6Clo monocytes (Figure 5. 21).  
The composition of the PEC was also compared between WT and Sema7a KO mice 
at 24 hours APAP injury. 57% of the live cells were CD11b+ in Sema7a KO mice, 
which was significantly higher (P=0.0181) than the 34% in WT mice (Figure 5. 22A). 
CD11b is a marker expressed on B1 cells monocytes, macrophages, natural killer 
(NK) cells 254,288, and is upregulated on activated neutrophils 289.  
WT and Sema7a KO mice had the same frequencies of neutrophils, Ly6G- cells, 
Ly6Chi monocytes (Figure 5. 22) and F4/80+ mature macrophages in the peritoneal 
exudate (Figure 5. 23). The increased frequency of CD11b may indicate Sema7a KO 
mice have a higher proportion of B1 or NK cells not analysed here, or more activated 
neutrophils.  
Overall, by 24 hours APAP post injury and differences in the macrophage 
compartment have been resolved. WT and Sema7a KO mice have the same 
frequency and number of macrophages as monocytes in the liver, blood and PEC. 
The increased neutrophil population the necrotic area at 24 hours post APAP 
administration in the Sema7a KO mice, is not due to an enhanced infiltration of 
neutrophils from the blood or peritoneum, as there was no significant difference in the 
frequency of Ly6G+ neutrophils in the blood or PEC between WT and Sema7a KO 
mice at both 12 or 24 hours post APAP administration. 
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Figure 5. 21 WT and Sema7a KO mice have the same frequency of circulating leukocytes at 24 hours post APAP 
injury 
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Figure 5. 22 Sema7a KO mice have more peritoneal CD11b+ cells than WT mice at 24 hours APAP post overdose  





Figure 5. 21 
Peripheral blood was collected from WT (left) and Sema7a KO mice (right), treated 
with 24 hours 350mg/kg APAP. Graphs show the frequency in live, CD45+ cells for 
the following populations: 
A) B & T cells (Lin +, (CD3+ & CD19+)); 
B) Neutrophils (quantified left); and monocytes (quantified right); 
C) Ly6Chi (quantified left, Mann Whitney test); and Ly6Clo monocytes (quantified 
right).  
For a gating strategy see Chapter 2. Data from three experiments is shown. Unpaired 
t-test, unless otherwise stated.  
 
Figure 5. 22 
PECs were collected from WT (left) and Sema7a KO (centre) mice at 24 hours post 
350mg/kg APAP administration.  
Quantification shows the frequency of: 
A) CD11b+ cells.  
B) Neutrophils (CD11b+, Ly6G+, quantified left, Mann Whitney test) and CD11b+ 
Ly6G- cells (quantified right, Mann Whitney test); as a percentage of live cells 
C) Ly6Chi in the CD11b+ Ly6G- cell fraction (Mann Whitney test).  
Data from three experiments is shown. Unpaired t-test, unless otherwise stated. *p< 
0.05. 
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Figure 5. 23 WT and Sema7a KO mice a have a similar frequency of 
peritoneal F4/80+ macrophages at 24 hours post APAP injury  
 
Figure 5. 23 
A) Macrophage populations in the peritoneal lavage were separated by the 
expression of F4/80 and MHC Class II on live cells from WT (left) and Sema7a 
KO (right) mice, treated with 24 hours APAP.  
B) Frequency of F4/80hi mature macrophages. Mann Whitney test. 
Data from three experiments is shown.   
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Comparing leukocyte composition between 12 and 24 hours post 
APAP overdose 
 
To further analyse the dynamics of the immune system during APAP injury, I 
compared the frequency of each population present between 12 hours and 24 hours 
post APAP administration in the WT mice, and separately in the Sema7a KO mice.  
In WT mice, the frequency of all NPC populations examined in the liver remained 
constant between 12 and 24 hours post APAP administration (Figure 5. 24). In our 
model, resident macrophages become depleted at 12 hours post APAP administration 
(Figure 5. 2). In Figure 5. 24, the resident macrophages have not significantly 
increased in frequency from 12 hours to 24 hours post APAP administration. This 
suggests that the resident macrophage population is not restored by 24 hours post 
APAP overdose, and the dominant macrophage of the liver is the infiltrating 
macrophage.  
Sema7a KO mice had a significantly lower frequency of infiltrating macrophages 
(P=0.0343) and Ly6Chi monocytes (P=0.0317) at 24 hours compared to 12 hours post 
APAP administration (Figure 5. 24). This reduction may reflect the Sema7a KO 
macrophage populations returning to normal levels, after the higher influx of infiltrating 
macrophages seen at 12 hours APAP injury.  
Circulatory neutrophils and monocytes remained constant in both the WT and 
Sema7a KO mice at 12 and 24 hours post APAP administration (Figure 5. 25).  
Peritoneal F4/80+ GATA6+ macrophages have been previously reported to infiltrate 
the liver from the peritoneum to promote recovery from a sterile thermal injury 70,71. 
This is not seen here between 12 and 24 hours post administration, as the frequency 
of peritoneal macrophages and neutrophils remained constant between these 
timepoints (Figure 5. 26).    
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Figure 5. 24 The frequency of infiltrating macrophages in the liver 
declines from 12 to 24 hours post APAP in Sema7a KO mice 
 
Figure 5. 24 
The frequency of NPC cells in the liver was compared between 12 and 24 hours post 
APAP administration in WT (blue) and Sema7a KO mice (red). Unpaired t-tests, 
unless otherwise indicated, tested the null hypothesis that there was no change in the 
frequency of the NPC population between 12 and 24 in WT mice, or Sema7a KO mice 
in a separate unpaired t-test.  
The following NPC populations were analysed: Ly6G+ neutrophils, resident 
macrophages (WT, Mann Whitney; Sema7a KO, Welch test), infiltrating 
macrophages, Ly6Chi and Ly6Clo (WT, Mann Whitney) macrophages. *p<0.05. The 
12 hour APAP experiment was performed once. The 24 hour APAP experiment was 
performed three times.  





Figure 5. 25 The frequency of neutrophils and monocytes are stable in 
the blood during APAP injury 
 
Figure 5. 25 
The frequency of circulating immune cells was compared between 12 and 24 hours 
post APAP administration in WT (blue) and Sema7a KO mice (red). Unpaired t-tests, 
unless otherwise indicated, tested the null hypothesis that there was no change in the 
frequency of the NPC population between the 12 hour and 24 hour time point in WT 
mice, or Sema7a KO mice in a separate unpaired t-test.  
The following populations were analysed: Ly6G+ neutrophils (WT, Mann Whitney), 
monocytes (WT, Mann Whitney), Ly6Chi (Sema7a KO, Mann Whitney) and Ly6Clo 
monocytes.  
The 12 hour APAP experiment was performed once. The 24 hour APAP experiment 
was performed three times.  
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Figure 5. 26 The frequencies of PEC populations do not change during 
APAP injury 
 
Figure 5. 26 
WT (blue) and Sema7a KO mice (red) were compared between 12 and 24 hours post 
APAP administration for the frequency of the following populations in the peritoneal 
exudate:  
CD11b+ cells (Sema7a KO, Unpaired t-test), Ly6G+ neutrophils, Ly6Chi monocytes 
and F4/80+ macrophages.  
Mann Whitney test unless otherwise stated.  The 12 hour APAP experiment was 
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Comparing in vitro phagocytosis of WT and Sema7a KO BMDMs 
Phagocytosis of necrotic debris is required for recovery from APAP injury, and is 
primarily performed by macrophages 32,51,81. Phagocytosing macrophages switch from 
an pro- inflammatory phenotype to a restorative phenotype 72,82,149, and secrete 
cytokines such as IL-10 35,62 to reduce inflammation and IL-6 and TNFα to promote 
hepatocyte proliferation 84,85. 
Previously, it has been shown that the herpes and vaccinia poxvirus (A39R) can avoid 
being phagocytosed by dendritic cells by structurally mimicking Sema7a 218,219. The 
viruses bind to Plexin C1 on dendritic cells to prevent the p-FAK dependant 
cytoskeletal rearrangements required for the dendritic cells to perform phagocytosis 
218,219,239. Therefore, Sema7a mediates phagocytosis through regulation of the 
cytoskeleton in dendritic cells. To the best of my knowledge, how Sema7a regulates 
macrophage phagocytosis has not been investigated. 
CD11b+ BMDMs were generated from WT and Sema7a KO mice. Apoptotic 
thymocytes were pre-labelled with the fluorescent CMTMR dye, and fed to BMDMs 
for two hours, to mimic macrophage phagocytosis of cellular debris during APAP 
injury. The frequency of phagocytosis (frequency of CD11b+ CMTMR+ BMDMs) was 
analysed by flow cytometry (Figure 5. 27 A&B).  
On average, 15.6% of WT BMDMs had phagocytosed apoptotic T cells after two 
hours, but only 7.0% Sema7a KO BMDMs had phagocytosed. Unfortunately, there is 
only 2 repeats of this experiment for the WT BMDMs, due to a fungal infection. With 
an equal sample number this result may have reached significance (Figure 5. 27C).  
When visualising the BMDMs by microscopy, the Sema7a KO BMDMs were less 
smooth in morphology. From each bone marrow isolation, Sema7a KO mice gave a 
had lower yield of BMDMs compared to their WT counterparts. In summary, Sema7a 
KO BMDMs had an altered growth, altered morphology and tended to have a lower 
frequency of phagocytosis.    
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Figure 5. 27 WT and Sema7a KO BMDMs have the same phagocytic 
capacity in vitro 
 
Figure 5. 27 
A) Schematic of in vitro phagocytosis experiment   
B) Diagram of in vitro phagocytosis experiment. BMDMs labelled with CD11b are 
fed 1:5 CMTMR labelled phagocytic thymocytes. BMDMs which have 
phagocytosed apoptotic thymocytes are CD11b+ CMTMR+. 
C) Flow cytometry analysis of in vitro phagocytosis experiment. Plots show 
single, Live CD11b+ cells. CMTMR- BMDMs blue, CMTMR+ BMDMs, orange. 
WT BMDMs (left) Sema7a KO BMDMs (centre), quantification (right).  
Samples were run in triplicate. Each dot represents one BMDM sample, with each 
colour representing a single experiment. Data from four experiments is shown. Mann 
Whitney test.  
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In vivo phagocytosis is unaltered in the Sema7a KO mice at 12 
hours post APAP injury 
 
To recover from APAP injury, phagocytosis is required to remove debris. In Figure 5. 
27, Sema7a KO BMDMs had the same frequency of phagocytosis as WT BMDMs. 
However, this study is underpowered. With the correct statistical power, the trend of 
Sema7a KO BMDMs having a lower frequency of phagocytosis in vitro, may be 
correct.  
To examine if defective phagocytosis in Sema7a KO mice caused the increased 
necrosis seen at 12 hours and raised LFTs at 12 and 24 hours post APAP 
administration, an in vivo phagocytosis assay was performed. A PKH phagocytic dye 
was injected i.v. 4 hours after APAP administration, mice were euthanised at 12 hours 
post APAP administration. Phagocytosis was then analysed in the liver, blood and 
PEC by flow cytometry. For a schematic of this experiment please see Figure 5. 14.  
In the liver neutrophils, resident macrophages, infiltrating macrophages and the 
Ly6Clo and Ly6Chi subpopulations had the same frequency of phagocytosis in WT and 
Sema7a KO mice at 12 hours post APAP administration (Figure 5. 28). Resident 
macrophages had the highest frequency of phagocytosis, with 87.0% and 89.7% 
PKH+ in the WT and Sema7a KO mice, respectively (Figure 5. 28B). Infiltrating 
macrophages had a low frequency of phagocytosis with 3.7% and 2.8% PKH+ in the 
WT and Sema7a KO mice, respectively. This may reflect that the infiltrating 
macrophages are yet to mature into Ly6Clo restorative macrophages. However, I 
previously detailed no difference in the frequency of Ly6Clo macrophages between 12 
and 24 hours post APAP administration (Figure 5. 24).  
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Figure 5. 28 Liver NPC have the same frequency of phagocytosis in WT 
and Sema7a KO mice at 12 hours post APAP administration  
 




Figure 5. 28 
In vivo phagocytosis by liver NPCs isolated from WT (left) and Sema7a KO mice 
(centre), at 12 hours 350 mg/kg APAP. Quantification (right) show the percentage of 
phagocytosing cells in each NPC population:  
A) Neutrophils,  
B) Resident macrophages (Mann Whitney test),  
C) Infiltrating macrophages, which was separated into  
D) Ly6Chi monocytes  
E) Ly6Clo macrophages 
Liver digestion and staining was performed by Jennifer Cartwright. Data shown is from 
one experiment. Each dot represents a single mouse. Purple dot, a mouse which 
received less PKH i.v.  
Unpaired t-test, unless otherwise stated.   
 
 
Phagocytosis was also examined in the blood. The populations were analysed as 
before in Figure 5. 16. WT and Sema7a KO mice had the same frequency of 
phagocytosis in Ly6G+ neutrophils, Ly6G- monocytes, Ly6Clo and Ly6Chi monocytes 
(Figure 5. 29). Overall, there was very little phagocytosis in the blood with most values 
below 5% PKH+.  
PECs were also analysed for phagocytosis. PEC populations were analysed as 
before in Figure 5. 17, or Figure 5. 18 specifically for peritoneal macrophages. 
Peritoneal neutrophils and macrophages had the same phagocytosis in WT and 
Sema7a KO mice at 12 hours post APAP overdose (Figure 5. 30A & C). However, 
Ly6Chi monocytes had significantly lower frequency of phagocytosis in Sema7a KO 
mice with 3.9% PKH+, compared to 22.6% PKH+ in WT mice (P=0.0159, Figure 5. 
30B). 
Altogether, there was no significant difference in the frequency of PKH phagocytosis 
between WT and Sema7a KO mice at 12 hours post APAP administration. The 
exception being peritoneal Ly6Chi monocytes, which had a lower frequency of 
phagocytosis in Sema7a KO mice. However, this result may be skewed by low cell 
counts of peritoneal Ly6Chi monocytes in the WT mice.  
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Figure 5. 29 Circulatory cells have the same phagocytosis in WT and 
Sema7a KO mice at 12 hours post APAP injury  
 
Figure 5. 29 
Populations in the peripheral blood from WT (left) and Sema7a KO mice (centre), 
collected at 12 hours post APAP administration, was analysed for the frequency of 
phagocytosis (PKH+), quantified (right): 
A) Neutrophils  
B) Monocytes, which were separated into:  
C) Ly6Chi and  
D) Ly6Clo  
Data from one experiment is shown. Each dot represents a single mouse. Purple dot, 
a mouse which received less PKH i.v. Unpaired t-test.   
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Figure 5. 30 Sema7a KO Peritoneal Ly6Chi monocytes have a lower 
frequency of phagocytosis at 12 hours post APAP overdose 
 
 
Figure 5. 30 
The frequency of PEC phagocytosis was assessed, at 12 hours post APAP overdose 
in WT and Sema7a KO mice, in the following populations:  
A) Neutrophils  
B) Ly6Chi monocytes  
C) F4/80+ macrophages 
Data from one experiment is shown. Mann Whitney test. *p<0.05.  
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In vivo phagocytosis is unaltered in the Sema7a KO mice at 24 
hours APAP injury  
 
After peak injury at 24 hours post APAP administration, mice begin to recover. This 
requires necrotic material to be removed by phagocytosis.  We questioned if in vivo 
phagocytosis was delayed or decreased in Sema7a KO mice. PKH was administered 
at 8 hours post APAP injection, and mice were sacrificed at 24 hours post APAP 
administration. For an experimental schematic, please see Figure 5. 19A. Gating for 
the analysed populations is outlined in Figure 5. 19, and detailed in Chapter 2. 
At 24 hours hepatic innate immune cell populations; neutrophils, resident 
macrophages and infiltrating macrophages, Ly6Clo macrophages and Ly6Chi 
monocytes, had the same frequency of phagocytosis in WT and Sema7a KO mice, 
(Figure 5. 31). Resident macrophages still had the highest phagocytic capacity with 
64.4% and 63.1% PKH+ in WT and Sema7a KO mice, respectively (Figure 5. 31B).  
Infiltrating macrophages had 11.1% and 20.7% PKH+ in WT and Sema7a KO mice, 
respectively (Figure 5. 31C). Indicating that the infiltrating macrophages are helping 
the resident macrophages to clear away the debris. Within the infiltrating macrophage 
population, the Ly6Clo macrophages had a frequency of 17.1% and 28.4% 
phagocytosis in WT and Sema7a KO mice respectively. This was similar to the 
frequency of phagocytosis in the Ly6Chi monocytes which had 13.2% and 22.4% 
PKH+ in WT and Sema7a KO mice, respectively.  
Phagocytosis was also analysed in the blood cells. WT and Sema7a KO mice had 
similar frequencies of phagocytosis in circulating neutrophils, monocytes and in the 
monocyte subpopulations of Ly6Clo and Ly6Chi (Figure 5. 32).  
PECs were also analysed for PKH phagocytosis. Peritoneal neutrophils, Ly6Chi 
monocytes and F4/80+ macrophages had the same frequency of phagocytosis in WT 
and Sema7a KO mice (Figure 5. 33).  
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Figure 5. 31 Liver NPC have the same phagocytosis in WT and Sema7a 
KO mice at 24 hours post APAP administration  
 




Figure 5. 31 
In vivo phagocytosis by liver NPCs isolated in WT (left) and Sema7a KO mice (centre), 
at 24 hours post APAP injection. Graphs (right) show the frequency of phagocytosing 
cells in each NPC population:  
A) Neutrophils (Mann Whitney test),  
B) Resident macrophages (Mann Whitney test),  
C) Infiltrating macrophages, which was separated into (D) and (E) 
D) Ly6Chi infiltrating macrophages  
E) Ly6Clo infiltrating macrophages 
Data from three experiments is shown. Liver digestion and staining was performed by 





Chapter 5 - Results 
224 
 
Figure 5. 32 Circulatory cells have the same phagocytosis in WT and 
Sema7a KO mice at 24 hours post APAP injury 
 
Figure 5. 32 
Peripheral blood was collected from WT (left) and Sema7a KO mice (centre) at 24 
hours APAP. The following populations were analysed for frequency phagocytosis 
(PKH+):  
A) Neutrophils,  
B) Monocytes  
C) Ly6Chi monocytes  
D) Ly6Clo monocytes 
Data is shown from three experiments, and quantified (right). Unpaired t-test, unless 
otherwise stated.   
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Figure 5. 33 PECs have the same phagocytosis in WT and Sema7a KO 
mice at 24 hours post APAP injury 
 
Figure 5. 33 
PECs were collected from WT (left) and Sema7a KO mice (centre) at 24 hours post 
APAP overdose. The following populations were analysed for frequency of 
phagocytosis (PKH+), quantified (right):  
A) Neutrophils  
B) Ly6Chi monocytes 
C) F4/80+ macrophages  
Data is shown from three experiments. Mann Whitney test.   
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The frequency of monocyte phagocytosis is significantly increased 
at 24 hours post APAP overdose 
 
At 24 hours post APAP administration, there was trend of increased in vivo 
phagocytosis, compared to 12 hours. To quantify this, the frequency of phagocytosis 
from each population was compared in the WT between 12 and 24 hours post APAP 
overdose, and in Sema7a KO mice between 12 and 24 hours post APAP overdose.  
The frequency of phagocytosis in infiltrating macrophages in the liver increased from 
3.7% at 12 hours to 11.1% at 24 hours post APAP overdose in WT mice. In Sema7a 
KO mice the frequency of phagocytosis rose significantly (P=0.0467) from 2.8% PKH+ 
at 12 hours, to 20.7% PKH+ at 24 hours post APAP overdose (Figure 5. 34). In 
addition, the Ly6Chi monocyte subpopulation of the infiltrating macrophages also had 
significantly higher %PKH+ (P=0.0206). This increased phagocytosis by infiltrating 
macrophages will clear debris created by APAP toxicity. The increase in phagocytosis 
by Ly6Chi monocytes may reflect a switch from a pro inflammatory phenotype to the 
Ly6Clo restorative phenotype. However, and increase in the percentage of Ly6Clo 
macrophages was not seen in the Sema7a KO mice at 24 hours post APAP 
administration. Perhaps 24 hours post APAP administration is the start switch 
between Ly6Chi and Ly6Clo phenotypes. A significant change may therefore be 
detected at later timepoints.   
In Sema7a KO mice, circulating neutrophils (P=0.0439), monocytes (P=0.0225) and 
the Ly6Chi (P=0.0232) and Ly6Clo monocytes (P=0.0152) all had increased frequency 
of phagocytosis at 24 hours compared to 12 hours post APAP administration. In WT 
mice, these populations had a trend to increase, but only the Ly6Clo population had a 
significant increase in the frequency of phagocytosis (P=0.0364) (Figure 5. 35).  
Peritoneal macrophages, Ly6Chi monocytes and neutrophils did not change their 
frequency of phagocytosis from 12 to 24 hours post APAP injury in either WT and 
Sema7a KO.  This suggests phagocytosis by PECs is not a major requirement 
following APAP injury (Figure 5. 36).  
On the whole, there is increased phagocytosis at 24 hours post APAP overdose. 
Sema7a KO mice had significantly more phagocytosis in infiltrating macrophages of 
the liver, and blood monocytes at 24 hours, compared to 12 hours post APAP 
administration, underlining the systemic nature of APAP injury.   
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Figure 5. 34 Infiltrating macrophages significantly increase their 
frequency of phagocytosis from 12 hours to 24 hours post APAP injury  
 
Figure 5. 34 
The frequency of liver NPC cells phagocytosis was compared between 12 and 24 
hours post APAP administration in WT (blue) and Sema7a KO mice (red).  
%PKH+ was analysed in the following NPC populations: Ly6G+ neutrophils (WT, 
Mann Whitney; Sema7a KO, Welch test), resident macrophages (WT and Sema7a 
KO, Mann Whitney), infiltrating macrophages (WT and Sema7a KO, Welch test), 
Ly6Chi (Sema7a KO, Welch test) and Ly6Clo (WT and Sema7a KO, Welch test) 
macrophages.  
Unpaired t-test, unless otherwise indicated, between 12 and 24 hours post APAP in 
WT or Sema7a KO mice. * p<0.05. The 12 hour APAP experiment was performed 
once. The 24 hour APAP experiment was performed three times.  




Figure 5. 35 Monocytes in the blood of Sema7a KO mice significantly 
increase their frequency of phagocytosis from 12 to 24 hours APAP 
injury  
 
Figure 5. 35 
The frequency of phagocytosis in circulating immune cells was compared between 12 
and 24 hours post APAP administration in WT (blue) and Sema7a KO mice (red), in 
the following populations: Ly6G+ neutrophils (WT and Sema7a KO mice, Welch test), 
monocytes (WT, Mann Whitney; Sema7a KO, Welch test), Ly6Chi (WT, Mann 
Whitney; Sema7a KO, Welch test) and Ly6Clo (Sema7a KO, Welch test).  
 
Unpaired t-tests, unless otherwise indicated. The 12 hour APAP experiment was 
performed once. The 24 hour APAP experiment was performed three times.  
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Figure 5. 36  PECs maintain the same frequency of phagocytosis 
between 12 and 24 hours APAP injury  
 
 
Figure 5. 36 
 
Frequency of phagocytosis (%PKH+) in PECs was compared in WT (blue) and 
Sema7a KO mice (red) at 12 and 24 hours post APAP administration.  
The following PEC populations were analysed: Ly6G+ neutrophils (WT unpaired t-
test), Ly6Chi monocytes (WT unpaired t-test) and F4/80hi mature macrophages. 
 
Mann Whitney test unless otherwise stated. The 12 hour APAP experiment was 









APAP injury is both enhanced and resolved by the innate immune system 35. Sema7a 
has been previously reported as an immunomodulator 151,228,230. During liver and lung 
injury Sema7a KO mice have less inflammation 212,246. In Chapter 4, Sema7a KO mice 
appeared to have more small mononuclear cells present in the necrotic area. This 
chapter investigates if Sema7a promotes inflammation during APAP injury.  
Firstly, the location of neutrophils and F4/80+ macrophages was examined during a 
time course of APAP injury.  Sema7a KO mice have an enhanced depletion of 
resident F4/80+ macrophages at 12 hours post APAP challenge. By 24 hours post 
APAP injury, the number of Sema7a KO F4/80+ macrophages matched the WT mice, 
but they could not infiltrate the central necrotic zone. In addition, Sema7a KO mice 
had more neutrophils in the necrotic area. 
Secondly, the composition of the liver, blood and peritoneum were examined at 12 
and 24 hours post APAP overdose. At 12 hours post APAP overdose, Sema7a KO 
mice had more infiltrating macrophages, and more blood Ly6Clo monocytes. At 24 
hours post APAP injury, there was no difference in the frequency of investigated 
populations in the liver, blood and peritoneum exudate in WT and Sema7a KO mice.  
Thirdly, phagocytosis was compared between the WT and Sema7a KO mice. There 
was no significant difference in the frequency of phagocytosis in vitro or in vivo.   
Taken together, Sema7a KO mice have more inflammation at 24 hours APAP, but 
this may be due to compensatory or knock on effects from the increased necrosis at 
12 hours post APAP injection.  The rest of this discussion examines why there was 
increased neutrophils in the necrotic area of Sema7a KO mice, and why there were 
less F4/80+ macrophages at 12 hours post APAP overdose. Within these analyses 
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Neutrophils are the first responders of the innate immune system. In our model, 
neutrophils infiltrated and accumulated in the liver from 12 to 24 hours post APAP 
overdose. By 42 hours post APAP overdose, the neutrophils had begun to recede. 
Sema7a KO mice had an increased neutrophil population in the necrotic area at 24 
hours post APAP overdose. This was not attributed to a lack of intrinsic Sema7a, or 
more patrolling neutrophils in the liver or blood of healthy mice.  
The increased neutrophil population is not due to an early accumulation or delayed 
entry to the liver. At 12 hours post APAP administration, Sema7a KO mice had a lower 
frequency of neutrophils in the CD45+ NPC fraction. However, this was not mirrored 
in the number of neutrophils per gram of liver, which was equal to WT mice. At 24 
hours APAP, WT and Sema7a KO mice had the same frequency and number of 
neutrophils present in the liver measured by flow cytometry, and at 24 and 42 hours 
post APAP overdose in the IHC analysis.   
The increased neutrophil population was not due to an enhanced infiltration or 
depletion of neutrophils from the blood or peritoneum. At 12 and 24 hours post APAP 
overdose, WT and Sema7a KO mice had the same frequency of neutrophils in the 
blood and peritoneal exudate.  
Potentially, the neutrophils are being retained in the necrotic area of the Sema7a KO 
mice by local signals. In Chapter 4, Sema7a KO mice had peri-necrotic hepatocytes 
with non-nuclear HMGB1. HMGB1 is normally localised to the nucleus, where it 
facilitates DNA transcription. During necrosis HMGB1 is passively released to act as 
a DAMP. Innate immune cells or epithelial cells can actively secrete HMGB1 as a 
cytokine under stress conditions 275. During APAP injury, HMGB1 attracts neutrophils 
to necrotic areas injury via their RAGE receptor. Deletion of hepatocyte HMGB1 
resulted in less neutrophil migration during APAP injury 53. Therefore, the non-nuclear 
HMGB1 detected in peri-necrotic Sema7a KO hepatocytes in Chapter 4, may act as 
a local signal to retain neutrophils in the necrotic area.  
In addition to localised HMGB1, Sema7a KO mice had more CXCL1 in the serum, at 
24 hours post APAP overdose compared to WT mice. CXCL1 is a known 
chemoattractant of neutrophils 52,282. This systemic cytokine expression may 
contribute to the persistent neutrophil population seen in the Sema7a KO mice. 
However, this was not reflected by an increased circulatory population of neutrophils, 
or increased presence of neutrophils in the whole liver, as shown by flow cytometry.   
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An alternative theory for persistent neutrophils in the necrotic area is that they are not 
being cleared by macrophages. Neutrophils recruit monocytes to areas of injury. 
Subsequently, the monocyte derived macrophages clear the apoptotic neutrophils 
through phagocytosis 91,111,121. However, less than 2% of the neutrophils expressed 
the apoptotic marker active caspase 3. This suggests the neutrophils are not 
undergoing apoptosis. However, this analysis does not exclude that neutrophils are 
undergoing necrosis or NETosis. Neutrophil necrosis could be assessed with a Ly6G 
and TUNEL dual stain, so far this protocol is not optimised in our lab. At 24 hours post 
APAP administration there was no difference in the frequency of macrophage 
phagocytosis in the liver of WT and Sema7a KO mice. Consequently, it is unlikely that 
neutrophils persist because they are not being cleared by macrophages. 
Neutrophils can reverse migrate back into the circulation, and are taken to the bone 
marrow to apoptose and be recycled 117. In zebra fish, macrophages “contact ” the 
neutrophil to induce reverse migration 122. As there were less macrophages in the 
central necrotic area of Sema7a KO mice, the contact reverse migration maybe 
reduced. In addition, endothelial Sema7a binds to Plexin C1 on PMNs to facilitate cell 
transmigration during hypoxia, or acute lung injury 211,237. Therefore, neutrophils may 
persist in the necrotic area due to incumbered reverse migration. Persistent 
neutrophils can lead to the formation of non-healing wounds, with incessant necrosis, 
and a delay in vascularisation 117. To assess this, a neutrophil transmigration study 
across endothelial cells overexpressing Sema7a or with Sema7a deleted could be 
performed. 
To conclude, neutrophils persist in the necrotic areas of Sema7a KO mice at 24 hours 
post APAP overdose. This may be a consequence of elevated CXCL1 or secreted 
HMGB1 signalling or delayed reverse migration.  
Sema7a is an attractant for monocytes, and modulates if macrophages secrete pro-
or anti-inflammatory cytokines 228,231,232,236. Macrophages are required for recovery 
after APAP 4,35. To investigate a deficiency of Sema7a affected macrophages during 
APAP injury, the monocyte and macrophages populations of the liver, blood and 
peritoneum were analysed at 12 and 24 hours post APAP administration in WT and 
Sema7a KO mice.  
Healthy WT and Sema7a KO mice had the same number of F4/80+ macrophages per 
field of view. In Sema7a KO mice, there were less F4/80+ macrophages in the central 
necrotic zone at 24 hours post APAP administration. This could be due to a migration 
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defect in the macrophages of the Sema7a KO mice, as Sema7a acts as a 
chemoattractant for monocytes and macrophages 228,229. In dendritic cells, Sema7a 
regulates migration and adhesion by modulating the cytoskeleton via p-FAK signalling 
228,230. To test macrophage migration, WT and Sema7a KO BMDMs migration towards 
dying cells could be assessed. To test if Sema7a is acting as a chemoattractant, 
migration of WT BMDMs could be examined towards a gradient of Sema7a.  
Alternatively, the F4/80+ macrophages may be being prevented from entering the 
central necrotic area by the persistent neutrophils. In a model of sterile thermal injury, 
invariant natural killer (iNKT) cells are retained at the edge of the necrotic lesion from 
4 hours post thermal injury. This is achieved by KC presenting self-antigens to the 
iNKTs and IL-12 and IL-18 signalling. 48 hours post thermal injury, the iNKT cells 
entered the necrotic lesion and promote recovery 290. Perhaps there is a similar 
spatial- temporal control of innate immune cells during APAP injury, which is delayed 
in the Sema7a KO mice.  
APAP injury induces resident macrophage depletion 48–51. Subsequently, infiltrating 
macrophages are recruited to the liver, significantly boosting the liver macrophage 
population, and become the dominant macrophage population in the liver 48. This loss 
and gain of macrophages can been seen in the IHC analysis presented here. At 12 
hours post APAP administration the number of F4/80+ macrophages is reduced. 
Depletion of F4/80+ macrophages was significantly enhanced in the Sema7a KO 
mice. This was not due to an intrinsic defect, as macrophages did not express 
Sema7a when examined in Chapter 3. At 12 hours post APAP administration, 
Sema7a KO mice had more necrosis. This increased injury may have enhanced 
F4/80+ macrophage depletion, or vice versa.  
From 12 to 24 hours post APAP challenge, there is a 2-3 fold increase in the number 
of F4/80+ macrophages in the liver. By 24 hours post APAP injury, WT and Sema7a 
KO mice have equivalent levels of F4/80+ macrophages. At this time point there are 
more F4/80+ macrophages present in the liver than in healthy mice. By 42 hours post 
APAP injury, the F4/80+ macrophage population is reduced. The resident 
macrophage population is replenished by self-renewal, or are replaced by the 
infiltrating macrophages 48,65–67.  
The enhanced depletion of F4/80+ macrophages in Sema7a KO mice, and the 
increase of F4/80+ macrophages in the liver, demonstrated by IHC, is not confirmed 
by flow cytometry analysis. Flow cytometry analysis of the NPC fraction of the liver 
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implies that WT and Sema7a KO mice have the same frequency and absolute count 
of resident macrophages at 12 and 24 hours post APAP overdose. To clarify this, 
staining for Clec4F, a more specific marker of KCs 65, could be utilised to distinguish 
between KCs and infiltrating macrophages which can both express F4/80.  
Our flow cytometry analysis agrees that the infiltrating macrophages are the most 
dominant population of the liver. However, the frequency of infiltrating macrophages 
did not significantly increase from 12 and 24 hours post APAP administration, as 
shown here in the IHC analysis and previously 48.  As APAP is a highly variable model, 
a minimum of n=8 is required to reach statistical significance. I would therefore like to 
repeat the 12 hours flow cytometry experiment and re-examine our findings.  
The conflicting results gained reflects the differences in the two techniques. Images 
taken for IHC focussed on the necrotic centrilobular areas, whereas flow cytometry 
analyses the NPC fraction from a digest of the whole left lobe. Unlike DAB staining, 
flow cytometry excludes dying cells and does not amplify the positive signal. Over 
90% of resident and infiltrating macrophage populations were viable at 12 hours post 
APAP administration. On the other hand, dying cells down regulate the expression of 
their surface antigens 291, without an amplification they may be excluded from the flow 
cytometry analysis. Therefore, the DAB IHC analysis may be including dying cells 
which are not detected by flow cytometry.  
To assess if the Sema7a KO F4/80+ macrophages are depleted through cell death at 
12 hours post APAP administration, I would like to perform an active caspase 3 or 
TUNEL stain with F4/80. Due to different antigen retrievals required for these stains, 
I do not yet have a working protocol to examine this.  
With these conflicting results, I revisited the F4/80 macrophage slides used for the 
IHC analysis. There was visibly less F4/80+ macrophages in Sema7a KO mice at 12 
hours post APAP administration.  At this current point, the IHC data is probably more 
reliable. There is the required n= 8 in each stain and the loss of F4/80+ macrophages 
is clearly visible across the liver. Whereas the flow cytometry data is under powered.  
Sema7a KO mice had significantly more infiltrating macrophages at 12 hours post 
APAP administration. This may be a compensatory effect to replace the more 
depleted resident macrophage compartment. Infiltrating macrophages originate in the 
bone marrow and travel via the blood to the liver 35,51. Healthy mice had the same 
frequency of circulating macrophages, so this increase in infiltrating monocytes is a 
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direct response to APAP injury. In line with this, Sema7a KO had more circulating 
Ly6Clo monocytes, which will contribute to the infiltrating macrophage population. 
Sema7a KO mice have more necrosis at 12 hours post APAP administration, 
presumably, there will be more DAMPs secreted to recruit innate immune cells, 
including infiltrating macrophages. Infiltrating macrophages are recruited by CCL2 
(MCP1) 49,63, and CSF1. CSF1 has the additional benefit of promoting macrophage 
infiltration and differentiation into restorative macrophages 32. It would be interesting 
to see if CCL2 or CSF1 were upregulated in Sema7a KO mice at 12 hours post APAP 
overdose.  
IL-6 is a highly diverse cytokine with both pro- and anti -inflammatory affects. At 24 
hours post APAP administration,  the concentration of IL-6 was higher in the serum of 
Sema7a KO mice, compared to WT. The IL-6 receptor is expressed by hepatocytes, 
neutrophils, and monocytes 292. As such it can regulate neutrophil and monocyte 
recruitment 293. In combination with CSF1, it can promote monocytes to differentiate 
into macrophages 294,295. In APAP injury, IL-6 is required for hepatocyte proliferation 
85, and facilitates macrophage phagocytosis 72. Sema7a signalling induces IL-6 
secretion from PMNs and macrophages 231,232,245. During chronic CCl4 injury, Sema7a 
enhances TGFβ induced IL-6 transcription 246. In alveolar cell lines IL-6 promotes the 
expression of Sema7a as part of a positive feedback loop 212. In these studies, it was 
implied IL-6 has a pro-inflammatory role.  
Without studies involving IL-6 deletion and overexpression it is impossible to know its 
role of elevated IL-6 in the Sema7a KO serum at 24 hours post APAP overdose. It 
may be an attempt initiate Sema7a production in the Sema7a KO mice, as IL-6 can 
promote Sema7a expression via NF-κB 212. It is unlikely to be to enhance recruitment 
or differentiation of macrophages, as WT and Sema7a KO mice had the same 
frequency of monocytes and macrophages in the blood, liver and peritoneal exudate. 
IL-6 might enhance proliferation and phagocytosis in the Sema7a KO mice, but again 
in vivo phagocytosis and proliferation was not affected in the Sema7a KO mice.  
Peritoneal F4/80+ GATA6+ macrophages infiltrated the liver within one hour of sterile 
thermal injury, and aided recovery by dismantling necrotic nuclei and promoted 
vascular regeneration 71. Depletion of peritoneal macrophages with liposomal 
chlodronate prevented mice recovering from CCl4 injury. It is unknown if peritoneal 
macrophages contribute to APAP injury and recovery. Here, I examined the frequency 
of neutrophils, macrophages and Ly6Chi monocytes in the peritoneal exudate. The 
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frequencies of these populations did not alter between 12 and 24 hours post APAP 
administration, suggesting they do not contribute to inflammation during APAP injury. 
However, Wang et al. observed these GATA6+ F4/80+ macrophages infiltrating the 
liver within 1 hour of injury. Perhaps they do contribute to APAP liver inflammation, 
but before the 12 hour time point.  
To recover from APAP injury, phagocytosis is required to remove debris. Sema7a KO 
BMDMs tended to have lower frequency of phagocytosis, compared to WT BMDMs. 
These experiments need repeating to be confirmed. In vivo, WT and Sema7a KO 
mice had the same phagocytosis in the liver, blood and PEC in all macrophage, 
monocyte and neutrophil populations examined. The only exception being peritoneal 
Ly6Chi monocytes, which had a higher frequency of phagocytosis at 12 hours post 
APAP administration in WT mice. Phagocytosis can induce a switch from Ly6Chi to 
Ly6Clo. However, this was not reflected in the frequency of Ly6Clo. 
The in vivo phagocytosis experiment used a fluorescent bead as phagocytic cargo, 
whereas the in vitro experiment used apoptotic thymocytes. This difference in cargo 
may explain why there was no difference in phagocytosis in vivo between WT and 
Sema7a KO mice. Sema7a KO mice may therefore have lower phagocytosis of cells, 
cellular debris or bacteria in vivo. In vivo LPS phagocytosis can be examined by 
injecting fluorescent LPS particles. However, as APAP is a sterile injury this 
experiment would not inform us if phagocytosis of host cellular debris was affected by 
a lack of Sema7a.  
Infiltrating macrophages drastically increased their frequency of phagocytosis in 
Sema7a KO mice from 12 to 24 hours post APAP overdose. Presumably, this is to 
remove debris. It is currently unknown what induces the switch from a 
proinflammatory to a restorative phenotype, and the onset of recovery at a specific 
time point. Cytokines including IL-10 and IL-4 296 and phagocytosis 72,149 are known to 
be important. The resident macrophages had a high rate of phagocytosis at both 12 
and 24 hours post APAP injury, but recovery only began after the 24 hour time point. 
Maybe the infiltrating macrophages needed time to mature, before they could start 
phagocytosing. Perhaps the APAP induced necrosis and inflammation needs to be 
contained, before the anti-inflammatory signals could take precedence, and recovery 
begin.   
In this chapter we have shown Sema7a KO mice have persistent neutrophils in the 
necrotic area at 24 hours post APAP administration. They may be being retained by 
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local HMGB1 signalling or systemic CXCL1, or due to a delay in their reverse 
migration.  
F4/80+ macrophages were more depleted in Sema7a KO mice, at 12 hours post 
APAP overdose, with an inability to enter the necrotic area. However, this was not 
confirmed by flow cytometry, where WT and Sema7a KO mice had the same 
frequency of resident macrophages at 12 and 24 hours post APAP overdose. Sema7a 
KO mice had more infiltrating macrophages at 12 hours post APAP overdose, and a 
greater upregulation in the frequency of phagocytosis from 12 to 24 hours post APAP 
overdose in the liver and blood. However, a Sema7a deficiency did not affect in vivo 
phagocytosis.  
Together, Sema7a aids the innate immune system to combat APAP toxicity. Sema7a 
KO mice have more inflammation at 24 hours post APAP injury, seen by elevated 
levels of IL-6 and CXCL1 in the serum and persistent neutrophils in the liver. However, 
this may be a consequence of the increased necrosis and depleted F4/80+ 
macrophages at 12 hours post APAP overdose. With this in mind and the conflicting 
data, more investigations are needed to establish if Sema7a is pro- or anti-





















Chapter 6 – Conclusions and 
future perspectives  
   





APAP overdose causes half of acute liver failure in the UK and the USA 1,2. NAC is 
an effective treatment in the first 12 hours following APAP overdose. After this 
timepoint, 22% of patients require a liver transplant, which is prevented by a scarcity 
of donors 3. After a moderate overdose, patients can spontaneously recover 3. 
Enhancing endogenous recovery mechanisms after the 12 hour time window of NAC 
is an attractive approach to treating APAP overdose. These essential recovery 
mechanisms include: preventing the spread of necrosis, a shift to the anti-
inflammatory phenotype, clearance of necrotic debris and proliferation of the 
remaining hepatocytes to restore the parenchyma.  
The innate immune system can perform or promote these recovery processes. 
Macrophages phagocytose cellular debris, providing space for hepatocytes to 
proliferate. Phagocytosis causes macrophages to switch from a pro-inflammatory to 
a restorative phenotype, which secrete anti-inflammatory cytokines such as IL-10  
which reduces inflammation  72,256. Restorative  macrophages also secrete TNFα and 
IL-6 to prime the hepatocytes to proliferate 17. Depletion of macrophages prevents 
recovery from APAP injury 21,51. Macrophages can also delay hepatocyte proliferation 
by secreting TGFβ to induce hepatocyte senescence 144. One potential therapeutic 
avenue is to manipulate the innate immune system to promote recovery. 
Administration of CSF1-Fc to mice at 12 hours APAP injury promotes recovery by 
enhancing Ly6Chi monocyte recruitment, KC and infiltrating macrophage proliferation 
and phagocytosis 32. In chronic liver injury, injection of BMDMs polarised to the pro-
inflammatory phenotype ameliorated liver fibrosis by reducing the number of activated 
HSCs and enhancing degradation of the collagen scars. The BMDMs also recruited 
endogenous macrophages which amplified and extended these beneficial effects 87,88. 
Therefore, understanding how the immune system promotes recovery, and being able 
to modulate these pathways will lead to novel therapies.  
Semaphorins are known immunomodulators 193. Sema7a chemoattracts monocytes, 
macrophages and DCs 228–230.  Sema7a can also modulate if macrophages secrete 
pro- inflammatory or anti- inflammatory cytokines, in a receptor dependant manner 
231,236. In DCs, Sema7a -Plexin C1 signalling prevents the DC from phagocytosing the 
herpes and smallpox virus 218,219,239. Sema7a deficiency in vivo either promotes or 
reduces inflammation. Pulmonary inflammation is reduced during an acute LPS 
inhalation model in Sema7a KO mice compared to WT mice 212. In CCl4 induced liver 




fibrosis, Sema7a promotes IL-6 and MCP-1 expression, F4/80+ macrophage 
infiltration and collagen deposition by enhancing the TGFβ - pAKT -pERK pathway 
246.  
My PhD project therefore investigated the following hypothesis: Sema7a promotes 
injury and inflammation during APAP injury, by investigating the following aims:   
1. Examine if Sema7a+ hepatocytes form a boundary to limit the spread of cell 
death 
2. Examine if Sema7a promotes p21 expression in hepatocytes 
3. Define if Sema7a delays proliferation during recovery from APAP injury 
4. Investigate if Sema7a has a pro- inflammatory effect during APAP injury 
To the best of our knowledge, this is the first investigation of APAP injury in Sema7a 
KO mice. I discovered that Sema7a becomes expressed on peri – necrotic, non-
proliferative, Hnf4α+ hepatocytes during APAP injury. By comparing WT mice to 
Sema7a deficient mice, I established that Sema7a+ hepatocytes prevent the spread 
of TUNEL+ cells into the healthy parenchyma, at 24 hours post APAP injection. The 
Sema7a KO mice succumbed more easily to APAP overdose and elevated LFTs 
throughout an APAP time course and had significantly more necrosis at 12 hours post 
APAP injection, compared to WT mice. At 24 hours post APAP injury, Sema7a KO 
mice had non-nuclear HMGB1 expression in peri-necrotic hepatocytes, indicative of 
increased cellular stress. p21 expression was not affected in Sema7a KO mice. 
During APAP recovery, BrdU labelling revealed WT and Sema7a KO mice have the 
same rate of proliferation. Together, this data shows that Sema7a acts to prevent the 
spread of necrosis and reduces APAP injury but does not impact hepatocyte 
proliferation.  
At 24 hours post APAP injury Sema7a KO have more inflammation. IL-6 and CXCL1 
were elevated in the serum, and there were more neutrophils in the necrotic area. At 
12 hours post APAP injury Sema7a KO mice have a greater depletion of F4/80+ 
macrophages. However, this could be a consequence of the increased necrosis at 12 
hours APAP injury. A Sema7a deficiency did not affect the frequency of phagocytosis 
in vivo. Together, I have shown Sema7a prevents the spread of necrosis and reduces 
inflammation during APAP injury. Sema7a does not directly influence in vivo 
phagocytosis, or hepatocyte proliferation. For a working model see Figure 6. 1. 
 




Figure 6. 1 Working model – Sema7a prevents spread of injury and 
reduces inflammation during APAP injury 
 
 
Figure 6. 1 
Sema7a becomes expressed peri-necrotic hepatocytes after APAP injury. Which 
limits the spread of APAP-toxic metabolites, and hepatocyte death in the healthy 
parenchyma. The Sema7a+ hepatocytes may regulate neutrophil migration into the 
necrotic area and facilitate neutrophil reverse migration.  
 
In Sema7a KO mice, the APAP induced toxicity spreads into the parenchyma 
increasing necrosis and exaggerating F4/80+ macrophage depletion and delays their 
migration into the necrotic area. Augmented cellular stress causes peri-necrotic 
hepatocytes to release HMGB1 from their nuclei. HMGB1 with CXCL1, may attract 
and retain neutrophils in the necrotic area. The delay in F4/80+ macrophages may 
postpone neutrophil clearance.   
 
 




My first aim examines if Sema7a+ hepatocytes limits the spreads of necrosis. Sema7a 
is first detected in peri-necrotic hepatocytes at 12 hours post APAP. The peri-necrotic 
expression of Sema7a peaks at 24 hours post APAP injury. To examine if these 
Sema7a+ peri-necrotic hepatocytes limited the spread of injury, Sema7a KO mice 
were compared to WT mice during an APAP time course. At 12 hours post APAP 
injection, Sema7a KO mice had more necrosis.  
In Sema7a KO mice, TUNEL+ cells were detected in the healthy parenchyma, which 
were not detected in the WT mice, at 24 hours post APAP injury. In the absence of 
Sema7a, peri-necrotic hepatocytes release HMGB1 from their nuclei, indicative of 
increased cellular stress or damage. Secreted HMGB1 acts as a cytokine or DAMP 
to recruit the immune system 275. This suggests Sema7a+ hepatocytes act as a barrier 
to contain necrosis during APAP injury.  
Epithelial barriers are physically maintained by cellular junctions. Epithelial barriers 
have been extensively researched in the skin and intestine 297–301. However, the 
concept of hepatocytes acting as a physical epithelial barrier against APAP injury has 
only been briefly examined. The main connexin in the liver is Cx32. Genetic deletion 
of Cx32, or application of the Cx32 small inhibitor, 2-ABP, prevents the spread of 
APAP induced necrosis through gap junctions in vivo 137. However, follow up studies 
indicate the protective effects of 2-ABP were partially mediated by the 
hepatoprotective vehicle DMSO 24 and a reduction of JNK signalling, and not a block 
of Cx32 junctions 138. In vitro, two individual hepatocytes were coupled together. 
Deletion of the Cx32, Cx26 gap junction in coupled hepatocytes prevented 
synchronised necrotic cell death 140. With these contradicting studies, further 
investigations are needed to assess if APAP can spread through Cx32 junctions.  
Cx43 is upregulated during APAP injury. At 24 hours post APAP injury, Cx43 +/- mice 
had elevated ALT and increased IL-1β and TNFα secretion, suggesting Cx43 protects 
against APAP injury 141, although further work is needed to confirm these results.  
Sema7a modulates the actin cytoskeleton 176,216–219,227. The actin cytoskeleton 
transports de novo Cx43 channels from the Golgi to the plasma membrane 281, and 
then stabilises the gap junction formation 131. Potentially, Sema7a mediates the 
formation of Cx43 channels to reduce the spread of necrosis during APAP injury.  
The spread of APAP toxicity may enhance cellular stress and senescence. My second 
hypothesis examined if Sema7a influenced p21 expression. In WT mice a fifth of the 




Sema7a+ hepatocytes co-expressed p21, the senescence marker. It has been shown 
that macrophages secrete TGFβ to induce p21 expression in peri-necrotic 
hepatocytes 144. Sema7a can enhance non-canonical TGFβ signalling and modulate 
macrophages to secrete cytokines 231,236,246,247. In addition, Sema3a is now recognised 
as a senescence marker 145. To see if Sema7a could induce cell cycle arrest during 
APAP injury, p21 expression was examined. WT and Sema7a KO mice had the same 
number or peri-necrotic hepatocytes at 24 hours post APAP injury. This implies 
Sema7a does not promote p21 expression, either directly or indirectly by enhancing 
TGFβ signalling. 
Plexin C1 expression was significantly reduced at 24 hours post APAP administration 
in Sema7a KO mice, compared to WT mice. This suggests that Sema7a upregulates 
Plexin C1 expression in HSCs at peak APAP injury. Sema7a – Plexin C1 – LMKII 
signalling results in the inactivation of cofilin and induces cell contraction and 
adhesion and prevents migration in melanocytes, DCs and GnRH neurones 179,216–
219,227. After acute CCl4 injury, damaged hepatocytes transiently secrete Sema3e 
which binds to Plexin D1 on LSECs causing the LSECs to contract 186. The authors 
suggested that contraction of LSECs might enable the migration of immune cells to 
the damaged regions, although this was not examined. Potentially, Sema7a – Plexin 
C1 signalling induces HSCs contraction or prevents HSC migration during APAP 
injury. In chronic injury, HSCs wrap around the sinusoids and contract, reducing blood 
flow along the sinusoid 302. However, the area of vimentin, an HSC marker was the 
same in WT and Sema7a KO mice at 24 hours APAP injury, suggesting Sema7a does 
not promoting the contraction of HSCs.  
Alternatively, Sema7a – Plexin C1 signalling might induce HSCs to secrete ECM 
factors required to remodel and regenerate the necrotic area after 24 hours post 
APAP. In chronic liver injury, activated HSCs produce collagen which drives fibrosis 
260,302. In CCl4 induced liver fibrosis, Sema7a KO mice had less collagen deposition 
and reduced expression of αSMA, a marker for activated HSCs 246. Sema7a KO mice 
also have reduced TGFβ induced pulmonary fibrosis, with reduced collagen and 
laminin synthesis 247. Future work could examine the consequences of Sema7a-
Plexin C1 signalling with mechanistic and cell behaviour studies. 
Factors secreted by HSCs are protective during APAP injury.  One group collected 
serum free conditioned media from cultured HSCs (HSC-CM) and injected it into mice 
2 hours after APAP administration. HSC-CM treatment improved necrosis and the 




survival of mice. Mass spectrometry on the HSC-CM and identified 144 proteins 266,267. 
However, the authors did not delineate which of these 144 proteins gave protective 
effects against APAP injury. They also failed to examine mice at later timepoints to 
ensure the HSC-CM did not trigger fibrosis, prolong the immune response or prevent 
final resolution of necrosis. Future work is needed to examine the exact roles of HSCs 
during APAP injury, and to define the protective factors.  
 
 
My fourth aim examined if Sema7a promotes inflammation during APAP injury. By 
comparing the macrophage and neutrophil populations in WT and Sema7a KO mice 
throughout an APAP time course, I demonstrated that F4/80+ macrophages were 
significantly more depleted in Sema7a KO mice at 12 hours post APAP injury and had 
more neutrophils in the necrotic area at 24 hours post APAP injury that WT mice. To 
the best of our knowledge this is the first time Sema7a KO mice have been treated 
with APAP. In WT mice APAP injury is known to deplete the resident macrophage 
population, as seen here and previously reported 48–51. Macrophage depletion is 
caused by ROS and mitochondrial stress 50. Possibly, the increased necrosis in 
Sema7a KO mice enhanced F4/80+ macrophage depletion. 
In contrast to this, flow cytometry analysis indicates WT and Sema7a KO mice have 
the same frequency and absolute count of resident macrophages at 12 hours post 
APAP overdose, conflicting with the IHC analysis. These conflicting results may reflect 
the differences between the techniques. The main advantage of flow cytometry is the 
ability to detect multiple cell markers in a whole tissue, enabling the analysis of 
immune composition and activation states of a sample. Dead cells or cells with a dim 
expression of the target antigen are excluded. Here flow cytometry was used to 
compare the infiltrating and resident macrophages present in the liver. Possibly, dying 
cells were excluded from the flow cytometry analysis. The 12 hour flow cytometry data 
is limited by a low sample number. Due to the variability in the APAP model, a sample 
number of 8 is required. Due to time restraints, the 12 hours experiment was 
performed once with n=4 WT mice and n=5 Sema7a KO mice, and is therefore 
underpowered.  
The advantages of DAB IHC are its sensitivity and its ability to describe the exact 
location of cells in a tissue. Here, imaging and quantification of the DAB stain focused 




on centrilobular areas. DAB IHC amplifies the positive signal and is therefore more 
sensitive than flow cytometry but will include dying cells. To assess if the Sema7a KO 
F4/80+ macrophages are depleted through cell death at 12 hours post APAP 
administration, I would like to perform an active caspase 3 or TUNEL stain with F4/80.  
When the DAB IHC was re-examined Sema7a KO mice had visibly less F4/80+ 
macrophages at 12 hours post APAP administration across the whole liver slice, 
compared to WT mice. This IHC analysis also has the required n=8 of WT and n=8 
Sema7a KO mice. For these reasons I believe the F4/80 DAB IHC is more reliable. 
Sema7a KO mice have significantly more infiltrating macrophages compared to WT 
mice, at 12 hours post APAP administration. This might be required to restore the 
enhanced depletion of resident macrophages, so that by 24 hours post APAP injury, 
Sema7a KO mice have the same frequency and absolute count of macrophages in 
the liver as WT mice, as measured by both IHC and flow cytometry. During APAP 
injury infiltrating macrophages are recruited to the liver by CCL2 49,296 to boost the liver 
macrophage population. Due to the depletion of resident macrophages, the infiltrating 
macrophages are the most dominant macrophage population in the liver, in both the 
WT and Sema7a KO mice at 12 and 24 hours post APAP injury. This agrees with 
previously published results 48. Blocking or deletion of CCR2 prevents macrophage 
infiltration, and delays recovery from APAP injury 21,51.  
WT and Sema7a KO mice have the same number of F4/80+ macrophages in the liver 
at 24 hours post APAP injury. In WT mice the F4/80+ macrophages are seen 
interacting with the Sema7a + hepatocytes at the edge of necrosis. Some F4/80+ 
macrophages migrate into the central necrotic zone. In Sema7a KO mice, the F4/80+ 
macrophages in the outer necrotic zone appear less organised, compared to the WT 
mice. Possibly the F4/80+ macrophages bind to Sema7a on the hepatocytes to 
facilitate barrier formation. Recently, macrophages were reported to line the synovial 
joint capsule in an “epithelial like barrier”. This barrier delayed PMN infiltration during 
rheumatoid arthritis, and phagocytosed apoptotic bodies 142. An intriguing idea is that 
the Sema7a+ hepatocytes prevent the spread of APAP toxicity by binding to HSCs, 
and by the regulation of macrophages.  
Sema7a KO mice have less F4/80+ macrophages in the central necrotic zone at 24 
hours post APAP challenge, compared to WT mice. This may indicate that Sema7a 
facilitates F4/80+ macrophage migration into the necrotic area. Sema7a is a 




monocyte and macrophage chemoattractant. Blocking Integrin β1 reduced 
macrophage migration towards Sema7a, and adherence to endothelial cells in vitro 
228,229.  
Alternatively, Sema7a+ hepatocytes may have a localised effect where they regulate 
the migration of neutrophils and macrophages into the necrotic area in a temporal 
manner. Invariant NK T cells (iNKTs) are prevented from entering the necrotic lesion 
in a temporal manner during a thermal sterile injury. iNKT were kept at the edge of 
the necrotic area by resident macrophage signalling and IL-12 and IL-18. At 48 hours 
post thermal injury, the iNKT cells entered the necrotic lesion and promote recovery 
290. 
Sema7a KO mice had more neutrophils in the necrotic area at 24 hours post APAP 
overdose. This was not attributed to a lack of intrinsic Sema7a, an increase or a delay 
in infiltration of neutrophils to the liver. Possibly the neutrophils are being retained in 
the necrotic area by chemoattractants.  
Sema7a KO mice had more non-nuclear HMGB1 expression in peri-necrotic 
hepatocytes than WT mice, at 24 post APAP administration. HMGB1 is a neutrophil 
chemoattractant. Specific deletion of hepatocyte HMGB1 reduced neutrophil 
infiltration and necrosis during APAP injury 53,275. In addition to localised HMGB1 
signalling, Sema7a KO mice had a higher expression of CXCL1 in the serum, at 24 
hours post APAP overdose compared to WT mice. CXCL1 is a known 
chemoattractant of neutrophils 52,282. This systemic cytokine expression may 
contribute to the persistent neutrophil population. However, this was not reflected by 
an increased circulatory population of neutrophils, or increased presence of 
neutrophils in the whole liver, as shown by flow cytometry.   
Alternatively, a deficiency of Sema7a may delay neutrophil transmigration out of the 
liver. Endothelial Sema7a binds to Plexin C1 on PMNs to facilitate PMN 
transmigration into the lung during acute ventilation injury 211,237. ICAM-1+ LSECs 
were negative for Sema7a, indicating endothelial Sema7a does not facilitate 
neutrophil reverse transmigration across LSECs in the liver.  
In a model of sterile thermal injury, neutrophils remodel the ECM to reverse migrate 
out of the liver 52,117. Deletion of cathepsin C, a serine proteinase which can mediate 
reverse migration through the basement membrane degradation, did not delay 
neutrophil entry into the necrotic zone, but delayed neutrophil exit. This delayed exit 




of neutrophils reduced revascularisation 117. This indicates a timely exit of neutrophils 
through the ECM is needed to facilitate regeneration. During lung fibrosis Sema7a KO 
mice have reduced mRNA expression of the elastase Cathepsin S, and more TIMP-
1, a metalloproteinase inhibitor 247,303, causing reduced ECM remodelling. The 
reduced number of macrophages in the Sema7a KO mice may also delay neutrophil 
transmigration. In zebra fish, macrophages contact neutrophils to induce neutrophil 
reverse migration 122. Collectively, the neutrophils in the Sema7a KO mice may persist 
due to less reverse migration facilitated by ECM remodelling, or reduced “contact” 
reverse migration from the decreased population of F4/80 macrophages in the central 
necrotic zone.  
The composition of the blood and peritoneal lavage were also examined. WT and 
Sema7a KO mice had the same frequency of neutrophils, monocytes and 
macrophages at 12 and 24 hours post APAP injury. Highlighting the localised effect 
Sema7a has during APAP injury. The only exception was Ly6Chi monocytes in the 
blood of Sema7a KO mice at 12 hours post APAP overdose. Presumably, these are 
the monocytes responsible for increasing the macrophage population in the liver at 
12 hours post APAP injury.  
To recover from APAP injury, the cellular debris must be cleared, and the hepatocytes 
must proliferate. Sema7a KO BMDMs tended to have a lower frequency of 
phagocytosis than WT mice, but more experimental repeats are needed to confirm 
this. In vivo, there was no difference in the frequency of phagocytosis between WT 
and Sema7a KO mice in the neutrophil, monocyte and macrophage population 
examined in the blood, peritoneal exudate or liver at 12 and 24 hours post APAP 
administration. The single exception being Ly6Chi monocytes in the peritoneal lavage, 
where Sema7a KO mice displayed reduced phagocytosis. However, this data may be 
skewed due to low cell counts. In the in vitro experiments, BMDMs were fed apoptotic 
thymocytes, whereas in the in vivo experiments, the cargo was an injected fluorescent 
dye. This difference in phagocytic cargo may explain the differences in the in vitro and 
in vivo data.   
In the liver, infiltrating macrophages quadrupled their frequency of phagocytosis 
between 12 and 24 hours post APAP overdose, which will facilitate debris removal. 
The increase in phagocytosis may reflect the maturation of infiltrating macrophages. 
It may also reflect the switch in the microenvironment from the injury setting to the 
regeneration phase. The factors which govern this switch are still a mystery.  




My third aim examined if Sema7a promotes proliferation. BrdU+ cells did not express 
Sema7a during APAP recovery, at 42 hours post APAP administration, or in the highly 
regenerative PHx model. WT and Sema7a KO mice had the same frequency of BrdU+ 
nuclei, and area of necrosis at 42 hours post APAP injury. This shows Sema7a does 
not have a direct role in proliferation. However, Sema7a KO mice have raised ALP 
levels, suggesting some ongoing damage. Therefore, Sema7a may have an indirect 
effect in recovery by limiting the spread of damage or by modulating the immune 
system.  
In the literature, Sema7a is not considered as a direct mitogen. It has been reported 
to promote proliferation of human oral squamous cell carcinoma derived cells lines by 
pERK – pAKT signalling 242, and can indirectly promote T cells proliferation by 
activating them. Conversely, Sema7a has no effect on HSC cell death or proliferation 
in vitro 246. Yet, Sema7a – Plexin C1 signalling inhibits melanocyte proliferation and 
migration in melanoma 243, and proliferation of adult neural progenitors in the SGZ 178. 
Together the role of Sema7a in cell proliferation is context and receptor dependant.  
One limitation of this PhD project is that we did not examine the recovery of WT and 
Sema7a KO mice from APAP injury at later time points. Sema7a KO mice had raised 
ALP at 42 hours APAP and more neutrophils in the necrotic area at 24 hours post 
APAP. Persistent neutrophils can lead to the formation of non-healing wounds, with 
incessant necrosis, and a delay in vascularisation 117. WT mice will recover from APAP 
by 72 hours post APAP. To be confident of recovery, WT mice are often examined at  
one week post APAP administration 147,304. To ensure the Sema7a KO mice do not 
have lingering necrosis or inflammation, and are completely recovered from APAP 
injury, they should be examined at 72 hours and one week post APAP administration 
Another limitation is the use of a constitutive KO mouse. Sema7a is expressed by T 
cells and DCs 230–232, and promotes cytokine secretion from macrophages 231,232,236. 
Therefore, the increased inflammation at 24 hours post APAP injury may be a due to 
a lack of Sema7a signalling in the immune system, and not due to a lack of Sema7a 
expression by hepatocytes. Performing a bone marrow transfer between the WT and 
Sema7a KO mice will convincingly answer this question.  
The question of do macrophages release pro- or anti-inflammatory cytokines after 
binding to Sema7a + hepatocytes is unanswered. This could be analysed in vitro by 
treating BMDMs with recombinant Sema7a. However, it is likely other signals govern 




which macrophage receptor binds Sema7a in vivo. Co-culture studies of BMDMs with 
Sema7a+ primary hepatocytes treated with APAP will reflect what happens in vivo 
more accurately.  
The underlying mechanisms which dictate how the Sema7a+ hepatocyte barrier forms 
have not been described. This is partly due to the localised nature of the Sema7a+ 
hepatocytes. The mRNA expression of genes reported here was performed on whole 
liver lysates. In the injury setting this will include all the hepatocytes, biliary cells and 
immune cells in the liver. Any change detected between the WT and Sema7a KO 
would indicate a profound change in gene expression, or protein expression if 
examined by ELISA or western blot. However, small changes in expression will be 
diluted into insignificance. To delineate the signalling mechanisms underlying 
Sema7a expression in hepatocytes, laser capture dissection could be performed, 
followed by mRNA expression profiling, and confirmed at the protein level.  
Could Sema7a be upregulated by DAMPs or ROS and therefore act as a stress 
signal? Sema7a was elevated in mouse serum and correlated with ALT. However, 
this was not seen in human serum. Possibly, this reflects that Sema7a is active during 
the early stages of APAP injury.  
Future investigations could examine if Sema7a+ hepatocytes prevent the spread of 
necrosis in other liver diseases. Viral hepatitis and ischemia reperfusion injury both 
induce necrosis 305. Sema7a has been shown to be expressed in humans with viral 
hepatitis C and alcoholics liver injury by western blot 246. However, the location of 
Sema7a expression was not examined.   
 
This PhD project discovered Sema7a+ hepatocytes surround the necrotic area during 
APAP injury, to limit the spread of necrosis. Sema7a deficiency resulted in increased 
necrosis at 12 hours post APAP administration, and more inflammation at 24 post 
hours APAP injury. Future work could identify the factors which initiate the formation 
of the Sema7a+ hepatocyte barrier, and the underlying signalling mechanisms that 
maintain it during APAP injury, and if it is present in other chronic injuries. 
Understanding these mechanisms will enable treatments which limit the spread of 
necrosis and reduce inflammation.  




It will be intriguing to see if and how the Sema7a+ hepatocytes regulate the migration 
of neutrophils and macrophages into the necrotic area. If macrophage migration to 
injured areas can be enhanced or guided, it may lead to targeted cellular therapies. 
Understanding these underlying mechanisms may help us find novel ways to contain 
the spread of damage and modulate the immune system during APAP overdose and 
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